documents incorporated reference portions definitive proxy statement registrants annual meeting shareholders filed within days conclusion registrant 's fiscal year ended december us securities exchange commission pursuant regulation securities exchange act amended incorporated reference part iii annual report extent described thereinbristolmyers squibb company index december part item business acquisitions divestitures licensing arrangements products intellectual property product exclusivity research development alliances marketing distribution customers competition pricing price constraints market access government regulation sources availability raw materials manufacturing quality assurance environmental regulation human capital management resources foreign operations bristolmyers squibb website item risk factors item b unresolved staff comments item properties item legal proceedings item mine safety disclosures part ia information executive officers part ii item market registrant 's common stock stockholder matters item selected financial data item management 's discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data consolidated statements earnings comprehensive lossincome consolidated balance sheets consolidated statements cash flows notes financial statements item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers registrant item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions item auditor fees part iv item exhibits financial statement schedule item summary signatures summary abbreviated terms exhibit index indicates brand names products trademarks owned bms specific trademark ownership information included exhibit index end part item business general bristolmyers squibb company incorporated laws state delaware august name bristolmyers company successor new york business started bristolmyers company changed name bristolmyers squibb company result merger completed celgene transaction november november completed acquisition myokardia approximately billion cash continue operate one segmentbiopharmaceuticals additional information business segment refer item financial statements supplementary datanote accounting policies recently issued accounting standards commencing celgene acquisition date consolidated financial statements include assets liabilities operating results cash flows celgene engaged discovery development licensing manufacturing marketing distribution sale biopharmaceutical products global basis expect acquisitions celgene myokardia position us leading biopharmaceutical company expanding oncology hematology immunology cardiovascular portfolios several nearterm assets additional external partnerships refer summary abbreviated terms end terms used throughout document principal strategy combine resources scale capability pharmaceutical company speed focus innovation biotech industry focus biopharmaceutical company discovering developing delivering transformational medicines patients facing serious diseases areas believe opportunity make meaningful difference oncology solid tumors hematology immunology cardiovascular fibrosis four strategic priorities drive enterprise performance maximize value commercial portfolio ensure longterm sustainability pipeline combined internal external innovation establish new culture embed people strategy committed reducing debt plan remain focused broadening portfolio marketed medicines pipeline assets discussion strategy initiatives refer item management 's discussion analysis financial condition results operations strategy compete worldwide researchbased drug companies smaller research companies generic drug manufacturers products sold worldwide primarily wholesalers distributors specialty pharmacies lesser extent directly retailers hospitals clinics government agencies manufacture products us puerto rico significant manufacturing operations two foreign countries revenues come products following therapeutic classes hematology oncology cardiovascular immunology percentage revenues significant regioncountry follows year ended december dollars millions united states europe rest world total revenues acquisitions divestitures licensing arrangements acquisitions divestitures licensing arrangements allow us focus resources behind growth opportunities drive greatest longterm value significant business development activities include november completed acquisition myokardia october obtained global exclusive license dragonflys interleukin il investigational immunotherapy program including extended halflife cytokine df september completed acquisition forbius additional information relating acquisitions divestitures licensing arrangements contained item financial statements supplementary data note acquisitions divestitures licensing arrangements products intellectual property product exclusivity pharmaceutical products include chemicallysynthesized small molecule drugs products produced biological processes called biologics small molecule drugs typically administered orally eg form pill tablet although drug delivery mechanisms used well biologics typically administered patients injections intravenous infusion summary significant products including approved indications information alliance arrangements certain products refer alliances item financial statements supplementary datanote alliances revlimid revlimid lenalidomide oral immunomodulatory drug combination dexamethasone indicated treatment patients multiple myeloma revlimid single agent also indicated maintenance therapy patients multiple myeloma following autologous hematopoietic stem cell transplant revlimid received approvals several indications hematological malignancies including lymphoma mds eliquis eliquis apixaban oral factor xa inhibitor indicated reduction risk strokesystemic embolism nvaf treatment dvtpe reduction risk recurrence following initial therapy opdivo opdivo nivolumab biological product fully human monoclonal antibody binds pd nkt cells opdivo received approvals several anticancer indications including bladder blood colon head neck kidney liver lung melanoma stomach opdivoyervoy regimen also approved multiple markets treatment nsclc melanoma rcc crc several ongoing potentially registrational studies opdivo across tumor types disease areas monotherapy combination yervoy various anticancer agents orencia orencia abatacept biological product fusion protein indicated adult patients moderately severely active ra psa also indicated reducing signs symptoms certain pediatric patients moderately severely active polyarticular jia pomalystimnovid pomalystimnovid pomalidomide small molecule administered orally modulates immune system biologically important targets pomalystimnovid indicated patients multiple myeloma received least two prior therapies including lenalidomide proteasome inhibitor demonstrated disease progression within days completion last therapy sprycel sprycel dasatinib oral inhibitor multiple tyrosine kinase indicated firstline treatment patients philadelphia chromosomepositive cml chronic phase treatment adults chronic accelerated myeloid lymphoid blast phase cml resistance intolerance prior therapy including gleevec imatinib mesylate treatment children adolescents aged year years chronic phase philadelphia chromosomepositive cml yervoy yervoy ipilimumab biological product monoclonal antibody treatment patients unresectable metastatic melanoma abraxane abraxane paclitaxel albuminbound particles injectable suspension solventfree proteinbound chemotherapy product combines paclitaxel albumin using proprietary nab technology platform used treat breast cancer nsclc pancreatic cancer among others empliciti empliciti elotuzumab biological product humanized monoclonal antibody treatment multiple myeloma reblozyl reblozyl luspaterceptaamt erythroid maturation agent indicated treatment anemia adult patients beta thalassemia require regular red blood cell transfusions inrebic inrebic fedratinib kinase inhibitor indicated treatment adult patients intermediate highrisk primary secondary post polycythemia vera postessential thrombocythemia myelofibrosis onureg onureg azacitidine oral hypomethylating agent incorporates dna rna indicated continued treatment adult patients aml achieved first complete remission complete remission incomplete blood count recovery following intensive induction chemotherapy able complete intensive curative therapy zeposia zeposia ozanimod oral immunomodulatory drug used treat relapsing forms multiple sclerosis include clinically isolated syndrome relapsingremitting disease active secondary progressive disease adults vidaza vidaza azacitidine injection pyrimidine nucleoside analog shown reverse effects deoxyribonucleic acid hypermethylation promote subsequent gene reexpression indicated treatment patients following myelodysplastic syndrome subtypes refractory anemia refractory anemia ringed sideroblasts accompanied neutropenia thrombocytopenia requiring transfusions refractory anemia excess blasts refractory anemia excess blasts transformation chronic myelomonocytic leukemia cmmol baraclude baraclude entecavir oral antiviral agent treatment chronic hepatitis b breyanzi breyanzi cddirected genetically modified autologous cell immunotherapy indicated treatment adult patients relapsed refractory large bcell lymphoma two lines systemic therapy including diffuse large bcell lymphoma dlbcl otherwise specified including dlbcl arising indolent lymphoma highgrade bcell lymphoma primary mediastinal large bcell lymphoma follicular lymphoma grade b license number patents us foreign countries primarily covering products also developed many brand names trademarks products consider overall protection patents trademarks licenses intellectual property rights material value act protect rights infringement pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity products market exclusivity generally determined two forms intellectual property patent rights held innovator company regulatory forms exclusivity innovative drug entitled patents key determinant market exclusivity branded pharmaceuticals patents provide innovator right exclude others practicing invention related medicine patents may cover among things active ingredients various uses drug product pharmaceutical formulations drug delivery mechanisms processes intermediates useful manufacture products protection individual products extends varying periods accordance expiration dates patents various countries protection afforded may also vary country country depends upon type patent scope coverage availability meaningful legal remedies country market exclusivity also sometimes influenced rdp exclusivity rights many developed countries provide certain nonpatent incentives development medicines example us eu japan certain countries rdp exclusivity rights offered incentives research medicines rare diseases orphan drugs medicines useful treating pediatric patients incentives provide market exclusivity period product expires beyond patent term us eu japan provide rdp period time approval new drug regulatory agency may rely upon innovators data approve competitors generic copy certain markets patent protection forms market exclusivity may expired rdp particular importance however regulatory forms exclusivity prevent competitor gaining regulatory approval prior expiration rdp exclusivity basis competitors safety efficacy data drug even drug identical marketed innovator patent rights forms exclusivity expire generic versions medicine approved marketed often substantial rapid declines sales original innovative product discussion impact generic competition business refer competition specific aspects law governing market exclusivity data regulatory protection pharmaceuticals vary country country following summarizes key exclusivity rules markets representing significant sales united states us key products protected patents varying terms depending type patent filing date significant portion products patent life however lost time takes innovative company develop obtain regulatory approval new drug compensation least part lost patent term due regulatory review periods innovator may depending number factors apply government restore lost patent term extending expiration date one patent maximum term five years provided extension cause patent effect years date drug approval company seeking market innovative pharmaceutical us must submit complete set safety efficacy data fda innovative pharmaceutical chemical product company files nda medicine biological product bla filed type application filed affects rdp exclusivity rights chemical products competitor seeking launch generic substitute chemical innovative drug us must file anda fda anda generic manufacturer needs demonstrate bioequivalence generic substitute approved nda drug anda relies upon safety efficacy data previously filed innovator nda innovator company required list certain patents covering medicine fda commonly known orange book absent successful patent challenge fda approve anda innovators listed patents expire however innovator marketed product four years generic manufacturer may file anda allege one patents listed orange book innovators nda invalid unenforceable infringed generic product allegation commonly known paragraph iv certification innovator must decide whether file patent infringement suit generic manufacturer time time andas including paragraph iv certifications filed respect certain products evaluate andas casebycase basis warranted file suit generic manufacturer protect patent rights addition patent protection certain innovative pharmaceutical products receive periods regulatory exclusivity nda designated orphan drug receive seven years exclusivity orphan indication time period neither ndas andas drug product approved orphan use company may also earn six months additional exclusivity drug specific clinical studies conducted written request fda study use medicine treat pediatric patients submission fda made prior loss basic exclusivity medicines approved nda also receive several types rdp innovative chemical pharmaceutical product entitled five years rdp us fda approve generic substitutes innovators patent challenged described generic manufacturer may file anda fourth year fiveyear rdp period pharmaceutical drug product contains active ingredient previously approved nda approved example new formulation new route administration drug new indication basis new clinical studies may receive three years rdp formulation route administration indication biologic products us healthcare legislation enacted created approval pathway biosimilar versions innovative biological products previously exist prior time innovative biologics essentially unlimited regulatory exclusivity new regulatory mechanism fda approve products similar generic copies innovative biologics basis less extensive data required full bla innovator marketed product four years manufacturer may file application approval biosimilar version innovator product however although application approval biosimilar version may filed four years approval innovator product qualified innovative biological products receive years regulatory exclusivity meaning fda may approve biosimilar version years innovative biological product first approved fda law also provides mechanism innovators enforce patents protect innovative biological products biosimilar applicants challenge patents patent litigation may begin early four years innovative biological product first approved fda increased likelihood generic biosimilar challenges innovators intellectual property increased risk loss innovators market exclusivity first generic companies increasingly sought challenge innovators basic patents covering major pharmaceutical products second statutory regulatory provisions may limit ability innovator company prevent generic biosimilar drugs approved launched patent litigation ongoing result developments among others possible predict length market exclusivity particular product certainty based solely expiration relevant patents current forms regulatory exclusivity european union patents pharmaceutical products generally enforceable eu us may extended compensate patent term lost regulatory review process extensions granted countrybycountry basis primary route use obtain marketing authorization pharmaceutical products eu centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds products company seeking market innovative pharmaceutical product centralized procedure must file complete set safety data efficacy data part maa ema ema evaluates maa provides recommendation ec ec approves denies maa also possible new chemical products obtain marketing authorization eu mutual recognition procedure application made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure member states obtaining marketing authorization approval company must obtain pricing reimbursement pharmaceutical product typically subject member state law certain eu countries process take place simultaneously product marketed eu countries process must completed company market new product pricing reimbursement procedure take months sometimes years complete throughout eu products marketing authorizations filed octobernovember subject regime eight years innovator received first community authorization medicinal product generic company may file maa product health authorities maa approved generic company may commercialize product either years elapsed initial marketing authorization granted innovator possible extension years available innovator first eight years marketing authorization obtains additional indication significant clinical benefit comparison existing treatments products filed prior octobernovember year period data protection centralized procedures period either six years mutual recognition procedure depending member state contrast us patents eu listed regulatory authorities generic versions pharmaceutical products approved data protection expires regardless whether innovator holds patents covering drug thus possible innovator may seeking enforce patents generic competitor already marketing product also european patent system opposition procedure generic manufacturers may challenge validity patents covering innovator products within nine months grant general eu law treats chemicallysynthesized drugs biologicallyderived drugs respect intellectual property data protection addition relevant legislation annexes related biologic medicinal products ema issued guidelines outline additional information provided biosimilar products also known generic biologics order review application marketing approval japan japan medicines new chemical entities generally afforded eight years data exclusivity approved indications dosage patents pharmaceutical products enforceable generic copies receive regulatory approval data exclusivity patent expirations us patents japan may extended compensate patent term lost regulatory review process general japanese law treats chemicallysynthesized biologicallyderived drugs respect intellectual property market exclusivity rest world countries outside us eu japan wide variety legal systems respect intellectual property market exclusivity pharmaceuticals developed countries utilize systems similar either us eu among developing countries adopted patent laws andor regulatory exclusivity laws others developing countries formally adopted laws order comply wto commitments taken steps implement laws meaningful way enforcement wto actions long process governments assurance outcome thus assessing likely future market exclusivity innovative drugs developing countries take account formal legal rights political factors well following chart shows key products together year earliest basic exclusivity loss patent rights data exclusivity occurred currently estimated occur us eu japan also sell pharmaceutical products countries however data provided country bycountry basis individual country revenues significant outside us eu japan many instances basic exclusivity loss date listed expiration date patent claims active ingredient drug method using drug approved indication one approved indication instances basic exclusivity loss date listed chart expiration date data exclusivity period situations data exclusivity without patent protection competitor could seek regulatory approval submitting clinical study data obtain marketing approval prior expiration data exclusivity estimate market exclusivity period products purpose business planning length market exclusivity products impossible predict certainty complex interaction patent regulatory forms exclusivity inherent uncertainties regarding patent litigation assurance particular product enjoy market exclusivity full period time appears estimate exclusivity limited estimate generally estimated loe table pertains rdp composition matter com patent expiration respective products patent term restoration ptr granted estimated loe us euk japan revlimid lenalidomidea opdivo nivolumab eliquis apixabanb orencia abataceptc pomalystimnovid pomalidomided sprycel dasatinibe yervoy ipilimumab abraxane paclitaxelf empliciti elotuzumab reblozyl luspaterceptaamtg inrebic fedratinibh zeposia ozanimodi onureg azacitidinej breyanzi lisocabtagene maraleucel see product footnote information currently market product country region indicated revlimid us part settlement natco pharma ltd natco partners affiliates natco granted volumelimited license sell generic lenalidomide us commencing march addition natco generic companies granted licenses sell generic lenalidomide products us without volume limitation beginning january eu licenses granted third parties market generic lenalidomide products prior expiry patent supplementary protection certificate spc rights uk beginning january various major market european countries eg france germany italy spain spc force beginning february refer item financial statements supplementary datanote legal proceedings contingencies information b eliquis us two patents listed fda orange book composition matter patent claiming apixaban specifically formulation patent challenged numerous generic companies subject patent infringement litigation prior august ruling bms along partner pfizer settled number generic companies settled generic companies continuing litigate three remaining generic companies remaining generic companies august us district court district delaware decided two challenged eliquis patents valid infringed remaining generic companies remaining generic companies appealed delaware court decision final decision case could determine generic versions eliquis come market predict outcome pending litigation alternatives might occur district courts decision upheld current appeal respect patents terms previously executed settlement agreements settled generic companies permitted date launch settled generic companies patents april formulation patent held invalid infringed current appeal settled generic companies remaining generic companies would permitted launch november patents held invalid infringed current appeal settled generic companies remaining generic companies could launch immediately upon adverse decision addition patents may subject subsequent challenges parties remaining generic companies occur depending outcome subsequent challenge potential launch generic companies including challengers successful could occur timelines similar discussed refer item financial statements supplementary datanote legal proceedings contingencies information c orencia us eu estimated loe dates based method use patents expire bms aware orencia biosimilar market us eu japan formulation additional patents expire beyond actual loe may extend beyond dates aforementioned reasons pomalyst us refer item financial statements supplementary datanote legal proceedings contingencies information europe japan estimated loe date based regulatory data protection exclusivity e sprycel us bms entered settlement agreement apotex inc apotex regarding patent infringement suit covering monohydrate form dasatinib whereby apotex launch generic dasatinib monohydrate anda product september earlier certain circumstances bms initiated patent litigation dr reddys laboratories october lupin june decision cases could determine generics come market eu epos opposition division upheld validity patent directed use dasatinib treat cml expires however generics may enter market indications covered patent refer item financial statements supplementary datanote legal proceedings contingencies information f abraxane us part settlement actavis llc actavis granted license certain patents required sell generic paclitaxel proteinbound particles injectable suspension product us beginning march eu generics may enter market japan estimated loe based method use patent refer item financial statements supplementary datanote legal proceedings contingencies information g reblozyl us europe estimated loe based regulatory data protection exclusivity us ptr application pending granted estimated patent expiry eu spc application method treatment patent pending granted estimated patent expiry h inrebic us ptr application pending granted estimated patent expiry zeposia us ptr application pending granted estimated patent expiry eu estimated loe date based regulatory data protection exclusivity eu spc application pending granted estimated patent expiry j onureg us estimated loe date based seven years orphan drug exclusivity formulation patent covering onureg expires us k estimated loe eu countries based france germany italy spain uk research development rd critical longterm competitiveness concentrate rd efforts following disease areas significant unmet medical needs oncology including io hematology cell therapy including multiple myeloma lymphoma chronic lymphocytic leukemia immunology including relapsing multiple sclerosis psoriasis lupus rheumatoid arthritis inflammatory bowel disease cardiovascular including cardiomyopathy heart failure thrombotic disorders fibrotic disease including lung ipf liver nash also continue analyze may selectively pursue promising leads areas rd pipeline includes potential medicines various modalities including small chemically manufactured molecules large protein moleculesalso known biologicsand also millamolecules antibody drug conjugates cellular therapies gene therapies addition discovering developing new molecular entities look ways expand value existing products new indications formulations provide additional benefits patients order new drug reach market industry practice government regulations us eu foreign countries provide determination drugs effectiveness safety preclinical tests controlled clinical evaluation clinical development potential new drug typically includes phase phase ii phase iii clinical studies designed specifically support application regulatory approval particular indication assuming studies successful phase clinical studies involve small number healthy volunteers patients suffering indicated disease test safety proper dosing phase ii clinical studies involve larger patient population investigate side effects efficacy optimal dosage drug candidate phase iii clinical studies conducted confirm phase ii results significantly larger patient population longer term provide reliable conclusive data regarding safety efficacy drug candidate although regulatory approval typically based results phase iii clinical studies times approval granted based data earlier studies consider registrational studies significant rd programs programs may include investigational compounds phases ii iii development initial indications marketed products development additional indications formulations substantial components rd program strategy include expanding portfolio marketed products hematology immunology io well opdivo combination yervoy agents first secondline therapy new indications drug development time consuming expensive risky rd process typically takes fourteen years approximately two half years spent phase iii latestage development average one molecules discovered pharmaceutical industry researchers proves medically effective safe enough become approved medicine drug candidates fail stage process even latestage product candidates sometimes fail receive regulatory approval according kmr group based industry success rates approximately small molecules enter phase development fail achieve regulatory approval small molecules enter phase ii development failure rate approximately approximately phase iii later stage small molecules fail achieve approval biologics failure rate approximately phase development approximately phase ii development approximately phase iii later stage development total rd expenses include costs discovery research preclinical development earlystage latestage clinical development drug formulation post commercialization medical support marketed products proportionate allocations enterprisewide costs upfront contingent milestone payments licensing acquiring assets rd expenses billion billion billion including license asset acquisition charges approximately billion million billion respectively rd expenses include full year expense resulting celgene acquisition occurred november addition billion iprd charge recognized myokardia acquisition manage rd programs product portfolio basis investing resources stage rd early discovery latestage development continually evaluate portfolio rd assets ensure appropriate balance earlystage latestage programs support future growth company spending latestage development programs represented approximately annual rd expenses opdivo individual investigational compound marketed product represent rd expenses part operating model evolution rd geographic footprint significantly transform foster speed innovation future transformation involves closing hopewell new jersey site accompanied additional investment expansion opening others example expanded lawrenceville new jersey site opening new rd facility cambridge massachusetts planned addition acquisition celgene added rd facilities strategic locations around us europe including san diego california seattle washington cambridge massachusetts summit new jersey san francisco california boudry switzerland supplement internal drug discovery development programs acquisitions alliances collaborative agreements help us bring new molecular agents capabilities platforms pipeline broad earlytomid stage pipeline unique compounds clinical development pipeline built coupling internal research development programs distributed research development model focused identifying supporting development disruptive innovative therapies outside company broad network external partnerships management continues emphasize leadership innovation productivity quality strategies success rd activities listed investigational compounds clinical studies well approved potential indications marketed products related therapeutic area february whether listed compounds ultimately becomes marketed product depends results clinical studies competitive landscape potential products market reimbursement decisions payers manufacturing processes necessary produce potential product commercial scale among factors assurance seek regulatory approval compounds approval sought obtained also assurance compound gets approved commercially successful stage development determine intellectual property issues patent protection may may available investigational compounds hematology phase phase ii phase iii approved indications opdivo opdivo opdivo revlimid hematologic malignancies nonhodgkin lymphoma diffuse refractory hodgkin lymphoma l multiple myeloma breyanzi lisocel large bcell lymphoma empliciti revlimid mantle cell lymphoma l mantle cell lymphoma nonhodgkin lymphoma follicular l multiple myeloma mds lymphoma idecel bcma car pediatric hodgkin lymphoma reblozyl multiple myeloma highrisk newlydiagnosed multiple esa nave mds previously treated follicular lymphoma myeloma primary testicular lymphoma inrebic relapsedrefractory adult tcell bcma car bb opdivo empliciti mf previously treated leukemialymphoma mr ye ela lop mse adrefractory multiple mr ye ela lop mse adrefractory multiple nu uxo rli etin gib ap dd viv ano c ed hodgkin lymphoma relatlimab idhifa angioimmunoblastic tcell pomalystimnovid hematologic malignancies dl h c mu ut te tm ioy neloid leukemia lymphoma multiple myeloma bet inhibitor cc reblozyl lower risk mds relapsedrefractory multiple myeloma nonhodgkin lymphoma mf anemia idhifa aids related kaposi sarcoma b e ht e min ah toib loi gto icr mc alc ig n n c ie tn ho lat sr sa en ms ausiondependent beta lr ee ula kp es iad wre itf hr idc hto r utc au tit oe n myeloid e mhiv p ln ie cg ia tt ii v e k pa opo ms ai la yr sco tm ima novid bet inhibitor bms onureg istodax relapsedrefractory multiple myeloma b che mm aa aol cgic malignancies bp ro es yt ah nm za f la isilu e c eld id el cp ee lr p bh cer mal cc ael rl l ty phoma e rep lal pi sc eit di r e f rr ae ctv ol ryim mi ud ltiple myeloma mr ye ela lop mse adrefractory multiple rl nd sif pfu las ne nl oa nrg ee l ib gi bc leell lymphoma el lo r alapsedrefractory multiple sprycel bcma tce lchronic lymphocytic leukemia breyanzi lisocel l cml mr ye ela lop mse adrefractory multiple z ol n e f lo ylli mcu pl ha mly amphoma marginal rl nd sif pfu las ne el la igr ig le bcell lymphoma p ed fria cri tc ra yl cl ml bcma nex l pediatric bcell acute vidaza relapsedrefractory multiple lymphoblastic leukemia acute myeloid leukemia myeloma l primary cns lymphoma chronic myelomonocytic leukemia gprcd car l high grade bcell lymphoma mds relapsedrefractory multiple idecel bcma car reblozyl myeloma highrisk newlydiagnosed multiple transfusiondependent betathalassemia cdxcd bispecific myeloma mds previously treated esa relapsedrefractory acute myeloid l relapsedrefractory multiple inrebic leukemia myeloma mf ai celmod cc l relapsedrefractory multiple relapsedrefractory multiple myeloma onureg myeloma iberdomide postinduction acute myeloid leukemia maintenance ai celmod cc relapsedrefractory multiple idhifa relapsedrefractory nonhodgkin myeloma relapsedrefractory aml lymphoma istodax gspt celmod cc cutaneous tcell lymphoma relapsedrefractory acute myeloid peripheral tcell lymphoma leukemia breyanzi lisocel antisirp l diffuse large bcell lymphoma nonhodgkin lymphoma lsd inhibitor relapsedrefractory nonhodgkin lymphoma cd nex relapsedrefractory nonhodgkin lymphoma cd adc lymnphoma iberdomide nonhodgkin lymphoma cd nke relapsedrefractory acute myeloid leukemia cdxcd nonhodgkin lymphoma oncology phase phase ii phase iii approved indications opdivo opdivo opdivo opdivo solid tumors solid tumors l glioblastoma l metastatic melanoma opdivo yervoy l crc l hcc adjuvant melanoma solid tumors pan tumor tmb high l head neck mesothelioma motolimod pediatric l head neck locally advanced previously treated advanced rcc scchn opdivo l esophageal previously treated gastric cancer japan relatlimab solid tumors l gastric china solid tumors opdivo yervoy highrisk nonmuscle invasive bladder previously treated hcc nlrp agonist solid tumors cancer previously treated metastatic head neck solid tumors metastatic castrationresistant adjuvant bladder previously treated metastatic melanoma antitim prostate adjuvant esophagealgastroesophageal previously treated metastatic msihigh crc solid tumors opdivo yervoy adjuvant gastric previously treated metastatic nonsquamous sting agonist solid tumors adjuvant hcc nsclc solid tumors opdivo cdk inhibitor adjuvant melanoma np sre cv lio cusly treated metastatic squamous ahr antagonist neoadjuvant erher breast adjuvant rcc previously treated metastatic urothelial solid tumors opdivo relatlimab metastatic castrationresistant prostate previously treated esophageal antictla nfprobody solid tumors neoadjuvant erher breast opdivo yervoy solid tumors opdivo linrodostat neoadjuvant nsclc l metastatic melanoma antitigit solid tumors periadjuvant nsclc l mesothelioma solid tumors opdivo bempegaldesleukin unresectable nsclc l nsclc anticd solid tumors opdivo yervoy l rcc solid tumors l bladder l bladder previously treated metastatic msihigh crc bet inhibitor cc pomalystimnovid l esophageal previously treated hcc solid tumors pediatric glioblastoma l gastric opdivo cabozantinib bet inhibitor cc antictla nf l hcc metastatic rcc solid tumors solid tumors intermediate hcc yervoy antisirp antictla probody l head neck adjuvant melanoma solid tumors solid tumors l crc msihigh metastatic melanoma cdxpsca ccr dual antagonist adjuvant melanoma abraxane solid tumors solid tumors adjuvant rcc breast antiil lsd inhibitor nsclc egfr mutant gastric solid tumors extensive stage sclc unresectable nsclc locally advanced metastatic nsclc antifucosyl gm opdivo relatlimab metastatic breast cancer solid tumors l melanoma nsclc arldd opdivo linrodostat pancreatic solid tumors l metastatic melanoma unresectable pancreatic antinkga neoadjuvant muscle invasive bladder cancer solid tumors opdivo bempegaldesleukin antiox l melanoma solid tumors adjuvant melanoma tgf inhibitor muscle invasive bladder cancer solid tumors l rcc il fc opdivo yervoy cabozantinib solid tumors metastatic rcc immunology phase phase ii phase iii approved indications tyk inhibitor branebrutinib orencia orencia autoimmune disease rheumatoid arthritis idiopathic inflammatory myopathy active polyarticular jia tyk inhibitor sjgrens disease nulojix early rheumatoid arthritis autoimmune disease systemic lupus erythematosus switch calcineurin inhibitor jia intravenous tlr inhibitor deucravacitinib renal transplant jia subcutaneous autoimmune disease crohn 's disease deucravacitinib psoriatic arthritis spr modulator lupus nephritis psoriasis ra auto injector autoimmune disease psoriatic arthritis zeposia ra intravenous il mutein systemic lupus erythematosus crohns disease ra subcutaneous autoimmune disease ulcerative colitis ulcerative colitis nulojix mk inhibitor iberdomide de novo renal transplant autoimmune disease systemic lupus erythematosus zeposia immune tolerance cendakimab relapsing multiple sclerosis multiple sclerosis eosinophilic esophagitis ilcd autoimmune disease anticd autoimmune disease cardiovascular phase phase ii phase iii approved indications factor xia inhibitor bms eliquis eliquis eliquis pediatric heart disease vte prevention pediatrics stroke prevention atrial fibrillation thrombotic disorders mavacamten venous thromboembolism prevention orthopedic fpr agonist nonobstructive hypertrophic mavacamten surgery heart failure cardiomyopathy obstructive hypertrophic venous thromboembolism treatment myk danicamtiv cardiomyopathy hypertrophic cardiomyopathy genetic dilated cardiomyopathy obstructive hypertrophic cardiomyopathy septal reduction factor xia inhibitor bms therapy eligible thrombotic disorders farelaxin heart failure fibrotic diseases phase phase ii lpa antagonist bms hsp pulmonary fibrosis fibrosis nme pegbelfermin fibrosis nonalcoholic steatohepatitis jnk inhibitor idiopathic pulmonary fibrosis nonalcoholic steatohepatitis lpa antagonist bms pulmonary fibrosis neuroscience phase faahmgll dual inhibitor neuroscience covid phase sarscov mab duo covid therapy prevention note pipeline excludes clinical collaborations development partnership opdivo yervoy relatlimab ono collaboration ono also includes early stage compounds empliciti abbvie bempegaldesleukin nektar cabozantinib exelixis inc eliquis pfizer factor xia inhibitor janssen pharmaceuticals inc hsp nitto denko corporation cdxcd cdxpsca gem gemoab monoclonals gmbh bb idecel bluebird reblozyl acceleron pharma inc idhifa agios pharmaceuticals inc ahr ikena oncology cd adc triphase accelerator tyk inhibitor nimbus nimbus therapeutics immune tolerance anokion trials exploring various combinations partnerrun study following potential registrational study readouts anticipated opdivoyervoy hematology asset tumor trial timing asset disease trial timing opdivo melanoma ca iberdomide l multiple myeloma ccmm relatlimab l chronic lymphocytic opdivo yervoy esophageal cm leukemia transcendcll l tne diffuse large b opdivo yervoy hcc cmdw breyanzi cell lymphoma pilot lisocel l te diffuse large bcell opdivo yervoy neoadjuvant nsclc cm lymphoma transform opdivo yervoy periadjuvant nsclc cmt l follicular lymphoma transcendfl opdivo rcc melanoma opdivo nktr l multiple myeloma karmma idecel l multiple myeloma karmma immunology reblozyl l mds esa nave commands asset disease trial timing moderate severe zeposia yellowstone crohns disease alliances enter alliance arrangements third parties development commercialization specific products drug candidates therapeutic areas focus alliances may structured codevelopment cocommercialization licensing joint venture arrangements arrangements may include upfront payments option payments develop commercialize specific asset technology payments various developmental regulatory salesbased performance milestones royalties cost reimbursements profit sharing equity investments provisions alliance arrangements lessen investment risk compounds leading revenue generating products reduce profitability marketed products due profit sharing royalty payments actively pursue arrangements view alliances important complement discovery development commercialization activities alliance arrangements contain customary early termination provisions following material breaches bankruptcy product safety concerns arrangements also typically provide termination bms without cause amount notice required early termination generally ranges immediately upon notice days receipt notice termination immediately upon notice generally available party files voluntary bankruptcy petition material safety issue arises product medical riskbenefit incompatible welfare patients continue develop commercialize product termination notice period generally available involuntary bankruptcy petition filed dismissed material breach party occurred cured bms terminates without cause sometimes bms 's right terminate without cause may exercisable specified period time elapsed alliance agreement signed alliances typically otherwise contain provisions provide party right terminate alliance typically retain rights another party 's product intellectual property alliance terminates loss rights one products marketed sold us pursuant alliance could material results operations loss cash flows caused loss rights could material financial condition liquidity alliance agreements may structured terminate specific dates upon product 's patent expiration date without expiry date profit sharing payments typically expiration date royalty payments cease upon loe including patent expiration refer item financial statements supplementary datanote alliances information significant alliance agreements well alliance agreements marketing distribution customers promote appropriate use products directly healthcare professionals organizations doctors nurse practitioners physician assistants pharmacists technologists hospitals pbms mcos also provide information appropriate use products consumers us directtoconsumer print radio television digital advertising promotion addition sponsor general advertising educate public innovative medical research corporate mission discussion regulation promotion marketing pharmaceuticals refer government regulation field sales medical organizations explain risks benefits approved uses products medical professionals work gain access products formularies reimbursement plans lists recommended approved medicines products including medicare part plans providing information clinical profiles products marketing sales prescription pharmaceuticals limited approved uses particular product continue develop scientific data information potential additional uses products provide information scientific exchange scientific congresses share information products appropriate ways including development publications response unsolicited inquiries doctors medical professionals mcos operations include several marketing sales organizations product marketing organization supported sales force may responsible selling one products also marketing organizations focus certain classes customers managed care entities certain types marketing tools digital consumer communications sales forces focus communicating information new approved products uses well approved uses established products promotion physicians increasingly targeted physician specialists treat patients need medicines products sold principally wholesalers specialty distributors specialty pharmacies lesser extent directly distributors retailers hospitals clinics government agencies revlimid pomalyst distributed united states primarily contracted pharmacies revlimid rems pomalyst rems programs respectively proprietary mandatory riskmanagement distribution programs tailored specifically provide safe appropriate distribution use revlimid pomalyst internationally revlimid imnovid distributed mandatory riskmanagement distribution programs tailored meet local authorities specifications provide products safe appropriate distribution use programs may vary country depending upon country design riskmanagement program product may sold hospitals retail pharmacies refer item financial statements supplementary datanote revenue gross revenues three largest pharmaceutical wholesalers us percentage global gross revenues us business dsas substantially direct wholesaler distributor customers allow us monitor us wholesaler distributor inventory levels requires wholesalers distributors maintain inventory levels one month demand dsas including three largest wholesalers expire march subject certain termination provisions nonus businesses significantly direct customers information available direct customer product level inventory corresponding movement information reliability thirdparty demand information varies widely limit direct customer sales channel inventory reporting reliably gather report inventory levels customers number countries outside us contract distributors support certain products services provided distributors vary market may include distribution logistics regulatory pharmacovigilance andor sales advertising promotion competition markets compete generally broad based highly competitive compete worldwide researchbased drug companies many smaller research companies limited therapeutic focus generic drug manufacturers important competitive factors include product efficacy safety ease use price demonstrated costeffectiveness marketing effectiveness product labeling customer service rd new products processes sales products impacted new studies indicate competitors product safer effective treating disease particular form disease one products revenues also impacted additional labeling requirements relating safety convenience may imposed products fda similar regulatory agencies different countries competitors introduce new products processes therapeutic cost advantages products subject progressive price reductions decreased volume sales advancements treating cancer io therapies continue evolve rapid pace io products particularly opdivo operate highly competitive marketplace addition competing market share io products approved indications lung cancer melanoma face increased competition existing competing io products receive fda approval additional indications new io agents receive fda approval enter market furthermore therapies combining different io products io products existing chemotherapy targeted therapy treatments investigated potential expanded approvals anticipate io products continue experience intense competition another competitive challenge face generic pharmaceutical manufacturers us eu regulatory approval process exempts generics costly timeconsuming clinical studies demonstrate safety efficacy allowing generic manufacturers rely safety efficacy innovator product result generic pharmaceutical manufacturers typically invest far less rd researchbased pharmaceutical companies therefore price products significantly lower branded products accordingly branded product loses market exclusivity normally faces intense price competition generic forms product upon expiration loss market exclusivity product lose major portion product 's revenue short period time expiration exclusivity rate revenue decline product varies country general decline us market rapid developed countries though observed rapid declines number eu countries well also declines developed countries tend rapid developing countries rate revenue decline expiration exclusivity also historically influenced product characteristics example drugs used large patient population eg prescribed key primary care physicians tend experience rapid declines drugs specialized areas medicine eg oncology drugs complex manufacture eg sterile injectable products usually experience slower decline simpler manufacture certain countries outside us patent protection weak nonexistent must compete generic versions shortly launch innovative products addition generic pharmaceutical companies may introduce generic product exclusivity expired resolution related patent litigation information market exclusivity refer products intellectual property product exclusivity believe longterm competitive position depends upon success discovering developing innovative costeffective products serve unmet medical needs along ability manufacture products efficiently market effectively highly competitive environment pricing price constraints market access medicines priced based number factors including value scientific innovation patients society context overall health care spend economic factors impacting health care systems ability provide appropriate sustainable access necessity sustain investment innovation platforms address serious unmet medical needs central price clinical value innovation brings market current landscape alternative treatment options goals ensuring appropriate patient access innovation sustaining investment creative platforms continue explore new pricing approaches ensure patients access medicines enhancing patient access medicines priority us focused offering creative tiered pricing reimbursement support patient assistance programs optimize access protecting innovation advocating sustainable healthcare policies infrastructure leveraging advocacypayers input utilizing partnerships appropriate improving access care supportive services vulnerable patients partnerships demonstration projects important factor pricing medicines depends government regulation subject increasing international domestic efforts various governments implement strengthen measures regulate pharmaceutical market access product pricing payment us required provide discounts purchases pharmaceutical products various federal state healthcare programs federal government officials legislators continue face intense pressure public manage perceived high cost pharmaceuticals responded pursuing legislation rules claim would reduce cost drugs federal government stakeholders also required comply recently enacted state laws seek additional transparency cost prescription drugs monitoring efforts states seek additional rebates limit state spending drugs light budget pressures international federal state legislative regulatory developments could create new constraints ability set prices andor impact market access certain areas discussion pricing pressure risk refer item risk factors growth consolidation mcos pbms us optum uhc cvs health cvs express scripts esi also major factor healthcare marketplace mcos pbms consolidating fewer larger entities also enhancing purchasing strength importance us half us population participates version managed care mcos include medical insurance companies medical plan administrators healthmaintenance organizations medicare part prescription drug plans alliances hospitals physicians physician organizations pbms third parties support formulary management contracting mcos successfully compete formulary position mcos pbms must often demonstrate products offer medical benefits also cost advantages compared forms care exclusion product formulary lead sharply reduced usage patient populations consequently pharmaceutical companies compete aggressively products included new products introduce compete products already market products later developed competitors possible companies compete inclusion based upon unique features products greater efficacy better patient ease use fewer side effects lower overall cost therapy also important factor products demonstrate fewer therapeutic advantages must compete inclusion based primarily price generally although universally successful major products included mco pbm formularies many markets outside us operate environment governmentmandated costcontainment programs markets significant portion funding healthcare services determination pricing reimbursement pharmaceutical products subject either direct government control point care governments significant power large single payers result products may face restricted access public private payers may subject assessments comparative value effectiveness existing standard care several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs andor enacted acrosstheboard price cuts rebate schemes methods cost control eu countries example government regulates pricing new product launch often direct price controls international price comparisons controlling profits andor reference pricing eu markets germany government set pricing restrictions launch pricing freedom subsequently limited companies may also face significant delays market access new products year elapse new medicines become available patients market additionally member states eu regularly imposed new additional cost containment measures pharmaceuticals volume discounts cost caps cost sharing increases excess prior year costs individual products aggregated market level spending outcomebased pricing schemes free products portion expected therapy period existence price differentials within eu due different national pricing reimbursement laws leads significant parallel trade flows government regulation pharmaceutical industry subject extensive global regulations regional country state local agencies federal food drug cosmetic act federal statutes regulations various state statutes regulations including newly enacted state laws regulating drug price transparency rebates drug spending laws regulations foreign governments govern varying degrees testing approval production labeling distribution postmarket surveillance advertising dissemination information promotion products lengthy process laboratory clinical testing data analysis manufacturing development regulatory review necessary required governmental approvals extremely costly significantly delay product introductions given market promotion marketing manufacturing distribution pharmaceutical products extensively regulated major world markets addition operations subject complex federal state local foreign environmental occupational safety laws regulations anticipate laws regulations affecting manufacture sale current products introduction new products continue require substantial scientific technical effort time expense well significant capital investments fda particular importance us jurisdiction virtually activities imposes requirements covering testing safety effectiveness manufacturing labeling marketing advertising postmarketing surveillance products many cases fda requirements increased amount time money necessary develop new products bring market us regulatory review process resource intensive undertaking fda pharmaceutical manufacturer improvements efficiency process significant impact bringing new therapies patients quickly fda employ several tools facilitate development certain drugs expedite certain applications including fast track designation breakthrough therapy designation priority review accelerated approval incentives orphan drugs developed rare diseases others example recent years fda oncology center excellence oce established two projects test novel approaches efficient regulatory review oncology drugs realtime oncology review pilot program assessment aid assessment aid pilot program fda approved opdivoyervoy given two cycles platinumdoublet chemotherapy may firstline treatment adult patients metastatic recurrent nsclc egfr alk genomic tumor aberrations approval achieved two months priority review pdufa date august develop framework concurrent review supplemental oncology applications among multiple approval authorities oce initiated project orbis project orbis earlier approvals australian therapeutic goods administration tga health canada singapore health sciences authority received combination opdivoyervoy given two cycles platinumdoublet chemotherapy fda mandates drugs manufactured packaged labeled conformity cgmp established fda complying cgmp regulations manufacturers must continue expend time money effort production recordkeeping quality control ensure products meet applicable specifications requirements ensure product safety efficacy fda periodically inspects drug manufacturing facilities ensure compliance applicable cgmp requirements failure comply statutory regulatory requirements subjects us possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse events use products must reported fda could result imposition market restrictions labeling changes product removal product approvals may withdrawn compliance regulatory requirements maintained problems concerning safety efficacy occur following approval federal government extensive enforcement powers activities pharmaceutical manufacturers including authority withdraw delay product approvals commence actions seize prohibit sale unapproved noncomplying products halt manufacturing operations compliance cgmps impose seek injunctions voluntary recalls civil monetary criminal penalties restriction prohibition sales withdrawal approval products marketed us could materially adversely affect business financial condition results operations cash flows marketing authorization products subject revocation applicable governmental agencies addition modifications enhancements approved products changes manufacturing locations many circumstances subject additional fda approvals may may received may subject lengthy application process distribution pharmaceutical products subject pdma part federal food drug cosmetic act regulates activities federal state level pdma implementing regulations states permitted require registration manufacturers distributors provide pharmaceuticals even manufacturers distributors place business within state states also permitted adopt regulations limiting distribution product samples licensed practitioners pdma also imposes extensive licensing personnel recordkeeping packaging quantity labeling product handling facility storage security requirements intended prevent sale pharmaceutical product samples product diversions fda amendments act imposed additional obligations pharmaceutical companies delegated enforcement authority fda area drug safety key elements legislation give fda authority require companies conduct postmarketing safety studies drugs ii impose certain safety related drug labeling changes iii mandate risk mitigation measures education healthcare providers restricted distribution medicines iv require companies publicly disclose data clinical studies v prereview television advertisements marketing practices us pharmaceutical manufacturers subject federal state healthcare laws used protect integrity government healthcare programs office inspector general oig oversees compliance applicable federal laws connection payment products government funded programs primarily medicaid medicare laws include federal antikickback statute criminalizes knowingly offering something value induce recommendation order purchase products services reimbursed government healthcare program oig issued series guidances segments healthcare industry including compliance program guidance pharmaceutical manufacturers includes recommendation pharmaceutical manufacturers minimum adhere phrma code voluntary industry code marketing practices subscribe phrma code implemented compliance program address requirements set forth guidance compliance healthcare laws failure comply healthcare laws could subject us administrative legal proceedings including actions federal state government agencies actions could result imposition civil criminal sanctions may include fines penalties injunctive remedies impact could materially adversely affect business financial condition results operations cash flows also subject jurisdiction various federal state regulatory enforcement departments agencies federal trade commission department justice department health human services us also licensed us drug enforcement administration procure produce controlled substances therefore subject possible administrative legal proceedings actions organizations actions may result imposition civil criminal sanctions may include fines penalties injunctive administrative remedies us healthcare industry subject various governmentimposed regulations authorizing prices price controls continue impact total revenues participate state government medicaid programs well certain qualifying federal state government programs whereby discounts rebates provided participating state local government entities also participate federal government programs specify discounts certain federal government entities significant us department defense us department veterans affairs entities receive minimum discounts based defined nonfederal average manufacturer price purchases result hr affordable care act reconciliation bill containing package changes healthcare bill continue experience additional financial costs certain changes business example required provide discount brandname drugs patients fall within medicare part coverage gap also referred donut hole pay annual nontaxdeductible fee federal government based allocation market share branded drug sales certain government programs including medicare medicaid department veterans affairs department defense tricare amount annual fee imposed pharmaceutical manufacturers whole billion thereafter activities outside us also subject regulatory requirements governing testing approval safety effectiveness manufacturing labeling marketing products regulatory requirements vary country country whether fda ec approval obtained product approval product comparable regulatory authorities countries outside us eu case may must obtained prior marketing product countries approval process may less rigorous country country time required approval may longer shorter required us approval one country assure product approved another country discussion rebates programs refer item managements discussion analysis financial condition results operations gtn adjustments critical accounting policies sources availability raw materials general purchase raw materials components supplies required production products open market products purchase raw materials components supplies one source source available us single source approved source among many available us thereby requiring us obtain raw materials supplies particular source attempt possible mitigate potential risk associated raw materials components supplies inventory management alternative sourcing strategies discussion sourcing refer manufacturing quality assurance discussions particular products manufacturing quality operate manage manufacturing network consisting internal external resources manner permits us improve efficiency maintaining flexibility reallocate manufacturing capacity pharmaceutical manufacturing processes complex highly regulated vary widely product product given shifting adding manufacturing capacity lengthy process requiring significant capital expenditures well regulatory approvals manage operate flexible manufacturing network minimizes unnecessary product transfers inefficient uses manufacturing capacity discussion regulatory impact manufacturing refer government regulation significant biologics cell therapy pharmaceutical manufacturing facilities located us puerto rico ireland switzerland require significant ongoing capital investment maintenance compliance increasing regulatory requirements example fda approved large scale multi product bulk biologics manufacturing facility devens massachusetts may continue make capital investments facility addition expect continue modification existing manufacturing network meet complex processing standards required growing portfolio particularly biologics cell therapy biologics manufacturing involves complex processes traditional pharmaceutical operations example completed new largescale biologics manufacturing facility cruiserath ireland approved fda december eu january cellular therapy product candidates including breyanzi lisocel idecel invested manufacturing network including facilities bothell washington summit new jersey well thirdparty manufacturers beyond regulatory requirements many products involve technically sophisticated manufacturing processes require specialized raw materials example manufacture clinical commercial use several sterile products biologic products cart products particularly complex involve highly specialized manufacturing technologies result even slight deviations point production process may lead production failures recalls addition manufacturing sites rely third parties manufacture supply us portion active product ingredient drug substance necessary us manufacture various products opdivo eliquis sprycel yervoy baraclude reyataz reblozyl inrebic abraxane pomalystimnovid sustiva franchise also expanding use thirdparty manufacturers drug product finished goods manufacturing continue shift towards using thirdparty manufacturers supply established brands respect revlimid thalomid operate manufacturing facility zofingen switzerland produce active product ingredient revlimid thalomid contract thirdparty manufacturer provide backup active product ingredient revlimid thalomid maintain stable supply products take variety actions including inventory management maintenance additional quantities materials possible designed provide reasonable level ingredients held thirdparty supplier us manufacturing operations interrupted certain supply arrangements extend multiple years committed amounts using expected near longterm demand requirements subject change additional protection cases take steps maintain approved backup source available needed example capability manufacture opdivo internally arrangements thirdparty manufacturers meet demand connection acquisitions divestitures licensing collaboration arrangements distribution agreements certain products certain circumstances entered agreements agreed supply products third parties intend continue enter arrangements agreements future addition liabilities could arise failure supply products agreements arrangements agreements could require us invest facilities manufacturing nonstrategic products case divestiture distribution arrangement resulting additional regulatory filings obligations causing interruption manufacturing strategic products success depends great measure upon customer confidence quality products integrity data support safety effectiveness product quality arises total commitment quality parts operations including research development purchasing facilities maintenance planning manufacturing warehousing logistics distribution maintain records demonstrate quality integrity data technical information production processes control production processes involves established specifications standards raw materials components ingredients equipment facilities manufacturing methods operations packaging materials labeling perform tests various stages production processes raw materials drug substance final product product samples held stability ensure product meets regulatory requirements conforms standards tests may involve chemical physical analyses microbiological testing combination along analyses quality control testing provided business unitsite thirdparty laboratories quality assurance groups routinely monitor manufacturing procedures systems used us subsidiaries thirdparty suppliers ensure quality compliance requirements met environmental regulation facilities operations subject extensive us foreign laws regulations relating environmental protection human health safety including governing discharges pollutants air water use management disposal hazardous radioactive biological materials wastes cleanup contamination pollution controls permits required many operations permits subject modification renewal revocation issuing authorities environment health safety group monitors operations around world providing us overview regulatory requirements overseeing implementation standards compliance also incur operating capital costs matters ongoing basis material addition invested projects reduce resource use energy water although believe substantial compliance applicable environmental health safety requirements permits required operations nevertheless could incur additional costs including civil criminal fines penalties cleanup costs thirdparty claims property damage personal injury violations liabilities laws many current former facilities operation many years time operators facilities generated used stored disposed substances wastes considered hazardous federal state andor foreign environmental laws including cercla result soil groundwater certain facilities may contaminated may required make significant expenditures investigate control remediate contamination cases provide compensation andor restoration damages natural resources currently involved investigation remediation current former facilities also identified prp applicable laws environmental conditions approximately former waste disposal reprocessing facilities operated third parties investigation andor remediation activities ongoing may face liability cercla federal state foreign laws entire cost investigation remediation contaminated sites natural resource damages regardless fault ownership time disposal release addition certain sites bear remediation responsibility pursuant contractual obligations generally thirdparty operator sites involving multiple prps liability expected apportioned based nature amount hazardous substances disposed party site number financially viable prps additional information matters refer item financial statements supplementary datanote legal proceedings contingencies human capital management resources believe employees around world embody mission discover develop deliver innovative medicines help patients prevail serious diseases together unyielding focus patients defines culture demographics december approximately employees countries approximately employees located us excluding puerto rico located outside us supplement employee population independent contractors contingent workers temporary workforce support needed average tenure employees approximately eight years people strategy people heart soul globally unified culture people strategy designed inspire individuals encourage teams work together patients communities invest workforce extensive programs policies initiatives described accelerate personal development collaboration service patients believe investments competitive advantage recruiting future workforce accelerate innovation strive match diverse knowledge skills capabilities talented employee community business needs following programs policies initiatives encompass objectives measures continue focus part people strategy diversity equity inclusion culture inclusion foster diverse mosaic people seek mirror patients communities worldwide create agile responsive work environment diversity people unique perspectives experiences help us achieve patientfocused mission business objectives believe inclusive culture encourages pursue innovative ideas develop leadership capabilities gain valuable experiences shape exciting careers implemented measures provide accountability continually increasing diversity commitment attracting diverse talent includes training workforce diversity sourcing strategies partnering external local national organizations develop supply diverse talent united negro college fund inc prospanica ascend inc women color pharma ongoing investment people business resource groups pbrgs represent one key lever use support acquisition development retention diverse talent business objectives career advancement development needs employees maintain pbrg chapters worldwide members network learn skills participate learning development events contribute business objectives tangible way pbrgs sponsored members leadership team led fulltime dedicated leader reports directly member leadership team pbrgs include black organization leadership development bristol myers squibb network women cultivating leadership innovation millennials beyond differentlyabled workplace network pride alliance organization latino achievement pan asian network veterans community network bms bristol myers squibb foundation announced august combined investment million part series commitments designed address health disparities increase clinical trial diversity increase amount business diverse suppliers announced intend expand diversity workforce leadership doubling blackafrican american hispaniclatino representation executive levels us end increasing representation women also remains area focus management committed achieving gender parity executive level globally end already achieved gender parity global bms employee population career growth development offer broad range professional training education career advancement leadership development employees programs designed help employees find purpose pursue passions achieve aspirations accelerate business performance stimulating work assignments structured learning opportunities pbrg sponsored programs diverse work experiences employees access expansive library resources covering wide range special interest topics multiple languages variety top learning development resources million learning activities completed employees consultants partners committed cultivating growth managers senior leaders virtual inclassroom learning new experienced managers senior leaders tuition reimbursement available globally eligible employees initiation desire development participate accredited educational programs employees encouraged take stretch assignments maximize learning experience employee engagement also routinely conduct confidential employee engagement surveys global workforce provide feedback employee satisfaction engagement cover variety topics company culture values execution strategy diversity inclusion individual development among others survey results reviewed executive officers board directors analyze areas progress opportunity company level well function level individual managers use survey results implement actions activities intended increase wellbeing employees believe employee engagement initiatives competitive pay benefit programs career growth development opportunities help increase employee satisfaction tenure reduce voluntary turnover total rewards provide highly competitive benefits compensation work life offerings reflect total rewards strategy enable empower energy talent workforce deliver business strategy transform patients ' lives science competitive pay benefit program aim attract retain incentivize diverse talented employees executives capable thriving leading business highly complex competitive environment benefits plans programs necessarily vary country include us choices health coverage including medical pharmacy dental vision pretax savings spending accounts financial protections life insurance supplemental health insurance personal coverage protections financial savings wellbeing highly competitive k savings plan financial well services similarly us work life offerings encourage growth wellbeing recognition tuition reimbursement living life better wellbeing platform bravo global recognition program encouraging team peer peer individual recognition aligned values onsite fitness centers select locations employee assistance program provide support welcoming nurturing family members paid parental leave care new child bridge back parent leave ease transition new parents back work adoptionsurrogacy reimbursement fertilityinfertility benefits support traveling mothers paid family care leave assist employees managing life workday beyond child elder pet care resources commuter accounts paid sick time provide employees opportunities recharge give back communities vacation holidays annual paid volunteer days paid bereavement leave paid military leave paid military family care leave addition offer market competitivebase salaries part overall total rewards package annual incentives recognize reward company performance well individual results longterm equity incentives spurs employees ' focus longterm value creation respect executives substantial proportion pay variable atrisk based financial operational results delivered form equity supporting alignment long term executives shareholders used targeted equitybased grants vesting conditions facilitate retention critical personnel refer item management 's discussion analysis financial condition results operationseconomic market factorscovid information human capital management actions response covid pandemic foreign operations significant operations outside us conducted subsidiaries distributors international operations subject certain risks inherent conducting business abroad including limited currency fluctuations possible nationalization expropriation price exchange controls counterfeit products limitations foreign participation local enterprises restrictive governmental actions international businesses also subject governmentimposed constraints including laws pricing reimbursement use products bristolmyers squibb website internet website address wwwbmscom website make available free charge annual quarterly current reports including amendments reports soon reasonably practicable electronically file material furnish material sec pursuant section securities exchange act amended exchange act documents also available secs website wwwsecgov information relating corporate governance bristolmyers squibb including principles integrity code ethics senior financial officers code business conduct ethics directors collectively codes corporate governance guidelines information concerning executive committee board directors including board committees committee charters transactions bristolmyers squibb securities directors executive officers available website usour company leadership investors captions print stockholder upon request waivers codes directors executive officers material amendment code business conduct ethics directors code ethics senior financial officers posted promptly website information relating stockholder services including dividend reinvestment plan direct deposit dividends available website investorsshareholder services caption addition information sustainability programs available website ussustainability caption foregoing information regarding website content convenience information contained connected website deemed incorporated reference filed sec incorporate reference certain information parts definitive proxy statement annual meeting shareholders proxy statement sec allows us disclose important information referring manner please refer information proxy statement available website investorssec filings caption within days end fiscal year item risk factors risks uncertainties described could significantly negatively affect business operations financial condition operating results including components financial results cash flows prospects reputation credit ratings future could cause trading price common stock decline significantly additional risks uncertainties presently known us risks currently consider immaterial could also impair business operations financial condition operating results cash flows following discussion risk factors contains forwardlooking statements discussed item managements discussion analysis financial condition results operationsspecial note regarding forwardlooking statements covid pandemic risks covid pandemic affecting business could material adverse effect us covid pandemic affecting operate business negative impact covid pandemic extends beyond assumed timelines results may worse expected full extent impact depend future developments ultimate duration severity spread covid us globally effectiveness federal state local foreign governments mitigation actions pandemics impact us global economies well factors affecting healthcare delivery medicines patients including limited discussed part iiitem managements discussion analysis financial condition results operations economic market factors quickly return normal operations among things although currently anticipate disruption supply medicines patients due covid possible could experience manufacturing supply issues due covid future would increase negative impact business results operations instance experiencing may continue experience scarcity certain raw materials components result influx covid vaccine orders receiving priority treatment vendors addition natural disaster potentially disruptive event occurs top current pandemic could deplete safety stock levels could experience manufacturing supply distribution issue started reengage inperson interactions customerfacing field personnel health care settings us number markets determine longer safe engage inperson interactions likely return remote model engagement transition could negative impact business also possible could longerlasting shift interactions field personnel health care professionals anticipated could negative impact business results operations although restarted clinical development activities continue experience delays initiation enrollment patients clinical trials may able fully mitigate delays could negatively impact timing pipeline development programs expected future revenues andor cash flows addition could experience additional delays difficulties enrolling patients clinical trials andor delays difficulties ongoing fully enrolled clinical trials could negatively impact timing pipeline development programs expected future revenues andor cash flows prolonged clinical trial delay could potentially significant negative effect business particularly new competitive products enter market clinical trial results competitors products affect value proposition product delays difficulties clinical development could also potentially lead material impairment intangible assets including approximately billion intangible assets december addition although research early development activities performed laboratories resumed suspended period time negatively impacted advancement early pipeline assets plans mitigate impact able fully mitigate breadth future pipeline opportunities could adversely affected predict reasonably estimate impact potential longterm changes healthcare industry covid example potential shift us payer channel mix due changes patient coverage current economic crisis able reliably estimate impact would results operations given highly variable uncertain situation also possible changes healthcare system could impose additional burdens clinical trials could increase costs sponsoring clinical trials lead additional delays difficulties completing clinical trials may also experience additional pricing pressures andor increased governmental regulation could face additional risks impact covid suppliers vendors outsourcing partners alliance partners third parties rely research develop manufacture commercialize copromote sell products manage certain marketing selling human resource finance business unit functional services example thirdparty providers suffer limited solvency pandemic could negatively impact operating model business possible estimate potential impact time covid pandemic increased volatility financial markets foreign currency exchanges interest rates although incurred downward adjustments equity investment fair values first quarter fair values subsequently recovered us dollar continues strengthen interest rates continue decline andor stock markets continue decline could see reduction revenues income additional charges equity investments could negative impact earnings cash flows facing could continue face potential negative consequences stemming covid pandemic including limited increased cyber threats us partners phishing social engineering malware attacks delays planned integration milestones ability collect receivables possible covid could exacerbate risks described well time predict full extent negative impact covid pandemic business financial condition results operations andor cash flows product industry operational risks increased pricing pressure restrictions us abroad continue negatively affect revenues profit margins products continue subject increasing pressures across portfolio pharmaceutical market access pricing controls discounting changes tax importation laws restrictions us eu regions around world result lower prices lower reimbursement rates smaller populations payers reimburse negatively impact revenues profit margins including impact increased pricing pressure medicare part formularies medicare part b reimbursement rates including potential implementation pilot program centers medicare medicaid services cms would among things set payment amounts physicians part b drugs based international drug prices would include top spending medicare part b single source drugs would apply many cancer medications expanded utilization b drug pricing program b well commercial formularies general ii rules practices mcos institutional governmental purchasers taking actions control costs shift cost burden manufacturers including actions could result exclusion product unfavorable placement product mco formulary iii government administrative policy changes changes laws regulations federal healthcare programs medicare medicaid government actions inquiries federal level seek amend pharmaceutical pricing reimbursement practices using international pricing indexes modifying federal antikickback statute discount safe harbor accelerating generic drug approval processes granting additional authority governmental agencies manage drug utilization negotiate drug prices including implementation regulation issued us federal government authorizing states private parties develop implement programs import certain prescription drugs canada sell us laws state level including laws enacted california vermont nevada new york focused drug cost transparency andor limiting state spending drugs iv potential impact changes us federal pharmaceutical coverage reimbursement policies practices including december final rule issued cms calculation average manufacturer price best price medicaid rebates addresses copay assistance product line extensions among topics previously issued rule addressing inclusion sales us territories calculation average manufacturer price best price beginning april v increased scrutiny drug manufacturers including additional review company celgene house oversight reform committee vi reimbursement delays vii government price erosion mechanisms across europe countries resulting deflation pharmaceutical product pricing viii increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries ix collection delays failures pay governmentfunded public hospitals outside us x impact pricing parallel trade drug importation across borders xi developments technology andor industry practices could impact reimbursement policies practices thirdparty payers xii inhibited market access due real perceived differences value propositions products compared competing products expect market access constraints pharmaceutical pricing controls discounting restrictions become acute continue negatively affect future revenues profit margins additionally early health resources services administration hrsa finalized regulation regarding b pricing methodology providing guidelines civil monetary penalties may issued knowing intentional manufacturer overcharges b covered entities effective date regulation january following effective date manufacturers found knowingly intentionally overcharged b covered entities could subject significant monetary penalties findings could also result negative publicity could harm manufacturers reputation cause business disruption december hrsa issued b drug pricing program alternative dispute resolution final rule adr final rule went effect january adr final rule establishes alternative dispute resolution adr process certain disputes including disputes overcharges duplicate discounts diversion december us department health human services hhs office general counsel released advisory opinion concluding drug manufacturers required deliver discounts b program covered outpatient drugs contract pharmacies acting agents b covered entities course past years celgene received inquiries hrsa regarding limited distribution networks revlimid pomalyst thalomid compliance b program believe complied applicable legal requirements ultimately required change sales pricing practices regard distribution drugs b program required pay penalties applicable regulations would adverse effect revenues profitability public announcement data clinical studies competitors news developments related competitors products latestage compounds may cause significant volatility stock price depending data may result adverse impact business financial condition results operations development key latestage product candidates delayed discontinued clinical study meet one primary endpoints stock price could decline significantly may adverse impact business financial condition results operations focusing efforts resources disease areas high unmet need focused portfolio investors placing heightened scrutiny products latestage compounds however experienced setbacks may continue developments clinical studies example december announced checkmate phase trial evaluating addition opdivo current standard care temozolomide radiation therapy patients newly diagnosed glioblastoma multiforme gbm methylguaninedna methyltransferase mgmt promoter methylation following surgical resection tumor meet primary endpoint overall survival os patients baseline corticosteroid use overall randomized population additionally inherited many latestage compounds well prioritized brand portfolio hematology immunology acquisition celgene may meet expectations announcement data clinical studies competitors news developments related competitors products latestage compounds opdivo continue cause significant volatility stock price depending news may result adverse impact business financial condition results operations furthermore announcement negative unexpected data discontinuation development key latestage product candidates delay anticipated timelines filing regulatory approval significant advancement competitor continue cause stock price decline significantly may adverse impact business financial condition results operations assurance data clinical studies support filings regulatory approval key product candidates may prove effective effective competing products even approved products become commercially successful approved indications indications key products approved us fdas accelerated approval program continued approval contingent upon verification description clinical benefit confirmatory trials withdrawn could lose market exclusivity product earlier expected pharmaceutical biotechnology industries majority innovative products commercial value realized market exclusivity period us countries market exclusivity expires generic versions approved marketed biosimilars introduced even competing product usually substantial rapid declines products revenues market exclusivity products based upon patent rights certain regulatory forms exclusivity scope patent rights varies country country may also dependent availability meaningful legal remedies country failure obtain maintain patent intellectual property rights limitations use loss rights could material us countries including certain eu member states basic patent protections products may exist certain countries historically offer right obtain specific types patents andor licensors file countries addition patent environment unpredictable validity enforceability patents predicted certainty addition manufacturers innovative drugs well generic drug manufacturers may able design products around owned licensed patents compete us using resulting alternative technology absent relevant patent protection product data exclusivity period expires generic alternative versions approved marketed generic biosimilar product manufacturers well groups seeking financial gain also increasingly seeking challenge patents expire could face earlierthanexpected competition products time patents covering key products likely continue subject validity enforceability noninfringement challenges patent litigations postgrant review patent office proceedings although confident strength intellectual property rights may possible generic drug companies successfully challenge rights launch generic versions drugs prior expiration intellectual property rights addition order avoid uncertainty expense litigation among reasons may decide enter settlements generic manufacturers permit generic competition prior expiration intellectual property rights example expect generic drug companies may market generic versions revlimid major european markets expiration intellectual property rights particular result patent settlements expect generic entry revlimid united kingdom beginning january various european countries supplemental protection certificate force beginning february cases manufacturers may seek regulatory approval submitting clinical study data obtain marketing approval choose launch generic product risk expiration applicable patents andor final resolution related patent litigation addition countries allowing competitors manufacture sell competing generic products negatively impacts protections afforded company lowerpriced generics biosimilars bms biologic products competing biologics could negatively impact volumes prices addition us congress us fda taken steps promote development approval generic drugs biosimilar biologics example december us congress enacted legislation intended facilitate generic companies access drug samples section consolidated appropriations act provides generic biosimilar developers private right action obtain sufficient quantities drug samples reference products manufacturer order conduct testing necessary obtain approval generic biosimilar products new law potential adverse impact business assurance particular product enjoy market exclusivity full time period appears estimates disclosed assume provide financial guidance may experience difficulties delays development commercialization new products compounds products may appear promising development fail reach market within expected optimal timeframe example receive decision bla lisocel treatment adults relapsed refractory rr large bcell lymphoma least two prior therapies december result january contingent value rights agreement dated november pursuant contingent value rights issued connection celgene transaction terminated automatically accordance terms contingent value rights longer eligible payment contingent value rights agreement addition product extensions additional indications may approved furthermore products indications approved us fdas accelerated approval program may contingent upon verification description clinical benefit confirmatory studies studies may successful example december announced withdrew opdivos indication treatment patients sclc whose disease progressed platinumbased chemotherapy least one line therapy granted accelerated approval action taken consultation us fda accordance standard procedures evaluating accelerated approvals met post marketing requirements part broader industrywide evaluation developing commercializing new compounds products involve inherent risks uncertainties including efficacy safety concerns delayed denied regulatory approvals delays challenges producing products commercial scale excessive costs manufacture products ii inability enroll patients timely completion clinical trials iii failure enter implement optimal alliances development andor commercialization new products iv failure maintain consistent scope variety promising latestage products v failure one products achieve maintain commercial viability vi changes regulatory approval processes may cause delays denials new product approvals unable predict whether changes laws regulatory policies affecting business could occur example us partial federal government shutdown halted work many federal agencies employees late december late january federal employees since returned work subsequent extended shutdown could result reductions delays us fdas activities including respect ongoing clinical programs manufacturing products product candidates product approvals regulatory approval delays especially common product expected rems required us fda address significant riskbenefit issues expect certain future key products distributed us primarily rems program inability bring product market significant delay expected approval related launch date new product could negatively impact revenues earnings addition certain acquired pipeline programs canceled believe commercial prospects reduced may recognize material noncash impairment charges programs finally losing key molecules intermediaries compound library natural manmade disaster act sabotage could negatively impact product development cycle certain novel approaches treatment diseases chimeric antigen receptor car cell therapy may present significant challenges risks us development novel approaches treatment diseases acquisition november celgenes junos car cell therapy programs including breyanzi lisocel idecel presents many new challenges risks due unique nature genetic modification patient cells ex vivo using certain viruses reengineer cells ultimately treat diseases including obtaining regulatory approval us fda regulatory agencies limited experience development cellular therapies involving genetic modification patient cells developing deploying consistent reliable processes limiting contamination engineering patients cells ex vivo infusing genetically modified cells back patient developing processes safe administration cellular therapies including longterm followup patients receiving cellular therapies sourcing additional clinical approved commercial supplies materials used manufacture process potential car products use reengineered cells potential cancer treatment recent development may broadly accepted regulatory patient medical communities may able satisfactorily establish safety efficacy reliability therapies health authority approval demonstrate potential advantages side effects compared existing future therapies regulatory requirements governing gene cell therapy products changed frequently may continue change future furthermore certain payment models could impact interest appropriate treatment sites administering car cell therapies thereby limiting patient access date products involve genetic modification patient cells approved commercial sale moreover safety profiles cellular therapies may adversely influence public perception may adversely influence willingness subjects participate clinical trials approved physicians payers subscribe novel treatment approaches fail overcome challenges significant adverse events reported similar therapies development novel treatment approaches may hampered delayed could adversely affect future anticipated revenues andor profitability related therapeutic programs face intense competition manufacturers bms dependent market access uptake expansion marketed brands new product introductions new indications product extensions copromotional activities alliance partners deliver future growth competition keen includes lowerpriced generics increasingly aggressive generic commercialization tactics ii new competitive products entering market particularly io iii lower prices companies products real perceived superior efficacy benefit safety risk profiles differentiating factors iv technological advances patents attained competitors v clinical study results products competitors products affect value proposition products vi business combinations among competitors major thirdparty payers vii competing interests external partnerships develop bring new products markets unable compete successfully competitors products marketplace could material negative impact revenues earnings could experience difficulties delays disruptions manufacturing distribution sale products product supply related patient access could future negatively impacted difficulties delays disruptions manufacturing distribution sale products difficulties delays disruptions include product seizures recalls forced closings manufacturing plants ii failure failure vendors suppliers comply cgmp applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing iii manufacturing quality assurancequality control supply problems governmental approval delays iv failure supplier including sole source single source suppliers provide us necessary raw materials supplies finished goods within reasonable timeframe required quality v failure thirdparty manufacturer supply us bulk active finished product time vi construction regulatory approval delays new facilities expansion existing facilities including intended support future demand biologics products opdivo vii failure meet new emerging regulations requiring products tracked throughout distribution channels using unique identifiers verify authenticity supply chain viii manufacturing distribution issues including limits manufacturing capacity changes types products produced biologics physical limitations business interruptions ix disruption supply chain continuity including natural disasters hurricanes global disease outbreaks covid acts war terrorism external factors control impacting one facilities critical supplier addition limited experience manufacturing car cell therapies processes may complicated expensive approaches taken current future competitors ability source raw materials supplies used manufacture car cell therapies develop consistent reliable manufacturing processes distribution networks attractive cost goods could impact future anticipated revenue gross profit car cell therapies addition may face challenges sourcing raw materials supplies clinical approved commercial manufacturing logistical shipment delays factors control could prevent delay delivery product candidates patients additionally required maintain complex chain identity custody respect patient material material enters moves manufacturing process result even slight deviations point production process car cell therapies material used car cell therapies could result loss product regulatory remedial action could adversely affect future anticipated revenues andor profitability related car cell therapies may encounter difficulties integrating celgenes businesses operations therefore may fully realize projected benefits acquisition celgene ultimate success acquisition celgene ability realize anticipated benefits acquisition including expected cost savings avoidance synergies innovation opportunities operational efficiencies depends among things effective integrating bristol myers squibb celgene operations products employees process integrating large number manufacturing operational administrative systems achieve consistency throughout combined company including respect human capital management portfolio rationalization finance accounting systems sales operations product distribution pricing systems methodologies cybersecurity systems compliance programs internal controls processes integration complex costly timeconsuming process difficulties integration operations occur could adversely affect business including among ways causing failure meet demand products adversely affect ability meet financial reporting obligations inconsistencies standards controls procedures policies may adversely affect ability maintain relationships customers suppliers distributors alliance partners creditors clinical trial investigators managers clinical trials unable successfully combine businesses efficient costeffective manner within anticipated timeframe projected benefits cost savings may realized fully may take longer realize expected business may unable grow planned could materially impact business cash flow financial condition results operations well adversely impact share price integration process may also result significant expenses charges cash noncash attention certain members management resources times focused integration businesses two companies diverted daytoday business operations may disrupt ongoing business events outside control including changes regulation laws well economic trends also could adversely affect ability realize expected benefits acquisition regulatory intellectual property litigation tax legal compliance risks litigation claiming infringement intellectual property may adversely affect future revenues operating earnings certain subsidiaries future may involved various legal proceedings including patent litigation claims patents invalid unenforceable andor cover product generic drug manufacturer third parties seek damages andor injunctive relief compensate alleged infringement patents commercial activities resolving intellectual property infringement claim costly time consuming may require us enter license agreements may available commercially reasonable terms successful claim patent intellectual property infringement could subject us significant damages injunction preventing manufacture sale use affected product products events could material adverse effect profitability financial condition adverse outcomes legal matters could negatively affect business current future lawsuits claims proceedings government investigations could preclude delay commercialization products could adversely affect operations profitability liquidity financial condition possible insurance recoveries available legal matters include intellectual property disputes ii adverse decisions litigation including product liability consumer protection commercial cases iii antibribery regulations us foreign corrupt practices act uk bribery act including compliance ongoing reporting obligations government resulting settlements iv recalls withdrawals pharmaceutical products forced closings manufacturing plants v alleged failure fulfill obligations supply contracts government customers agreements relating business vi product pricing promotional matters vii lawsuits claims asserting investigations violations securities antitrust federal state pricing consumer protection data privacy laws regulations viii environmental health safety sustainability matters ix tax liabilities resulting assessments tax authorities subject variety us international laws regulations currently subject number government laws regulations future could become subject new government laws regulations costs compliance laws regulations negative results noncompliance could adversely affect business operating results financial condition company include new healthcare reform initiatives us countries including pharmaceutical market access pricing controls discounting changes tax importation laws restrictions ii judicial governmental decisions affecting pricing drug reimbursement receivable payments access marketing within across jurisdictions iii changes intellectual property law iv changes respect us fda compliance manufacturing products especially concerning good practice guidelines regulations v changes accounting standards vi new increasing data privacy regulations enforcement particularly eu us vii emerging new global regulatory requirements reporting payments value transfers healthcare professionals viii potential impact importation restrictions legislative andor regulatory changes addition us healthcare industry highly regulated subject frequent substantial changes example us fda indicated undertaking industrywide review indications received accelerated approval confirmatory studies meet primary endpoints specific company december announced withdrew opdivos indication treatment patients sclc whose disease progressed platinumbased chemotherapy least one line therapy granted accelerated approval action taken consultation us fda accordance standard procedures evaluating accelerated approvals met postmarketing requirements part broader industrywide evaluation also anticipate continued us congressional interest modifying provisions affordable care act particularly given ruling texas v azar invalidate law unconstitutional revenues generate health insurance exchanges medicaid expansion affordable care act material impact change law similar recent administration actions expected limited future replacement modification repeal affordable care act may adversely affect business financial results particularly legislation reduces incentives employersponsored insurance coverage predict future federal state legislative administrative changes relating healthcare reform affect business changes tax regulations could negatively impact earnings subject income taxes us various countries globally particular although passage tax cuts jobs act reduced us tax rate law complex regulations interpretations still issued could face audit challenges apply new law could negative impact provision income taxes addition future earnings could negatively impacted changes tax legislation including repeal modification tax cuts jobs act changes tax rates tax base limiting phasingout eliminating deductions tax credits increase taxing certain excess income intellectual property revising tax law interpretations domestic foreign jurisdictions changes rules earnings repatriations changes tax laws us countries failure third parties meet contractual regulatory obligations could adversely affect business rely suppliers vendors outsourcing partners alliance partners third parties research develop manufacture commercialize co promote sell products manage certain marketing human resource finance business unit functional services meet contractual regulatory obligations using third parties poses number risks may perform standards legal requirements example relation outsourcing significant clinical development activities innovative medicines contract research organizations ii may produce reliable results iii may perform timely manner iv may maintain confidentiality proprietary information v may incur significant cyberattack business disruption vi may subject government orders mandates require give priority government set aside preexisting commercial orders vii disputes may arise respect ownership rights technology developed partners viii disagreements could cause delays termination research development commercialization product result litigation arbitration moreover third parties located markets subject political social risks corruption infrastructure problems natural disasters addition country specific privacy data security risks given current legal regulatory environments failure critical third party meet obligations including future royalty milestone payments adequately deploy business continuity plans event crisis andor satisfactorily resolve significant disagreements us address factors could material adverse impact operations results addition third parties violate alleged violated laws regulations including local pharmaceutical code us foreign corrupt practice act uk bribery act eus general data protection regulation similar laws regulations performance obligations us possible could suffer financial reputational harm negative outcomes including possible legal consequences product labeling changes marketed products could result negative impact revenues profit margins regulatory authorities may need change labeling pharmaceutical product including product marketed several years changes often result additional data postmarketing studies headtohead studies adverse events reports studies identify biomarkers objective characteristics indicate particular response product therapy studies postmarketing experience produce important additional information product new information added products label affect riskbenefit profile leading potential recalls withdrawals declining revenue well product liability claims sometimes additional information studies identifies portion patient population may nonresponsive medicine would higher risk adverse reactions labeling changes based studies may limit patient population studies providing additional information may sponsored us could also sponsored competitors insurance companies government institutions mcos scientists investigators interested parties additional safety efficacy information studies assist us healthcare providers identifying best patient population product also negatively impact revenues due inventory returns limited patient population going forward additionally certain study results especially headtohead studies could affect products formulary listing could also adversely affect revenues illegal distribution sale third parties counterfeit unregistered versions products stolen products could negative impact revenues earnings reputation business third parties may illegally distribute sell counterfeit versions products meet rigorous manufacturing testing standards patient receives counterfeit drug product diverted authorized market may risk number dangerous health consequences reputation business could suffer harm result counterfeit drugs sold brand name diverted products thefts inventory warehouses plants intransit properly stored later sold unauthorized channels could adversely impact patient safety reputation business addition diversion products authorized market channels may result reduced revenues negatively affect profitability increased use social media platforms present risks challenges increasing use social media communicate company news events inappropriate andor unauthorized use certain media vehicles could cause brand damage information leakage could lead legal implications including improper collection andor dissemination personally identifiable information employees patients healthcare professionals stakeholders addition negative inaccurate posts comments us social networking website could damage reputation brand image goodwill disclosure nonpublic companysensitive information workforce others whether intentional unintentional external media channels could lead information loss information technology cybersecurity risks dependent information technology systems infrastructure face certain risks including cybersecurity breaches data leakage rely extensively information technology systems networks services including internet sites data hosting processing facilities tools physical security systems hardware software technical applications platforms managed hosted provided andor used thirdparties vendors assist conducting business significant breakdown invasion corruption destruction interruption critical information technology systems infrastructure workforce others authorized access systems unauthorized persons could negatively impact operations everincreasing use evolution technology including cloudbased computing creates opportunities unintentional dissemination intentional destruction confidential information stored thirdparty providers systems portable media storage devices could also experience business interruption theft confidential information reputational damage industrial espionage attacks malware cyberattacks may compromise system infrastructure lead data leakage either internally thirdparty providers although aggregate impact operations financial condition material date target events nature expect continue cybersecurity threats rapidly evolving sophistication becoming prevalent industry invested industry appropriate protections monitoring practices data reduce risks continue monitor systems ongoing basis current potential threats maintain cyber insurance insurance may however sufficient cover financial legal business reputational losses may result interruption breach systems assurance continuing efforts prevent breakdowns breaches thirdparty providers databases systems could adversely affect business strategic business development employee attraction retention risks failure execute business strategy could adversely impact growth profitability strategy focused delivering innovative transformational medicines patients focused set disease areas unable successfully execute strategy could negatively impact future results operations market capitalization connection strategy process integrating celgene myokardia ability successfully integrate celgene myokardia could impact results operations able achieve cost savings expect could negatively impact operating margin earnings results addition may unable consistently maintain adequate pipeline internal rd programs transactions third parties support future revenue growth competition among pharmaceutical companies acquisition product licensing opportunities intense may able locate suitable acquisition targets licensing partners reasonable prices successfully execute transactions unable support grow marketed products successfully execute launches newly approved products advance latestage pipeline manage change operating model evolution manage costs effectively operating results financial condition could negatively impacted depend several key products revenues cash flows earnings derive majority revenue earnings several key products prioritized brands comprised approximately revenues expect revlimid eliquis opdivo pomalystimnovid represent significant percentage revenue earnings cash flows reduction revenue products could adversely impact earnings cash flows also one major products become subject issues loss patent protection significant changes demand formulary access changes material product liability unexpected side effects regulatory proceedings negative publicity supply disruption manufacturing operations thirdparty supplier significant advancement competing products may incur adverse impact business financial condition results operations trading price stock thirdparty royalties represent significant percentage pretax income operating cash flow entered several arrangements entitle us potential royalties third parties outlicensed intellectual property commercialization rights salesbased contingent proceeds related divestiture businesses many arrangements minimal continuing involvement contribute financial success activities royalties continued represent significant percentage pretax income including royalties related divestiture diabetes business including transfer certain future royalty rights pertaining amylin onglyza farxiga product sales outlicensed intellectual property merck patent infringement settlement pretax income generated royalties approximately billion pretax income could adversely affected royalty streams decline future periods failure effectively manage acquisitions divestitures alliances portfolio actions could adversely impact future results addition businesses assets acquire future may underperform may able successfully integrate existing business occurrence number unexpected factors could prevent substantially delay consummation anticipated acquisition divestiture merger acquired inlicensed number assets although committed reducing debt expect continue support pipeline compounds products obtained licensing acquisitions future revenues profits cash flows acquired companys products technologies pipeline candidates may materialize due low product uptake delayed missed pipeline opportunities inability capture expected synergies resulting cost savings avoidance increased competition safety concerns regulatory issues supply chain problems factors beyond control substantial difficulties costs delays could result integrating acquisitions including rd manufacturing distribution sales marketing promotion information technology activities ii policies procedures processes controls compliance iii tax considerations acquire debt equity securities part consideration business development activities connection joint venture value securities fluctuate may depreciate value may control company acquire securities connection collaborative arrangement result limited ability determine management operational decisions internal controls compliance policies result additional financial reputational risks may successful separating underperforming nonstrategic assets gains losses divestiture lost operating income assets may affect earnings divestitures also may result continued financial exposure divested businesses guarantees financial arrangements continued supply services arrangements potential litigation following transaction arrangements nonperformance us could result obligations imposed us could material adverse effect competitive position cash flows results operations financial condition reputation particular divested otezla connection obtaining regulatory approval acquisition celgene ftc determines violated consent order agreed connection divestiture ftc may seek civil penalty reputation may adversely affected might incur asset impairment charges related acquisitions divestitures reduce earnings value allocated certain assets could substantially impaired due number factors beyond control new revised accounting standards rules interpretations could result changes recognition income expense may materially adversely affect financial results execution implementation acquisitions divestitures alliances joint ventures portfolio actions successful could adversely impact financial condition cash flows results operations moreover due substantial amount debt incurred finance cash portion celgene myokardia acquisitions assurance able expand business development capacity pursuing opportunities may require us obtain additional equity debt financing could result increased leverage andor downgrade credit ratings failure attract retain highly qualified workforce could affect ability successfully develop commercialize products success largely dependent continued ability attract retain highly qualified scientific technical management workforce including people expertise clinical rd governmental regulation commercialization connection celgene acquisition integrate two unique corporate cultures maintain employee morale competition qualified talent biopharmaceutical field intense sure able retain quality talent bristol myers squibb celgene costs materially increase market liquidity credit risks significant additional indebtedness incurred connection celgene myokardia acquisitions issuance additional shares connection celgene acquisition could negative consequences acquisitions celgene myokardia increased amount debt resulting additional interest expense additional cash required dividends declared due additional shares issued connection celgene acquisition factors could reduce financial flexibility continue capital investments develop new products declare future dividends adverse changes us global economic political conditions could adversely affect profitability global economic political risks pose significant challenges companys growth profitability difficult mitigate generated approximately revenues outside us revenues earnings cash flow exposed risk strengthening us dollar exposure customer credit risks europe south america markets including governmentguaranteed hospital receivables markets payments received time significant operations europe including manufacturing distribution results operations could negatively impacted member country exiting eurozone monetary union eu particular exit uk eu occurred january created uncertainties affecting business operations uk eu may impact research commercial general business operations uk eu including approval supply products may require changes legal entity structure uk eu still assessing details euuk trade cooperation agreement formally approved uk house commons december expected formally approved eu legislature march related impact uk business operations currently believe matters related financial effects material impact consolidated results operations financial position liquidity addition currently uncertainty around phase libor july united kingdom regulator regulates libor announced intention phase libor rates end however ice benchmark administration capacity administrator usdlibor announced intends extend publication usd libor oneweek twomonth tenors months june notwithstanding possible extension joint statement key regulatory authorities calls banks cease entering new contracts use usdlibor reference rate later december alternative reference rates committee steering committee comprised large us financial institutions proposed replacing usdlibor new index calculated shortterm repurchase agreements secured overnight financing rate sofr time consensus exists rate rates may become accepted alternatives libor impossible predict whether extent banks continue provide libor submissions administrator libor whether libor rates cease published supported issued variable rate debt based libor undertook interest rate swaps contain variable element based libor also entered certain agreements amended certain agreements rely sofr alternative interest rate method libor predict impact agreements amendments sofr could us although sofr appears preferred replacement rate usd libor time financial market coalesces around alternative benchmark rate method libor different sofr may need renegotiate agreements may negatively impacted renegotiated terms may adversely affect interest rates result higher borrowing costs predict addition phase replacement libor could cause disruptions credit markets leads downgrade current credit rating could increase future borrowing costs cost capital impair ability access capital credit markets terms commercially acceptable us adversely affect liquidity capital resources finally business operations may adversely affected political volatility conflicts crises individual countries regions including terrorist activities war guarantee pay dividends repurchase stock declaration amount timing dividends fall within discretion board directors boards decision depend many factors including financial condition earnings capital requirements debt service obligations industry practice legal requirements regulatory constraints factors board may deem relevant reduction elimination dividend payments dividend program could adversely affect stock price addition could time decide buy back shares market could also adversely affect stock price amended bylaws designate court chancery state delaware sole exclusive forum certain lawsuits us stockholders could limit stockholders ability obtain judicial forum finds favorable lawsuits make costly stockholders bring lawsuits may effect discouraging lawsuits amended bylaws provide unless consent writing selection alternative forum court chancery state delaware fullest extent permitted law sole exclusive forum derivative action proceeding brought behalf ii action asserting claim breach fiduciary duty owed directors officers employees us stockholders creditors constituents iii action asserting claim arising pursuant provision general corporation law state delaware amended restated certificate incorporation amended bylaws iv action asserting claim us directors officers employees governed internal affairs doctrine provided however event court chancery state delaware lacks jurisdiction action proceeding sole exclusive forum action proceeding another state federal court state delaware bylaws also provide person entity purchasing otherwise acquiring holding interest shares capital stock deemed notice consented forum selection provision court chancery state delaware court chancery jurisdiction another state federal court state delaware fullest authority allowed law issue antisuit injunction enforce forum selection clause preclude suit forum however forum selection provision intended apply actions brought securities act securities act amended exchange act section exchange act creates exclusive federal jurisdiction suits brought enforce duty liability created exchange act rules regulations thereunder section securities act creates concurrent jurisdiction federal state courts suits brought enforce duty liability created securities act rules regulations thereunder accordingly forum selection provision amended bylaws relieve us duties comply federal securities laws rules regulations thereunder stockholders deemed waived compliance laws rules regulations nevertheless forum selection provision bylaws may limit stockholders ability bring claim judicial forum finds favorable disputes us directors officers employees may discourage lawsuits respect claims although stockholders deemed waived compliance federal securities laws rules regulations thereunder addition stockholders bring claim court chancery state delaware could face additional litigation costs pursuing claim particularly reside near delaware believe risk court declining enforce forum selection provision contained amended bylaws low court find provision inapplicable unenforceable respect one specified types actions proceedings may incur additional costs associated resolving action jurisdictions could harm business operating results financial condition item b unresolved staff comments none item properties principal executive offices located east th street th floor new york ny lease manufacturing rd administration storage distribution facilities approximately sites worldwide believe manufacturing properties combination thirdparty manufacturers good operating condition provide adequate production capacity current projected operations also believe none properties subject material encumbrance easement restriction would detract materially value impair use operation business information manufacturing properties refer item businessmanufacturing quality assurance significant manufacturing rd locations geographic area follows december manufacturing rd united states europe total item legal proceedings information pertaining legal proceedings found item financial statements supplementary datanote legal proceedings contingencies incorporated reference herein item mine safety disclosures applicable part ia information executive officers listed information executive officers february executive officers elected board directors initial term continues first board meeting following next annual meeting shareholders thereafter elected oneyear term successors elected executive officers serve discretion board directors name current position age employment history past years giovanni caforio md chief operating officer director company chairman board chief executive officer chief executive officer director company member leadership team present chairman board chief executive officer christopher boerner phd executive vice president seattle genetics executive vice president chief commercialization officer president head us commercial member leadership team president head international markets present executive vice president chief commercial officer adam dubow vice president assistant general counsel china japan intercon region emac senior vice president chief compliance ethics officer region member leadership team vice president associate general counsel research development present senior vice president chief compliance ethics officer joseph e eid md vice president head oncology global medical affairs merck senior vice president head global medical affairs head global medical member leadership team present senior vice president head global medical affairs david v elkins group vice president chief financial officer consumer consumer medicines executive vice president chief financial officer johnson johnson member leadership team worldwide vice president chief financial officer consumer products medical devices corporate functions johnson johnson chief financial officer celgene present executive vice president chief financial officer samit hirawat md senior vice president global program head novartis executive vice president chief medical officer global drug executive vice president head oncology development novartis development present executive vice president chief medical officer global drug development member leadership team sandra leung general counsel corporate secretary executive vice president general counsel executive vice president general counsel corporate secretary member leadership team present executive vice president general counsel elizabeth mily managing director barclays investment bank executive vice president strategy business development present executive vice president strategy business development member leadership team ann powell chief human resources officer shire pharmaceuticals executive vice president chief human resources officer senior vice president global human resources member leadership team senior vice president chief human resources officer present executive vice president chief human resources officer karen santiago vice president finance global manufacturing supply senior vice president corporate controller vice president finance us commercial global capability hub lead enabling functions finance transformation present senior vice president corporate controller louis schmukler president global product development supply executive vice president president global product development senior vice president president global product development supply supply present executive vice president president global product development supply member leadership team rupert vessey bm bch frcp dphil president research early development celgene executive vice president research early development present executive vice president research early development member leadership team paul von autenried senior vice president enterprise services chief information officer executive vice president chief information officer senior vice president chief information officer member leadership team present executive vice president chief information officer part ii item market registrants common stock stockholder matters bristolmyers squibb common stock traded new york stock exchange symbol bmy holders common stock number record holders common stock january number record holders based upon actual number holders registered books date based information provided eq shareowner services transfer agent include holders shares street names persons partnerships associations corporations entities identified security position listings maintained depository trust companies equity compensation plan information information required item contained proxy statement heading items voted uponitem advisory vote approve compensation named executive officersequity compensation plan information information incorporated herein reference performance graph following graph compares cumulative total stockholders returns common shares cumulative total stockholders returns companies listed standard poors index composite peer group major pharmaceutical companies comprised abbvie amgen astrazeneca biogen gilead glaxosmithkline johnson johnson lilly merck novartis pfizer roche sanofi graph assumes investment december common shares sp index stock peer group companies including reinvestment dividends years ended december stock price performance following graph necessarily indicative future stock price performance bristolmyers squibb sp peer group unregistered sales equity securities use proceeds following table summarizes surrenders equity securities three months ended december total number shares approximate dollar value purchased part shares may yet total number average price paid per publicly announced purchased period shares purchaseda sharea programsb programsb dollars millions except per share data october november december three months ended december includes shares repurchased part publicly announced programs shares common stock surrendered company satisfy tax withholding obligations connection vesting awards longterm incentive program b may board directors authorized repurchase billion common stock june increased authorization repurchase common stock additional billion october board directors approved new share repurchase program authorizing repurchase additional billion common stock november increased authorization repurchase common stock approximately billion february board directors approved increase billion total outstanding share repurchase authorization remaining share repurchase capacity program approximately billion december refer item financial statementsnote equity information share repurchase program january board directors approved increase billion share repurchase authorization common stock item selected financial data following table sets forth selected historical consolidated financial information five periods indicated information read together item managements discussion analysis financial condition results operations consolidated financial statements related notes included elsewhere including disclosures related november acquisition celgene selected historical financial information years ended december derived audited consolidated financial statements related notes five year financial summary amounts millions except per share data income statement data total revenues net lossearnings net lossearnings attributable noncontrolling interest bms net lossearnings per common share attributable bms basic diluted weighted average common shares outstanding basic diluted cash dividends paid bms common preferred stock cash dividends declared per common share financial position data december cash cash equivalents marketable debt securitiesab total assets longterm debta equity includes current noncurrent portion b prior period amounts conformed current period presentation item managements discussion analysis financial condition results operations managements discussion analysis financial condition results operations provided supplement read conjunction consolidated financial statements related notes included elsewhere enhance understanding results operations financial condition cash flows comparison results omitted referenced year ended december item managements discussion analysis financial condition results operations filed february executive summary bristolmyers squibb company global biopharmaceutical company whose mission discover develop deliver innovative medicines help patients prevail serious diseases refer summary abbreviated terms end terms used throughout document completed celgene transaction november consolidated financial statements include full year celgene operations november completed acquisition myokardia approximately billion cash expect acquisitions celgene myokardia position us leading biopharmaceutical company expanding oncology hematology immunology cardiovascular portfolios several nearterm assets additional external partnerships refer acquisitions divestitures licensing arrangements information covid pandemic resulting significant risks disruptions health welfare global population economy although pandemic significant impact results operations remains difficult reasonably assess predict full extent negative impact covid pandemic may business financial condition results operations cash flows impact depend future developments ultimate duration recovery pandemic government actions impact us global economies customer behavior changes timing resumption normal operations among others refer economic market factors information received approvals new medicines additional indications formulations currently marketed medicines major markets us eu japan including multiple regulatory milestone achievements opdivo opdivoyervoy combinations unique compounds clinical development investigating opdivo alone combination yervoy anticancer agents wide array tumor types continue expand field hematology leading presence inline assets revlimid pomalyst received regulatory approvals zeposia onureg received ema validation lisocel treatment large bcell lymphoma additionally pipeline shows significant added promise hematology malignancies celmod agents iberdomide cc multiple modalities targeting bcell maturation antigen bcma next generation cell therapy agents expanding portfolio immunology near term launch opportunity deucravacitinib tyk inhibitor additionally cardiovascular space eliquis leading oral anticoagulant drug continue experience growth eliquis brand market also advancing factor xia inhibitor program acquisition myokardia bolstered leading cardiovascular franchise added exceptional scientific capabilities mavacamten potentially transformative new medicine significant commercial potential promising pipeline candidates revenues increased result celgene acquisition contributed billion revenues growth higher demand eliquis gaap loss per share compared gaap eps primarily due iprd charge resulting myokardia asset acquisition charges relating celgene acquisition including amortization acquired intangible assets ii unwinding inventory fair value adjustments iii tax charges resulting internal transfer certain intangible assets otezla divestiture partially offset higher revenues fair value adjustments contingent value rights equity investments adjusting specified items nongaap eps increased result celgene acquisition highlights following table summarizes financial information year ended december dollars millions except per share data total revenues diluted lossearnings per share gaap nongaap nongaap financial measures including nongaap earnings related eps information adjusted exclude specified items represent certain costs expenses gains losses items impacting comparability financial results detailed listing specified items information reconciliations nongaap financial measures refer nongaap financial measures economic market factors covid covid pandemic continues affect global healthcare systems well major economic financial markets virtually industries facing challenges associated economic conditions resulting efforts address pandemic example many entities certain industries seen sharp declines revenues due regulatory organizational mandates eg shelter place mandates nonessential business school closures voluntary changes consumer behavior eg physical distancing many entities continue experience conditions often associated sudden severe economic downturn conditions may include financial market volatility erosion market value deteriorating credit liquidity concerns increases government intervention increasing unemployment broad declines consumer discretionary spending increasing inventory levels reductions production decreased demand supply constraints layoffs furloughs restructuring activities continue monitor impact business resulting wider restrictions select states nonus countries dynamically changing environment continue react outbreaks throughout world reenforcing directives keep workforce safe order provide patients lifesustaining medicines continued escalating infection rates could negatively affect planned recovery pressuring demand less patient visits channel mix unemployment data trends remain unfavorable incurred anticipate disruptions supply medicines patients due covid pandemic however experiencing scarcity certain raw materials components result influx covid vaccine orders receiving priority treatment vendors internal manufacturing facilities key contract manufacturers operating proper measures taken help ensure employee safety increased number lab workers safe implemented number measures protect health safety workforce including needed mandatory workfromhome policy global workforce perform jobs home well restrictions business travel workplace person meetings depending local conditions fieldbased personnel began inperson customer interactions healthcare settings safe approved government remote engagement model continued support healthcare professionals patient care access medicines although certain fieldbased sales teams begun person engagement selected states nonus regions majority interactions remain remote situation remains dynamic challenging assess potential impact operations ability willingness patients access treatment centers obtain prescription changes prescribing patterns may potentially affect operations longterm certain changes buying patterns occurred including payers implementing policies encourage larger prescription sizes earlier refills help patients avoid trips pharmacy however fewer patient office visits resulting lower previously expected new patient starts although difficult estimate impact factors believe significant impact revenues timing specific product launches depends relevant facts circumstances situation example delayed commercialization zeposia us based best health interest patients customers workforce contrast reblozyl available mds patients following approval additional indication april onureg available patients aml september expanded us patient assistance programs provided certain covered bms medicines free eligible patients lost employment health insurance due covid uncertain aggregate impact factors potential changes channel mix revenues expenses restarted clinical development activities pausing opening additional sites first months onset covid pandemic however experienced slight slowdown clinical studies fourth quarter addition certain delays occurred due slower enrollment patient enrollment certain new clinical studies ongoing studies new sites carefully started safety study participants employees staff clinical trial sites regulatory compliance scientific integrity trial data assured expect many new studies start first quarter following completion feasibility assessments rigorous planning selected protocol simplifications previously suspended research early development activities performed laboratories recommenced major sites us although close monitoring situation continues covid pandemic increased volatility financial markets foreign currency exchanges interest rates although incurred downward adjustments equity investment fair values first quarter fair values subsequently recovered lower interest rates changes us dollar relative foreign currencies material impact operations carrying value intangible assets approximately billion december significant charges might occur future periods due decline previously expected cash flows direct indirect result pandemic may occur due delays enrollment timely completion clinical programs fda site inspections interactions regulatory bodies general regulatory approvals launches newly approved products lower demand general see risk factor companys risk factors resulting covid pandemic included part iitem risk factorsthe covid pandemic affecting business could material adverse effect us governmental actions additional regulations us may occur future including healthcare reform initiatives changes tax laws pricing laws potential importation restrictions may reduce results operations operating cash flow liquidity financial flexibility example november us federal government issued regulations regarding us drug prices payment pharmaceutical products including regulations would reduce physician reimbursement certain medicare part b drugs administered doctors offices hospitals favored nation price drawn lowest price paid certain countries organisation economic cooperation development would apply many cancer medications would authorize states private parties develop implement programs import certain prescription drugs canada sell us would reform use rebates medicare part outcome regulations remains uncertain result ongoing litigation factors see risk factor companys risk factors executive orders included part iitem risk factorsincreased pricing pressure restrictions us abroad continue negatively affect revenues profit margins continue monitor potential impact economic conditions certain european countries related impact prescription trends pricing discounts creditworthiness customers believe economic conditions material impact liquidity cash flow financial flexibility uk departed eu january departure began transition period ended december signature trade cooperation agreement uk eu similar companies industry certain regulatory trade labor aspects business affected transition period time matters related financial effects material impact consolidated results operations financial position liquidity sales uk represent less total revenues see item risk factorsadverse changes us global economic political conditions could adversely affect profitability information impact company exit uk eu significant product pipeline approvals following summary significant approvals received product date approval ec approval opdivo treatment adults unresectable advanced recurrent metastatic escc opdivo november prior fluoropyrimidine platinumbased combination chemotherapy ec approval opdivo plus yervoy two cycles platinumbased chemotherapy firstline opdivoyervoy november treatment adult patients metastatic nsclc whose tumors sensitizing epidermal growth factor receptor mutation anaplastic lymphoma kinase translocation opdivoyervoy october fda approval opdivoyervoy firstline treatment adult patients unresectable mpm fda approval onureg azacitidine continued treatment adult patients aml onureg september achieved first complete remission complete remission incomplete blood count recovery following intensive induction chemotherapy able complete intensive curative therapy ec approval reblozyl treatment adult patients transfusiondependent anemia due reblozyl june low low intermediaterisk mds ring sideroblasts unsatisfactory response ineligible erythropoietinbased therapy beta thalassemia fda approval opdivo treatment patients unresectable advanced recurrent metastic escc opdivo june prior fluoropyrimidine platinumbased chemotherapy ec approval zeposia treatment adult patients rrms active disease defined zeposia may clinical imaging features fda approval opdivoyervoy given two cycles platinumdoublet chemotherapy first line treatment adult patients metastatic recurrent nsclc egfr alk genomic tumor opdivoyervoy may aberrations therapy approved patients squamous nonsquamous disease regardless pdl expression fda approval opdivoyervoy firstline treatment adult patients metastatic nsclc opdivoyervoy may whose tumors express pdl egfr alk genomic tumor aberrations fda approval pomalyst patients aidsrelated kaposi sarcoma whose disease become pomalyst may resistant highly active antiretroviral therapy patients kaposi sarcoma hivnegative fda approval reblozyl treatment anemia failing erythropoiesis stimulating agent adult reblozyl april patients low intermediaterisk mds ring sideroblasts require rbc transfusions fda approval zeposia ozanimod treatment adults rms including clinically isolated zeposia march syndrome relapsingremitting disease active secondary progressive disease fda approval opdivoyervoy combination treatment hcc patients opdivoyervoy march previously treated sorafenib fda indicated undertaking industrywide review indications received accelerated approval confirmatory studies meet primary endpoints specific bms two opdivo indications subject review fda thirdline treatment sclc secondline treatment hcc december consultation fda made decision withdraw opdivo indication third line treatment sclc us market secondline treatment hcc reviewed fda following summary significant approvals received january fda approved use opdivo combination cabometyx firstline treatment patients advanced rcc february fda approved breyanzi lisocabtagene maraleucel lisocel treatment adult patients relapsed refractory large bcell lymphoma two lines systemic therapy february ec approved inrebic treatment diseaserelated splenomegaly symptoms adult patients primary myelofibrosis post polycythaemia vera myelofibrosis postessential thrombocythaemia myelofibrosis janus associated kinase inhibitor nave treated ruxolitinib refer product pipeline developments developments marketed products latestage pipeline early strategy principal strategy combine resources scale capability pharmaceutical company speed focus innovation biotech industry focus biopharmaceutical company discovering developing delivering transformational medicines patients facing serious diseases areas believe opportunity make meaningful difference oncology solid tumors hematology immunology cardiovascular fibrosis four strategic priorities drive enterprise performance maximize value commercial portfolio ensure longterm sustainability pipeline combined internal external innovation establish new culture embed people strategy developing new medicines following core therapeutic areas oncology priority certain tumor types ii hematology opportunities broaden franchise potentially sustain leadership position multiple myeloma iii immunology priorities relapsing multiple sclerosis psoriasis lupus ra inflammatory bowel disease iv cardiovascular disease v fibrotic disease priorities lung liver continue advance next wave innovative medicines investing significantly pipeline internally business development activities expanded oncology hematology immunology portfolios several nearterm assets additional external partnerships invested oncology portfolio pursuing monotherapy combination approaches advancing next wave early assets explore new collaboration opportunities across therapeutic areas focus remain focused wellresourced cancer development programs seek broaden use opdivo earlier lines therapy expand new tumors accelerate next wave oncology mechanisms develop treatment options refractory oncology patients hematology opportunities launch several new medicines nearterm additional pipeline opportunities longer term broad effort continue address unmet medical need multiple myeloma working across multiple modalities mechanisms action cereblon modulator celmod tcell engager car tcell therapy beyond cancer continue advance early stage portfolio immunology cardiovascular fibrotic diseases strengthen partnerships diverse group companies academic institutions new expanded research activities believe differentiated internal external focus contributes advancing pipeline potentially transformational medicines commercial model successful revenues prioritized brands continuing grow demonstrates strong execution strategy continue drive adoption opdivo expanding additional indications tumor types monotherapy combination yervoy anticancer agents eliquis continues grow leveraging best class clinical profile extensive real world data number one novel oral anticoagulant total prescriptions globally revlimid pomalyst transformed treatment multiple myeloma leading presence continue seek opportunities leverage significant medical commercial expertise address areas high unmet medical need building continued success prioritized brands remain strongly committed orencia sprycel also optimistic future growth nearterm opportunities reblozyl firstinclass medicine inrebic zeposia onureg operating model transformation commercial infrastructure leveraged potential growth operating model continues evolve successful focusing commercial rd manufacturing resources prioritized brands markets strengthening rd capabilities tumor biology patient selection new biomarkers delivering leaner administrative functions streamlining manufacturing network reflect importance biologics current future portfolio evolution operating model focuses maintaining disciplined approach marketing selling administrative expenses enable us deliver necessary strategic financial operational flexibility invest highest priority opportunities within portfolio continue make progress towards integrating companies commercial research development area celgene acquisition restructuring activities expect realize billion synergies resulting cost savings avoidance integration efforts across general administrative manufacturing rd procurement streamlining company 's pricing information technology infrastructure looking ahead continue implement biopharma strategy driving growth prioritized brands executing product launches investing diverse innovative pipeline aided strategic business development focusing prioritized markets increasing investments biologics manufacturing capabilities maintaining culture continuous improvement acquisitions divestitures licensing arrangements significant acquisitions divestitures licensing arrangements summarized refer item financial statements supplementary data note alliances note acquisitions divestitures licensing arrangements information myokardia acquired myokardia clinicalstage biopharmaceutical company pioneering precision medicine approach discover develop commercialize targeted therapies treatment serious cardiovascular diseases acquisition provides us rights myokardias lead asset mavacamten potential firstinclass cardiovascular medicine treatment obstructive hypertrophic cardiomyopathy completed phase iii development anticipated nda submission first quarter dragonfly obtained global exclusive license dragonflys interleukin il investigational immunotherapy program including extended halflife cytokine df forbius acquired forbius privately held clinicalstage protein engineering company designs develops biotherapeutics treatment cancer fibrotic diseases acquisition provides us full rights forbiuss tgfbeta program including programs lead investigational asset avid phase development results operations regional revenues composition changes revenues follows year ended december vs dollars millions change foreign exchangeb united states europe rest world othera total revenues include royalties alliancerelated revenues products sold regional commercial organizations b foreign exchange impacts derived applying prior period average currency rates current period revenues united states us revenues impacted increase revlimid pomalystimnovid celgene products billion contributed growth higher demand eliquis partially offset lower demand opdivo average net selling prices increased europe europe revenues impacted increase celgene products billion contributed growth higher demand eliquis opdivo partially offset lower demand established brands average net selling prices lower rest world rest world revenues impacted increase celgene products billion contributed approximately growth higher demand eliquis partially offset lower demand established brands average net selling prices lower single country outside us contributed total revenues business typically seasonal gtn adjustments recognize revenue net gtn adjustments described critical accounting policies activities ending reserve balances significant category gtn adjustments follows year ended december rebates chargebacks medicaid returns discounts dollars millions cash discounts medicare rebates adjustments total balance january provision related sales made current period prior period payments returns foreign currency translation balance december reconciliation gross product sales net product sales significant category gtn adjustments follows year ended december change dollars millions vs gross product sales gtn adjustments chargebacks cash discounts medicaid medicare rebates rebates returns discounts adjustments total gtn adjustments net product sales gtn adjustments percentage us nonus reductions provisions product sales made prior periods resulting changes estimates million million respectively gtn adjustments primarily function product sales volume regional payer channel mix contractual legislative discounts rebates us gtn adjustments percentage decreased primarily due addition celgene hematology brands lower gtn adjustment percentages partially offset higher us eliquis gross product sales higher us gtn adjustment percentages product revenues year ended december change dollars millions vs prioritized brands revlimid us nonus eliquis us nonus opdivo us nonus orencia us nonus pomalystimnovid us nonus sprycel us nonus yervoy us nonus abraxane us nonus empliciti us nonus reblozyl na us na nonus na inrebic us nonus na onureg na us na nonus na zeposia na us na nonus na year ended december change dollars millions vs established brands vidaza us nonus baraclude us nonus brandsa us nonus total revenues us nonus change excess includes bms celgene products revlimid lenalidomide oral immunomodulatory drug combination dexamethasone indicated treatment patients multiple myeloma revlimid single agent also indicated maintenance therapy patients multiple myeloma following autologous hematopoietic stem cell transplant us international revenues increased due inclusion full year celgene product revenues eliquis apixaban oral factor xa inhibitor indicated reduction risk strokesystemic embolism nvaf treatment dvtpe reduction risk recurrence following initial therapy us revenues increased due higher demand partially offset lower average net selling prices approximately lower average net selling price primarily due unfavorable channel mix increase medicare part coverage gap per patient lesser extent higher contractual rebates international revenues increased due higher demand partially offset lower average net selling prices opdivo nivolumab fully human monoclonal antibody binds pd nkt cells approved several anticancer indications including bladder blood colon head neck kidney liver lung melanoma stomach opdivoyervoy regimen also approved multiple markets treatment nsclc melanoma rcc crc several ongoing potentially registrational studies opdivo across tumor types disease areas monotherapy combination yervoy various anticancer agents us revenues decreased due lower demand caused declining secondline eligibility across tumor indications increased competition adjuvant melanoma lower demand covid primarily lower new patient starts patient visits partially offset higher demand due launch opdivoyervoy combination nsclc continued growth rcc indication international revenues increased due higher demand result additional indication launches new countries orencia abatacept fusion protein indicated adult patients moderately severely active ra psa also indicated reducing signs symptoms certain pediatric patients moderately severely active polyarticular jia us revenues increased due higher demand international revenues increased due higher demand pomalystimnovid pomalidomide proprietary distinct small molecule administered orally modulates immune system biologically important targets pomalystimnovid indicated patients multiple myeloma received least two prior therapies including lenalidomide proteasome inhibitor demonstrated disease progression within days completion last therapy us international revenues increased due inclusion full year celgene product revenues sprycel dasatinib oral inhibitor multiple tyrosine kinase indicated firstline treatment patients philadelphia chromosomepositive cml chronic phase treatment adults chronic accelerated myeloid lymphoid blast phase cml resistance intolerance prior therapy including gleevec imatinib mesylate treatment children adolescents aged year years chronic phase philadelphia chromosomepositive cml us revenues increased due higher demand higher average net selling prices international revenues decreased due lower demand result increased generic competition yervoy ipilimumab monoclonal antibody treatment patients unresectable metastatic melanoma us revenues increased due launch opdivoyervoy combination nsclc international revenues increased due higher demand result approvals additional indications launches primarily europe partially offset lower average net selling prices abraxane paclitaxel albuminbound particles injectable suspension solventfree proteinbound chemotherapy product combines paclitaxel albumin using proprietary nab technology platform used treat breast cancer nsclc pancreatic cancer among others us international revenues increased due inclusion full year celgene product revenues reblozyl luspaterceptaamt erythroid maturation agent indicated treatment anemia adult patients beta thalassemia require regular red blood cell transfusions november fda approved reblozyl treatment anemia adult patients beta thalassemia require rbc transfusions april fda approved reblozyl treatment anemia failing erythropoiesis stimulating agent adult patients low intermediaterisk mds ring sideroblasts require rbc transfusions reblozyl launched april inrebic fedratinib oral kinase inhibitor indicated treatment adult patients intermediate highrisk primary secondary postpolycythemia vera postessential thrombocythemia myelofibrosis onureg azacitidine oral hypomethylating agent incorporates dna rna indicated continued treatment adult patients aml achieved first complete remission complete remission incomplete blood count recovery following intensive induction chemotherapy able complete intensive curative therapy onureg launched september zeposia ozanimod oral immunomodulatory drug used treat relapsing forms multiple sclerosis include clinically isolated syndrome relapsingremitting disease active secondary progressive disease adults zeposia launched june vidaza azacitidine injection pyrimidine nucleoside analog shown reverse effects deoxyribonucleic acid hypermethylation promote subsequent gene reexpression indicated treatment patients following myelodysplastic syndrome subtypes refractory anemia refractory anemia ringed sideroblasts accompanied neutropenia thrombocytopenia requiring transfusions refractory anemia excess blasts refractory anemia excess blasts transformation chronic myelomonocytic leukemia cmmol international revenues increased due inclusion full year celgene product revenues baraclude entecavir oral antiviral agent treatment chronic hepatitis b international revenues decreased due lower demand average net selling prices resulting generic competition brands includes brands including lost exclusivity major markets otc brands royalty revenue us revenues include million million celgene products respectively international revenues decreased primarily due divestiture upsa business certain brands continued generic erosion estimated enduser demand pursuant sec consent order described sec consent order monitor level inventory hand us wholesaler distribution channel outside us direct customer distribution channel obligated disclose products levels inventory excess one month hand expected demand subject de minimis exception estimated levels inventory distribution channel excess one month hand following products material results operations dates indicated onureg months inventory hand december us support product launch inventory expected worked demand increases post launch zeposia months inventory hand internationally distribution channel september support product launch germany inventory expected worked demand increases post launch us generally determine months hand estimates using inventory levels product hand amount outmovement provided three largest wholesalers account approximately total gross sales us products year ended december factors may influence estimates include generic competition seasonality products wholesaler purchases light increases wholesaler list prices new product launches new warehouse openings wholesalers new customer stockings wholesalers addition estimates calculated using thirdparty data may impacted recordkeeping processes revlimid pomalyst distributed us primarily contracted pharmacies revlimid rems pomalyst rems programs respectively proprietary riskmanagement distribution programs tailored specifically provide safe appropriate distribution use revlimid pomalyst internationally revlimid imnovid distributed mandatory riskmanagement distribution programs tailored meet local authorities specifications provide products safe appropriate distribution use programs may vary country depending upon country design riskmanagement program product may sold hospitals retail pharmacies nonus businesses significantly direct customers information available direct customer product level inventory corresponding movement information reliability thirdparty demand information varies widely limit direct customer sales channel inventory reporting influence demand information exist otherwise available developed variety methodologies estimate data including using historical sales made direct customers thirdparty market research data related prescription trends enduser demand given difficulties inherent estimating thirdparty demand information evaluate methodologies estimate direct customer product level inventory calculate months hand ongoing basis make changes necessary factors may affect estimates include generic competition seasonality products price increases new product launches new warehouse openings direct customers new customer stockings direct customers expected direct customer purchases governmental bidding situations information required estimate months hand direct customer distribution channel nonus business year ended december available prior filing disclose product levels inventory excess one month hand expected demand subject de minimis exception next quarterly report form q expenses year ended december change dollar millions vs cost products solda marketing selling administrative research development iprd charge myokardia acquisition na amortization acquired intangible assets incomeexpense net total expenses excess excludes amortization acquired intangible assets cost products sold cost products sold include material internal labor overhead costs owned manufacturing sites thirdparty product supply costs supply chain costs managed global manufacturing supply organization cost products sold also includes royalties profit sharing certain excise taxes foreign currency hedge settlement gains losses impairment charges cost products sold typically vary periods result product mix volume particularly royalties profit sharing lesser extent changes foreign currency price inflation costs attributed manufacturing site exits impairment charges cost products sold excludes amortization acquired intangible assets cost products sold increased billion primarily due unwinding inventory fair value adjustments billion higher royalties eliquis profit sharing million higher celgene product costs approximately million impairment charge related inrebic marketed product rights million marketing selling administrative marketing selling administrative expenses primarily include salary benefit costs thirdparty professional marketing fees outsourcing fees shipping handling costs advertising product promotion costs expenses managed regional commercialization organizations global enabling functions finance legal information technology human resources certain expenses shared alliance partners based upon contractual agreements marketing selling administrative expenses increased billion primarily due costs associated broader portfolio resulting celgene acquisition approximately billion higher advertising promotion expenses cash settlement myokardia unvested stock awards million research development research development activities include discovery research preclinical clinical development drug formulation medical support marketed products expenses include salary benefit costs thirdparty grants fees paid clinical research organizations supplies upfront contingent milestone payments licensing asset acquisitions investigational compounds iprd impairment charges proportionate allocations enterprisewide costs allocations include facilities information technology employee stock compensation costs appropriate costs certain expenses shared alliance partners based upon contractual agreements expenses typically vary periods number reasons including timing license asset acquisition charges iprd impairment charges research development expense increased billion primarily due costs associated broader portfolio resulting celgene acquisition approximately billion excluding bluebird dragonfly charges license asset acquisition charges billion relating dragonfly bluebird forbius cormorant nektar iprd impairment charge resulting decision discontinue development orvacel program million cash settlement myokardia unvested stock awards million iprd charge myokardia acquisition iprd charges represents costs iprd assets acquired transaction business combination myokardia acquisition accounted asset acquisition substantially fair value gross assets acquired excluding cash deferred taxes allocated single asset mavacamten iprd charge related myokardia transaction presented separately due significance charge amortization acquired intangible assets amortization intangible assets acquired result business combinations amortization acquired intangible assets increased billion due full year amortization revlimid pomalystimnovid marketed product rights obtained celgene acquisition incomeexpense net incomeexpense net changed billion primarily due fair value adjustments contingent value rights equity investments items discussed components incomeexpense net follows year ended december dollars millions interest expense contingent consideration royalties licensing income equity investment gains integration expenses provision restructuring litigation settlements transition service fees investment income reversion excise tax divestiture gains intangible asset impairment pension postretirement acquisition expenses incomeexpense net interest expense increased due billion notes issued may billion celgene debt assumed acquisition contingent consideration primarily includes fair value adjustments resulting change traded price contingent value rights issued celgene acquisition contractual obligation pay contingent value rights terminated january fda approve lisocel jcar december royalties licensing income includes diabetes business royalties keytruda tecentriq royalties upfront milestone licensing fees products obtained commercial approval refer item financial statements supplementary datanote acquisitions divestitures licensing arrangements information equity investment gains includes fair value adjustments equity investments readily determinable fair value observable price changes equity investments without readily determinable fair values refer item financial statements supplementary datanote financial instruments fair value measurements information share income equity method investments million termination fee related europe asia partnership sanofi million included integration expenses include consulting fees incurred primarily connection celgene integration activities provision restructuring includes exit costs primarily related celgene acquisition plans achieved approximately billion annualized pretax cost savings related celgene acquisition plan track achieve annualized pretax cost savings approximately billion detailed restructuring activities refer item financial statements supplementary datanote restructuring information transition service fees primarily includes otezla divestiture related fees investment income includes million interest income earned net proceeds notes issued may fund portion celgene acquisition reversion excise tax resulted transfer retiree medical plan assets back company refer item financial statements supplementary datanote retirement benefits information divestiture gains includes billion gain sale upsa business pension postretirement includes special termination benefits charge billion relating termination bristolmyers squibb retirement income plan acquisition expenses include following items related celgene transaction upfront bridge facility commitment fee acquisition financing hedge losses financial advisory legal proxy filing regulatory fees income taxes year ended december dollars millions lossearnings income taxes provision income taxes effective tax rate impact specified items effective tax rate excluding specified items tax impact attributed specified items primarily due unwinding inventory fair value adjustments intangible asset amortization resulting celgene acquisition nondeductible myokardia iprd charge nontaxable fair value adjustments contingent value rights current year addition million deferred tax charge resulting internal transfer certain intangible assets additional million gilti tax charge upon finalization otezla divestiture tax consequences tax authorities included tax impact attributed specified items including otezla divestiture pension settlement charges gain sale upsa business divestiture specified items increased effective tax rate prior year effective tax rate excluding specified items includes tax reserve release due lapse statue million favorable discrete tax adjustments approximately million million primarily resulting finalization prior year tax returns impact swiss tax reform refer item financial statements supplementary datanote income taxes information nongaap financial measures nongaap financial measures nongaap earnings related eps information adjusted exclude certain costs expenses gains losses specified items evaluated individual basis items adjusted considering quantitative qualitative aspects typically one following characteristics highly variable difficult project unusual nature significant results particular period indicative future operating results similar charges gains recognized prior periods likely reoccur future periods including amortization acquired intangible assets beginning fourth quarter including product rights generate significant portion ongoing revenue recur intangible assets fully amortized ii unwind inventory fair value adjustments iii acquisition integration expenses iv restructuring costs v accelerated depreciation impairment property plant equipment intangible assets vi rd charges income resulting upfront contingent milestone payments connection acquisition licensing thirdparty intellectual property rights vii costs acquiring priority review voucher viii iprd charge resulting myokardia acquisition ix divestiture gains losses x stock compensation resulting accelerated vesting celgene awards certain retentionrelated employee compensation charges related celgene transaction xi pension legal contractual settlement charges xii interest expense notes issued may incurred prior celgene transaction interest income earned net proceeds notes xiii equity investment contingent value rights fair value adjustments xiv amortization fair value adjustments debt acquired celgene exchange offer among items deferred current income taxes attributed items also adjusted considering individual impact overall tax expense deductibility jurisdictional tax rates certain significant tax items also excluded impact resulting internal transfer intangible assets otezla divestiture also provide international revenues priority products excluding impact foreign exchange reconciliations nongaap measures comparable gaap measures included exhibit form k filed february incorporated herein reference nongaap information intended portray results baseline performance supplement enhance management analysts investors overall understanding underlying financial performance facilitate comparisons among current past future periods example nongaap earnings eps information indication baseline performance items considered us reflective ongoing results addition information among primary indicators use basis evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods information intended considered isolation substitute net earnings diluted eps prepared accordance gaap may comparable similarly titled measures presented companies due possible differences method items adjusted encourage investors review financial statements publiclyfiled reports entirety rely single financial measure specified items follows year ended december dollars millions inventory purchase price accounting adjustments intangible asset impairment employee compensation charges site exit costs cost products sold employee compensation charges site exit costs marketing selling administrative license asset acquisition charges iprd impairments inventory purchase price accounting adjustments employee compensation charges site exit costs research development iprd charge myokardia acquisition amortization acquired intangible assets interest expensea contingent consideration royalties licensing income equity investment gains integration expenses provision restructuring litigation settlements investment income reversion excise tax divestiture gains pension postretirement acquisition expenses incomeexpense net increase pretax income income taxes items income taxes attributed otezla divestiture income taxes attributed internal transfer intangible assets income taxes increase net earnings includes amortization purchase price adjustments celgene debt reconciliations gaap nongaap follows year ended december dollars millions except per share data net lossearnings attributable bms used diluted eps calculation gaap specified items net earnings attributable bms used diluted eps calculation nongaap weightedaverage common shares outstanding diluted gaap incremental shares attributable sharebased compensation plans weighted average common shares outstanding diluted nongaap diluted lossearnings per share attributable bms gaap diluted eps attributable specified items diluted eps attributable bms nongaap financial position liquidity capital resources net debt position follows december dollars millions cash cash equivalents marketable debt securities current marketable debt securities noncurrent total cash cash equivalents marketable debt securities shortterm debt obligations longterm debt net debt position regularly assess anticipated working capital needs debt leverage levels debt maturities capital expenditure requirements dividend payouts potential share repurchases future investments acquisitions order maximize shareholder return efficiently finance ongoing operations maintain flexibility future strategic transactions also regularly evaluate capital structure ensure financial risks adequate liquidity access lower cost capital efficiently managed may lead issuance additional debt securities repurchase debt securities prior maturity common stock believe existing cash cash equivalents marketable debt securities together cash generated operations required issuance commercial paper sufficient satisfy anticipated cash needs least next years including dividends capital expenditures milestone payments working capital restructuring initiatives business development approximately billion debt maturing well debt repurchases redemptions tender offers share repurchase program authorized board directors allowing repurchases shares specific timing number shares repurchased determined management discretion vary based market conditions securities law limitations factors share repurchase program obligate us repurchase specific number shares specific expiration date may suspended discontinued time repurchases may effected combination one open market repurchases privately negotiated transactions transactions structured investment banking institutions derivative transactions relying rule b rule b exchange act remaining share repurchase authority authorization program billion december board directors approved increase billion share repurchase authorization common stock february increasing total outstanding share repurchase authorization approximately billion asr agreements executed repurchase aggregate billion common stock settled also repurchased approximately million shares common stock billion year ended december remaining share repurchase capacity share repurchase program approximately billion december refer item financial statements supplementary datanote equity additional information january board directors approved increase billion share repurchase authorization common stock dividend payments billion billion billion dividend decisions made quarterly basis board directors annual capital expenditures approximately million million billion expected approximately billion billion continue make capital expenditures connection expansion manufacturing capabilities research development facilityrelated activities commercial paper program may issue maximum billion unsecured notes maturities days date issuance commercial paper borrowings outstanding december december four revolving credit facilities totaling billion consisted day billion facility expired january threeyear billion facility expiring january two fiveyear billion facilities extended january september july respectively facilities provide customary terms conditions financial covenants may used provide backup liquidity commercial paper borrowings billion facility two billion revolving facilities extendable annually one year anniversary date consent lenders borrowings outstanding revolving credit facilities december january entered day billion facility expiring january extendable annually one year anniversary date consent lenders november entered billion delayed draw term loan credit agreement consisting billion day tranche billion twoyear tranche term facility provides customary terms conditions financial covenants may used general corporate purposes unused credit expires april borrowings outstanding term loan december february terminated delayed draw term loan credit agreement also november issued aggregate principal amount billion fixed rate unsecured senior notes maturities ranging years years net proceeds used fund portion aggregate cash consideration payable myokardia shareholders connection acquisition myokardia pay related fees expenses interest payable semiannually notes rank equally right payment existing future senior unsecured indebtedness redeemable time whole part varying specified redemption prices plus accrued unpaid interest investment portfolio includes noncurrent marketable securities subject changes fair value result interest rate fluctuations market factors investment policy establishes limits amount time maturity investments institution policy also requires investments entered corporate financial institutions meet high credit quality standards refer item financial statements supplementary datanote financial instruments fair value measurements information credit ratings current longterm shortterm credit ratings assigned moodys investors service prime respectively stable longterm credit outlook current longterm shortterm credit ratings assigned standard poors respectively negative longterm credit outlook longterm ratings reflect agencies opinion low default risk somewhat susceptible adverse effects changes circumstances economic conditions shortterm ratings reflect agencies opinion good extremely strong capacity timely repayment credit rating downgrade may affect interest rate debt may incur fair market value existing debt ability access capital markets generally cash flows following discussion cash flow activities year ended december dollars millions cash flow provided byused operating activities investing activities financing activities operating activities cash flow operating activities represents cash receipts disbursements activities investing financing activities operating cash flow derived adjusting net earnings noncontrolling interest noncash operating items gains losses attributed investing financing activities changes operating assets liabilities resulting timing differences receipts payments cash transactions recognized results operations result changes cash operating activities reflect timing cash collections customers alliance partners payments suppliers alliance partners employees customer discounts rebates tax payments ordinary course business example annual employee bonuses typically paid first quarter subsequent year addition cash collections continue impacted longer payment terms certain biologic products us primarily newer oncology products including opdivo yervoy empliciti days days longer payment terms used closely align insurance reimbursement timing physicians cancer centers following administration patients billion change cash flow operating activities compared primarily due celgene acquisition including higher collection payments ordinary course business partially offset higher interest payments billion income tax payments billion including billion attributed otezla divestiture cash settlement unvested myokardia stock awards approximately million investing activities cash requirements investing activities include cash used acquisitions manufacturing facilityrelated capital expenditures purchases marketable securities original maturities greater days time purchase proceeds business divestitures including royalties sale maturity marketable securities upfront contingent milestones licensing arrangements million change cash flow investing activities compared primarily attributable lower business divestiture proceeds approximately billion primarily due divestitures otezla upsa consumer health business partially offset lower net acquisition payments approximately billion primarily due acquisitions celgene myokardia changes amount marketable debt securities held billion financing activities cash requirements financing activities include cash used pay dividends repurchase common stock repay longterm debt borrowings reduced proceeds exercise stock options issuance longterm debt borrowings billion change cash flow financing activities compared primarily attributable lower net borrowing activity billion primarily resulting issuance notes fund acquisitions celgene myokardia lower repayments debt maturities higher dividend payments approximately billion partially offset lower stock repurchase billion primarily resulting accelerated stock repurchase cash payment billion contractual obligations offbalance sheet arrangements payments due period contractual obligations december follows obligations expiring period dollars millions total later years shortterm borrowings longterm debt interest longterm debta operating leasesb purchase obligations uncertain tax positionsc deemed repatriation transition tax totald includes estimated future interest payments periodic cash settlements derivatives b refer item financial statements supplementary datanote leases information regarding leases c includes shortterm uncertain tax benefits uncertainties regarding timing resolution excludes noncurrent liabilities uncertainties regarding timing resolution committed aggregate billion potential future research development milestone payments third parties inlicensing asset acquisitions development programs including earlystage milestones billion milestones achieved phase iii clinical studies latestage milestones billion milestones achieved post phase iii clinical studies payments generally due payable upon achievement certain developmental regulatory milestones specific timing predicted certain agreements also provide salesbased milestones aggregating billion would obligated pay alliance partners upon achievement certain sales levels addition royalties also certain manufacturing development commercialization obligations connection alliance arrangements practicable estimate amount obligations refer item financial statements supplementary datanote alliances information regarding alliances contingent value rights issued connection celgene acquisition rights measured fair value payments contingent upon achievement future regulatory milestones cvr right entitled shareholder receive onetime potential payment cash upon fda approval three following milestones ozanimod december ii lisocel jcar december iii idecel bb march contractual obligation pay contingent value rights terminated january fda approve lisocel jcar december offbalance sheet arrangements material reasonably likely become material financial condition results operations sec consent order fcpa settlement previously disclosed august entered final settlement sec concluding investigation concerning certain wholesaler inventory accounting matters settlement reached consent copy attached exhibit quarterly report form q period ended september terms consent agreed subject certain defined exceptions limit sales products sold direct customers including wholesalers distributors hospitals retail outlets pharmacies government purchasers based expected demand amounts exceed approximately one month inventory hand without making timely public disclosure change practice also agreed consent certain measures implemented including establishing formal review certification process annual quarterly reports filed sec b establishing business risk disclosure group c retaining outside consultant comprehensively study help reengineer accounting financial reporting processes publicly disclosing sales incentives offered direct customers purpose inducing purchase products excess expected demand e ensuring budget process gives appropriate weight inputs come bottom top top bottom adequately documenting process established companywide policy concerning sales direct customers purpose complying consent includes adoption various procedures monitor limit sales direct customers accordance terms consent procedures include governance process escalate appropriate management levels potential questions concerns regarding compliance policy timely resolution questions concerns addition compliance policy monitored regular basis maintain dsas us pharmaceutical wholesalers account nearly gross us revenues current terms dsas wholesaler customers provide us weekly information respect months hand productlevel inventories amount outmovement products three largest wholesalers currently account approximately gross us revenues inventory information received wholesalers together internal information used estimate months hand product level inventories wholesalers estimate months hand product inventory levels us businesss wholesaler customers three largest wholesalers extrapolating months hand calculated three largest wholesalers contrast nonus business significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely accordingly rely variety methods estimate months hand product level inventories business units believe abovedescribed procedures provide reasonable basis ensure compliance consent recently issued accounting standards recently issued accounting standards refer item financial statements supplementary datanote accounting policies recently issued accounting standards critical accounting policies preparation financial statements requires use estimates assumptions affect reported amounts assets liabilities reported amounts revenue expenses critical accounting policies significantly affect financial condition results operations require difficult subjective complex judgments often need make estimates effect matters inherently uncertain uncertainty actual results may vary estimates revenue recognition accounting policy revenue recognition substantial impact reported results relies certain estimates revenue recognized following five step model identify customer contract ii identify contracts performance obligation iii determine transaction price iv allocate transaction price performance obligation v recognize revenue performance obligation satisfied revenue also reduced gtn sales adjustments discussed involve significant estimates judgment considering legal interpretations applicable laws regulations historical experience payer channel mix eg medicare medicaid current contract prices applicable programs unbilled claims processing time lags inventory levels distribution channel estimates assessed period adjusted required revise information actual experience following categories gtn adjustments involve significant estimates judgments information obtained external sources refer item financial statements supplementary datanote revenue discussion analysis significant category gtn sales adjustments chargebacks cash discounts us business participates programs government entities significant us department defense us department veterans affairs parties including covered entities b drug pricing program whereby pricing products extended wholesaler list price participating entities entities purchase products wholesalers lower program price wholesalers charge us difference acquisition cost lower program price accounts receivable reduced estimated amount unprocessed chargeback claims attributable sale typically within two four week time lag us certain countries customers offered cash discounts incentive prompt payment generally approximating invoiced sales price accounts receivable reduced estimated amount cash discount time sale discount typically taken customer within one month medicaid medicare rebates us business participates state government medicaid programs qualifying federal state government programs requiring discounts rebates participating state local government entities discounts rebates provided programs included medicaid rebate accrual medicaid rebates also extended drugs used managed medicaid plans estimated amount unpaid unbilled rebates presented liability rebates discounts offered managed healthcare organizations us managing prescription drug programs medicare advantage prescription drug plans covering medicare part drug benefit also pay point service discount cms medicare part beneficiaries coverage gap donut hole estimated amount unpaid unbilled rebates discounts presented liability rebates returns discounts adjustments gtn sales adjustments include sales returns programs based applicable laws regulations individual nonus countries well rebates offered managed healthcare organizations us lesser extent nonus programs include several different pricing schemes cost caps volume discounts outcomebased pricing schemes pricing clawbacks based sales individual companies aggregation companies participating specific market estimated amount unpaid unbilled rebates discounts presented liability estimated returns established products determined considering historical experience factors including levels inventory distribution channel estimated shelf life product recalls product discontinuances price changes competitive products introductions generic products introductions competitive new products lower demand following loe estimated returns new products determined considering historical sales return experience similar products within product line similar therapeutic area andor similar distribution model estimated levels inventory distribution channel projected demand estimated amount product returns presented liability use information external sources information external sources used estimate gtn adjustments estimate inventory wholesalers based projected prescription demand based sales products historical inventory experience well analysis thirdparty information including written oral information obtained certain wholesalers respect inventory levels sellthrough customers thirdparty market research data internal information inventory information received wholesalers product recordkeeping process excludes inventory held intermediaries sell retailers hospitals also continued practice combining retail mail prescription volume retailequivalent basis use methodology internal demand forecasts also use information external sources identify prescription trends patient demand average selling prices estimates subject inherent limitations estimates rely thirdparty information certain thirdparty information form estimates reflect limitations including lags date thirdparty information generated date receive thirdparty information longlived assets intangible assets valuations significant amount purchase price celgene acquisition allocated intangible assets including commercially marketed products iprd assets intangible assets billion december billion december identifiable intangible assets measured respective fair values acquisition date engaged independent thirdparty valuation firm assist determining fair values assets acquisition date fair value assets estimated using discounted cash flow models models required use following significant estimates assumptions among others identification product candidates sufficient substance requiring separate recognition estimates revenues operating profits related commercial products product candidates eligible patients pricing market share used estimating future revenues probability success unapproved product candidates additional indications commercial products resources required complete development approval product candidates timing regulatory approvals exclusivity appropriate discount rate products market participant income tax rates allocation expected synergies products believe estimated preliminary fair value assigned intangible assets acquired used reasonable estimates assumptions considering facts circumstances acquisition date impairment amortization longlived assets including intangible assets longlived assets include intangible assets property plant equipment reviewed impairment whenever events changes circumstances indicate carrying amount assets may recoverable least annually iprd intangible assets highly vulnerable impairment charges particularly newly acquired assets recently launched products iprd assets initially measured fair value therefore reduction expectations used valuations could potentially lead impairment common potential risks leading impairment include competition earlier expected loe pricing reductions adverse regulatory changes clinical study results delay failure obtain regulatory approval initial follow indications unanticipated development costs inability achieve expected synergies resulting cost savings avoidance higher operating costs changes tax laws macroeconomic changes complexity estimating fair value intangible assets connection impairment test similar initial valuation carrying value longlived assets exceeds fair value asset writtendown fair value expectations future cash flows subject change based upon near longterm production volumes margins generated asset well potential alternative future use estimated useful lives longlived assets subjective requires significant judgment regarding patent lives future plans external market factors longlived assets also periodically reviewed changes facts circumstances resulting reduction estimated useful life asset requiring acceleration depreciation million impairment charge recorded cost products sold resulting lower cash flow projections reflecting revised commercial forecasts inrebic resulting full impairment asset additionally million impairment charge recorded research development expense resulting decision discontinue development orvacel program inrebic orvacel obtained connection acquisition celgene goodwill goodwill represents excess consideration transferred estimated fair values net assets acquired business combination goodwill billion billion december respectively assess goodwill balance within single reporting unit annually whenever events changes circumstances indicate carrying value goodwill may recoverable determine whether impairment asset may exist extent impairment goodwill reviewed impairment assessing qualitative factors including comparing market capitalization carrying value assets events circumstances might require interim evaluation include unexpected adverse business conditions economic factors unanticipated technological changes competitive activities acts governments courts income taxes valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecasts future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made deferred tax assets billion december net valuation allowances billion billion december net valuation allowances billion us federal net operating loss carryforwards billion december carryforwards acquired result certain acquisitions subject limitations section internal revenue code net operating loss carryforwards expire varying amounts beginning foreign state net operating loss carryforwards expire varying amounts beginning certain amounts unlimited lives prior mead johnson splitoff following transactions occurred internal spinoff mead johnson shares still owned us ii conversion mead johnson class b shares class shares iii conversion mead johnson company limited liability company transactions well splitoff mead johnson exchange offer qualify taxexempt transactions internal revenue code based upon private letter ruling received internal revenue service related conversion mead johnson class b shares class shares outside legal opinions certain assumptions representations covenants mead johnson relied upon regarding future conduct business matters could affect tax treatment exchange example current tax law generally creates presumption exchange would taxable us mead johnson shareholders engage transactions result greater change stock ownership four year period beginning two years exchange offer unless established exchange offer part plan series related transactions effect change ownership internal spinoff exchange offer determined qualify tax exempt transaction transaction could subject tax exchange taxable sale us market value addition negative basis excess loss account ela existed investment stock mead johnson prior transactions received opinion outside legal counsel effect likely eliminated ela part transactions taxable income respect ela tax law area complex possible even internal spinoff exchange offer tax exempt internal revenue code internal revenue service could assert additional taxable income period respect ela could exposed additional taxes occur based upon understanding internal revenue code opinion outside legal counsel tax reserve million established reducing gain disposal mead johnson included discontinued operations agreed certain tax related indemnities mead johnson set forth tax sharing agreement including certain taxes related business prior completion initial public offering created part restructuring facilitate ipo mead johnson also agreed indemnify us potential tax effects resulting breach certain representations discussed well certain transactions related acquisition mead johnsons stock assets liabilities established possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known discussions income taxes refer item financial statements supplementary datanote accounting policies recently issued accounting standardsincome taxes note income taxes contingencies normal course business subject contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability contractual claims tax matters recognize accruals contingencies probable liability incurred amount loss reasonably estimated estimates subject uncertainties difficult predict actual results could vary estimates discussions contingencies refer item financial statements supplementary datanote accounting policies recently issued accounting standardscontingencies note income taxes note legal proceedings contingencies product pipeline developments rd programs managed portfolio basis early discovery latestage development include balance earlystage latestage programs support future growth late stage rd programs phase iii development include investigational compounds initial indications additional indications formulations marketed products spending programs represent approximately annual rd expenses last three years opdivo investigational compound marketed product represented greater rd expenses last three years late stage development programs could potentially impact revenue earnings within next years regulatory approvals obtained products successfully commercialized following developments marketed products latestage pipeline product indication date developments received supplemental japan nda approval revlimid relapsed refractory follicular lymphoma revlimid lymphoma february marginal zone lymphoma product indication date developments announced phase iii checkmate trial met primary endpoint pathologic complete response october resectable nsclc ono alliance partner opdivo japan announced topline results phase iii clinical study tasuki evaluating opdivo combination bevacizumab chemotherapy versus placebo august combination bevacizumab chemotherapy chemotherapynaive patients stage iiibiv nsclc recurrent nonsquamous nsclc opdivo combination group demonstrated statistically significant improvement primary endpoint progressionfree survival prespecified interim analysis ono alliance partner opdivo japan announced submission supplemental application japan opdivo expand use treatment unresectable advanced recurrent nsclc february combination treatment platinumdoublet chemotherapy partial change approved items manufacturing marketing approval announced fda approval opdivo combination cabometyx firstline treatment patients january advanced rcc approval based phase iii checkmateer trial ono alliance partner opdivo japan announced companies submitted supplemental application combination therapy opdivo cabometyx development commercialization october japan expand use combination therapy treatment unresectable metastatic rcc partial change approved items manufacturing marketing approval rcc announced exelixis checkmate er pivotal phase iii trial evaluating opdivo combination cabometyx compared sunitinib previously untreated advanced metastatic rcc met primary april endpoint progressionfree survival final analysis well secondary endpoints overall survival prespecified interim analysis objective response rate announced fiveyear followup results phase iii checkmate study continue february demonstrate treatment opdivo delivers superior overall survival objective response rates patients previously treated advanced metastatic rcc compared treated everolimus announced fda accepted sbla opdivo treatment patients resected esophageal gastroesophageal junction cancer adjuvant setting neoadjuvant chemoradiation opdivo january therapy fda granted application priority review assigned pdufa goal date may application based results phase iii checkmate trial announced ema validated maa opdivo adjuvant treatment esophageal january gastroesophageal junction cancer adult patients residual pathologic disease neoadjuvant chemoradiotherapy resection application based results phase iii checkmate trial announced fda accepted sbla opdivo combination fluoropyrimidine platinumcontaining chemotherapy treatment patients advanced metastatic gastric cancer january gastroesophageal junction cancer esophageal adenocarcinoma based results checkmate trial fda granted application priority review assigned pdufa goal date may application based results pivotal phase iii checkmate trial announced ema validated type ii variation maa opdivo combination gastric esophageal fluoropyrimidine platinumbased combination chemotherapy firstline treatment adult patients january cancers advanced metastatic gastric cancer gastroesophageal junction cancer esophageal adenocarcinoma application based results pivotal phase iii checkmate trial ono alliance partner opdivo japan announced submission supplemental application december opdivo expand use treatment unresectable advanced recurrent gastric cancer partial change approved items manufacturing marketing approval announced ec approval opdivo treatment adults unresectable advanced recurrent november metastatic esophageal squamous cell carcinoma prior fluoropyrimidine platinumbased combination chemotherapy ono alliance partner opdivo japan announced results phase iiiii clinical study evaluating opdivo combination chemotherapy versus placebo combination chemotherapy patients unresectable advanced recurrent gastric cancer negative human epidermal growth september factor receptor previously untreated firstline therapy japan south korea taiwan opdivo combination group demonstrated statistically significant improvement one two primary endpoints progressionfree survival show statistically significant improvement overall survival primary endpoint versus control combination group product indication date developments announced checkmate pivotal phase iii trial evaluating opdivo plus chemotherapy compared chemotherapy alone firstline treatment metastatic gastric cancer gastroesophageal junction cancer august esophageal adenocarcinoma met primary endpoints overall survival prespecified interim analysis progressionfree survival final analysis patients whose tumors express pdl combined positive score overall survival benefit also observed allrandomized population announced phase iii checkmate trial evaluating opdivo adjuvant therapy patients august resected esophageal gastroesophageal junction cancer met primary endpoint diseasefree survival prespecified interim analysis announced opdivo approved fda treatment patients unresectable advanced recurrent metastatic escc prior fluoropyrimidine platinumbased chemotherapy june application granted priority review designation fda opdivo first approved gastric esophageal immunotherapy setting regardless tumor pdl expression level cancers ono alliance partner opdivo japan announced submission supplemental application opdivo expand use treatment patients unresectable advanced recurrent gastric cancer may previously treated partial change approved items manufacturing marketing approval received nmpa approval opdivo l gastric cancer china approval supported march ono phase iii study ono alliance partner opdivo japan announced japans mhlw approved opdivo treatment patients unresectable advanced recurrent escc progressed following chemotherapy approval based phase iii attraction trial conducted ono february collaboration bms evaluated opdivo versus chemotherapy docetaxel paclitaxel treatment patients unresectable advanced recurrent escc refractory intolerant combination therapy fluoropyrimidine platinumbased drugs announced consultation fda withdrew us indication opdivo sclc following platinumbased chemotherapy least one line therapy opdivo granted opdivo accelerated approval sclc based surrogate endpoints phase iii checkmate trial sclc december advanced metastatic solid tumors demonstrated encouraging response rates duration response sclc however subsequent confirmatory studies different treatment settings checkmate checkmate meet primary endpoints overall survival ono alliance partner opdivo japan announced japan 's mhlw approved opdivo treatment patients msih unresectable advanced recurrent crc progressed following chemotherapy approval based result opdivo monotherapy cohort multicenter crc february openlabel phase ii checkmate study conducted bms evaluating opdivo patients hsih mismatch repair deficient recurrent metastatic crc progressed intolerant prior treatment chemotherapy including fluoropyrimidine anticancer drugs following routine review independent data monitoring commitee dmc bms informed phase iii checkmate trial evaluating opdivo plus standard care temozolomide radiation therapy newly diagnosed glioblastoma multiforme omethylguaninedna methyltransferase promoter glioblastoma december methylation following surgical resection tumor meet primary endpoint overall survival patients baseline corticosteroid use overall randomized population based dmc recommendation investigators unblinded treatment assignments patients currently deriving benefit opdivo permitted continue treatment agreed physician announced results phase iii checkmate trial showed opdivo significantly improved diseasefree survival adjuvant treatment across randomized patients surgically bladder february resected highrisk muscleinvasive urothelial carcinoma subgroup patients whose tumors express pdl meeting studys primary endpoints ono alliance partner opdivo japan announced opdivo demonstrate significant improvement overall survival primary endpoint versus chemotherapy patients platinum ovarian cancer january refractory advanced recurrent ovarian cancer final analysis multicenter randomized openlabel phase iii clinical study ono conducted japan product indication date developments announced ec approval opdivo plus yervoy two cycles platinumbased chemotherapy november firstline treatment adult patients metastatic nsclc whose tumors sensitizing epidermal growth factor receptor mutation anaplastic lymphoma kinase translocation ono alliance partner opdivo japan announced companies received approval japan following combination therapies opdivo yervoy firstline treatment unresectable november advanced recurrent nsclc partial change approved items manufacturing marketing approval japan combination therapy opdivo yervoy ii combination therapy opdivo yervoy plus chemotherapy iii combination therapy opdivo chemotherapy announced fda approval opdivoyervoy given two cycles platinumdoublet chemotherapy firstline treatment adult patients metastatic recurrent nsclc egfr alk may genomic tumor aberrations therapy approved patients squamous nonsquamous disease regardless pdl expression announced fda approval opdivoyervoy firstline treatment adult patients metastatic may nsclc whose tumors express pdl determined fdaapproved test egfr nsclc alk genomic tumor aberrations announced threeyear followup results part phase iii checkmate trial metastic nsclc demonstrating opdivoyervoy provided sustained improvements overall survival may additional efficacy measures firstline treatment compared chemotherapy among patients whose tumors expressed pdl announced voluntary withdrawal company 's application eu combination opdivo yervoy treatment advanced nsclc based data checkmate application originally filed patients firstline nsclc tumor mutational burden mutationsmegabase based final analysis progressionfree survival coprimary endpoint trial application subsequently amended include statistically significant result overall opdivoyervoy january survival coprimary endpoint checkmate part evaluating opdivoyervoy versus chemotherapy patients whose tumors expressed pdl though chmp acknowledged integrity patient level data chmp determined full assessment application possible following multiple protocol changes company made response rapidly evolving science data company plans refile application eu announced results coprimary endpoint checkmate randomized phase iii study evaluating opdivo plus yervoy versus opdivo patients complete surgical removal melanoma october stage iiibcd stage iv melanoma addition yervoy opdivo trial result statistically significant improvement recurrencefree survival allcomer intenttotreat population announced fda approval opdivoyervoy firstline treatment adult patients unresectable mpm approval based prespecified interim analysis phase iii october checkmate trial opdivoyervoy demonstrated superior overall survival versus platinum based standard care chemotherapy ono alliance partner opdivo japan announced companies submitted supplemental applications japan opdivo yervoy combination treatment expand use firstline october treatment unresectable advanced recurrent mpm partial change aprpoved items manufacturing marketing approval mpm announced ema validated type ii variation application opdivo plus yervoy treatment september patients previously untreated unresectable mpm announced checkmate pivotal phase iii trial evaluating opdivo combination yervoy previously untreated mpm met primary endpoint overall survival based prespecified interim april analysis conducted independent data monitoring committee opdivo combination yervoy resulted statistically significant clinically meaningful improvement overall survival compared chemotherapy pemetrexed cisplatin carboplatin product indication date developments announced half advanced rcc patients treated opdivo plus yervoy combination alive four years across entire study population phase iii checkmate clinical trial september combination continuing show superior longterm overall survival durable responses compared sunitinib announced updated results phase iii checkmate study evaluating combination rcc opdivoyervoy versus sunitinib patients previously untreated advanced metastatic rcc minimum followup months combination opdivoyervoy continues show superior overall february survival objective response rates duration response complete response rates safety profile opdivoyervoy consistent prior findings new safety signals drugrelated death occurred extended followup data presented american society clinical oncology genitourinary cancers symposium san francisco opdivoyervoy ono alliance partner opdivo japan announced companies received approval combination therapy opdivo yervoy japan expand combination use treatment crc september microsatellite instability high unresectable advanced recurrent crc progressed following chemotherapy partial change approved items manufacturing marketing approval announced opdivo mgkg plus yervoy mgkg injections intravenous use approved fda treat hcc patients previously treated sorafenib approval indication hcc march granted accelerated approval based overall response rate duration response seen opdivoyervoy cohort phase iii checkmate trial continued approval indication may contingent upon verification description clinical benefit confirmatory trials announced results openlabel switch period early ample phase iv exploratory biomarker study assessing differences orencia adalimumab interfere disease progression moderateto severe early ra patients seropositive certain autoantibodies early seropositive ra patients treated june orencia demonstrated substantial clinical improvements week sustaining level responses achieved week compared adalimumab seropositive patients switching adalimumab orencia efficacy responses generally increased openlabel period week orencia ra ono alliance partner orencia japan announced companies received approval orencia intravenous infusion mg orencia subcutaneous injection mg syringe ml february orencia subcutaneous injection mg autoinjector ml orencia include description prevention structural damage joints currently approved indication ra partial change approved items manufacturing marketing approval japan announced fda approval pomalyst patients aidsrelated kaposi sarcoma whose disease become resistant highly active antiretroviral therapy patients kaposi sarcoma hiv pomalyst kaposi sarcoma may negative pomalyst granted accelerated approval breakthrough therapy designation orphan drug designation indications announced topline results phase iii eloquent trial evaluating combination empliciti plus revlimid dexamethasone versus revlimid dexamethasone alone patients newly diagnosed empliciti multiple myeloma march previously untreated multiple myeloma transplant ineligible final analysis addition revlimid empliciti show statistically significant improvement progressionfree survival studys primary endpoint announced ec approval reblozyl treatment adult patients transfusiondependent anemia due june low low intermediaterisk mds ring sideroblasts unsatisfactory response ineligible erythropoietinbased therapy mds announced fda approval reblozyl treatment anemia failing erythropoiesis stimulating agent reblozyl requiring red blood cell units weeks adult patients low intermediaterisk mds april ring sideroblasts myelodysplasticmyeloproliferative neoplasm ring sideroblasts thrombocytosis announced ec approval reblozyl adult patients transfusiondependent anemia associated beta beta thalassemia june thalassemia product indication date developments announced fda accepted snda zeposia treatment adults moderately february severely active uc fda granted application priority review assigned pdufa goal date may announced ema validated maa zeposia treatment adults moderately december severely active uc uc announced pivotal phase iii trial true north evaluating oral zeposia induction maintenance therapy adult patients moderate severe uc met primary endpoints induction clinical june remission week maintenance week pvalue study also met key secondary endpoints clinical response endoscopic improvement induction timepoints safety profile consistent observed previously reported trials announced interim results phase iii openlabel extension trial daybreak demonstrating long zeposia september term efficacy safety profile zeposia patients rms trial included patients previously completed phase ii iii zeposia clinical trial average treatment time months daybreak new safety concerns emerged longterm use zeposia announced ec approval zeposia treatment adult patients rrms active disease defined clinical imaging features ec marketing authorization zeposia oral medication taken may rms daily becomes approved sphingosinephosphate receptor modulator rrms patients active disease announced fda approved zeposia ozanimod mg treatment adults rms including clinically isolated syndrome relapsingremitting disease active secondary progressive disease zeposia oral medication taken daily approved sphingosinephosphate receptor modulator march offers rms patients initiation genetic test labelbased firstdose observation required patients uptitration scheme used reach maintenance dosage zeposia transient decrease heart rate atrioventricular conduction delays may occur announced ec approval inrebic treatment diseaserelated splenomegaly enlarged spleen inrebic myelofibrosis february symptoms adult patients primary myelofibrosis postpolycythaemia vera myelofibrosis post essential thrombocythaemia myelofibrosis jak inhibitor nave treated ruxolitinib announced fda approval onureg azacitidine continued treatment adult patients aml september achieved first complete remission complete remission incomplete blood count recovery following intensive induction chemotherapy able complete intensive curative therapy onureg aml announced ema validated maa cc onureg maintenance treatment adult patients aml achieved complete remission complete remission incomplete blood count may recovery following induction therapy without consolidation treatment candidates choose proceed hematopoietic stem cell transplantation announced fda approved breyanzi lisocabtagene maraleucel lisocel treatment adult patients relapsed refractory large bcell lymphoma two lines systemic therapy february including diffuse large bcell lymphoma otherwise specified including dlbcl arising indolent lymphoma highgrade bcell lymphoma primary mediastinal large bcell lymphoma follicular breyanzi lymphoma grade b lymphoma lisocel announced ema validated maa lisocel investigational cddirected car cell july therapy treatment adults relapsed refractory diffuse large bcell lymphoma primary mediastinal bcell lymphoma follicular lymphoma grade b least two prior therapies announced bluebird bio fda accepted priority review bla idecel treatment adult patients multiple myeloma received least three prior therapies including september immunomodulatory agent proteasome inhibitor anticd antibody fda set pdufa goal date march announced ema validated maa idecel bb treatment adult patients multiple myeloma received least three prior therapies including immunomodulatory agent may proteasome inhibitor anticd antibody idecel granted accelerated assessment status ema march reducing maximum timeframe review application days idecel bb multiple myeloma bluebird announced updated results pivotal phase ii karmma study evaluating efficacy safety idecel bb rrmm patients heavily pretreated rrmm exposed least three prior therapies refractory last regimen treated idecel across range target may dose levels orr across dose levels including patients complete remission stringent complete remission clinically meaningful benefit consistently observed across subgroups nearly subgroups orr greater including older highrisk patients announced positive results poetyk pso second pivotal phase iii trial evaluating deucravacitinib novel oral selective tyrosine kinase inhibitor treatment patients moderate severe plaque psoriasis poetyk pso evaluated deucravacitinib mg daily met february coprimary endpoints versus placebo significantly patients achieving psoriasis area severity index pasi defined least percent improvement baseline pasi static physician 's global assessment spga score clear almost clear spga weeks treatment deucravacitinib deucravacitinib bms plaque psoriasis announced results phase iii poetyk pso trial evaluating deucravacitinib bms novel oral selective tyrosine kinase inhibitor treatment patients moderate severe plaque psoriasis poetyk pso met coprimary endpoints versus placebo patients achieving psoriasis area severity index pasi defined least percent improvement november pasi static physicians global assessment spga score clear almost clear spga weeks treatment trial also met multiple key secondary endpoints including showing deucravacitinib superior otezla proportion patients reaching pasi response spga week announced phase iii idhentify study evaluating idhifa plus best supportive care bsc versus conventional care regimens include bsc azacitidine plus bsc lowdose cytarabine plus bsc idhifa aml august intermediatedose cytarabine plus bsc meet primary endpoint overall survival patients relapsed refractory aml isocitrate dehydrogenase mutation special note regarding forwardlooking statements including documents incorporated reference written oral statements make time time contain certain forward looking statements within meaning section securities act section e exchange act identify forwardlooking statements fact use words could expect anticipate estimate target may project guidance intend plan believe words terms similar meaning expression connection discussion future operating financial performance one also identify forwardlooking statements fact relate strictly historical current facts forwardlooking statements based historical performance current expectations projections future financial results goals plans objectives involve inherent risks assumptions uncertainties including internal external factors could delay divert change next several years could cause future financial results goals plans objectives differ materially expressed implied statements statements likely relate among things goals plans objectives regarding financial position results operations cash flows market position product development product approvals sales efforts expenses performance results current anticipated products business development strategy generally relation ability realize projected benefits acquisitions celgene myokardia full extent impact covid pandemic operations development commercialization products potential laws regulations lower drug costs market actions taken private government payers manage drug utilization contain costs expiration patents data protection certain products including assumptions ability retain patent exclusivity certain products outcome contingencies legal proceedings financial results forwardlooking statement guaranteed included important factors cautionary statements included particularly item risk factors believe could cause actual results differ materially forwardlooking statement although believe prudent plans assumptions assurance given goal plan set forth forwardlooking statements achieved readers cautioned place undue reliance statements speak date made additional risks may currently deem immaterial presently known us could also cause forwardlooking events discussed occur except otherwise required federal securities law undertake obligation release publicly updates revisions forwardlooking statements result new information future events changed circumstances otherwise date item quantitative qualitative disclosures market risk exposed market risk resulting changes currency exchange rates interest rates certain derivative financial instruments used available costeffective basis hedge underlying economic exposure financial instruments including derivatives subject counterparty credit risk considered part overall fair value measurement derivative financial instruments used trading purposes foreign exchange risk significant amounts revenues earnings cash flow exposed changes foreign currency rates primary net foreign currency translation exposures euro japanese yen foreign currency forward contracts used manage risk primarily arising certain intercompany sales purchases transactions also exposed foreign exchange transaction risk arising nonfunctional currency denominated assets liabilities earnings denominated nonus dollar currencies foreign currency forward contracts used offset exposures designated hedges estimate appreciation underlying currencies hedged levels us dollar variables held constant would decrease fair value foreign exchange forward contracts million million december december respectively reducing earnings remaining life contracts also exposed translation risk nonus dollardenominated net assets nonus dollar borrowings used hedge foreign currency exposures net investment certain foreign affiliates designated hedges net investments effective portion foreign exchange gains losses hedges included foreign currency translation component accumulated comprehensive loss net investment decreases equivalent value nonus debt borrowings change remeasurement basis debt would subject recognition income changes occur additional information refer item financial statements supplementary datanote financial instruments fair value measurements interest rate risk use fixedtofloating interest rate swap contracts designated fair value hedges provide appropriate balance fixed floating rate debt use cross currency interest rate swap contracts designated hedge company 's net investment japan subsidiary fair values contracts well marketable debt securities analyzed yearend determine sensitivity interest rate changes sensitivity analysis basis point increase shortterm longterm interest rates december december expected adverse impact earnings would material estimate increase basis points longterm interest rates december december would decrease fair value longterm debt billion billion respectively credit risk monitor investments counterparties objective minimizing concentrations credit risk investment policy invest institutions meet high credit quality standards establishes limits amount time maturity investments individual counterparty policy also requires investments entered corporate financial institutions meet high credit quality standards use derivative instruments exposes us credit risk counterparty fails perform fair value derivative instrument contract positive counterparty fails perform collateral required party whether derivatives asset liability position policy diversifying derivatives counterparties mitigate overall risk counterparty defaults additional information refer item financial statements supplementary datanote financial instruments fair value measurements item financial statements supplementary data bristolmyers squibb company consolidated statements earnings dollars millions except per share data year ended december earnings net product sales alliance revenues total revenues cost products solda marketing selling administrative research development iprd charge myokardia acquisition amortization acquired intangible assets incomeexpense net total expenses lossearnings income taxes provision income taxes net lossearnings noncontrolling interest net lossearnings attributable bms lossearnings per common share basic diluted excludes amortization acquired intangible assets consolidated statements comprehensive lossincome dollars millions year ended december comprehensive lossincome net lossearnings comprehensive lossincome net taxes reclassifications earnings derivatives qualifying cash flow hedges pension postretirement benefits availableforsale securities foreign currency translation total comprehensive lossincome comprehensive lossincome comprehensive income attributable noncontrolling interest comprehensive lossincome attributable bms accompanying notes integral part consolidated financial statements bristolmyers squibb company consolidated balance sheets dollars millions except share per share data december assets current assets cash cash equivalents marketable debt securities receivables inventories current assets total current assets property plant equipment goodwill intangible assets deferred income taxes marketable debt securities noncurrent assets total assets liabilities current liabilities shortterm debt obligations accounts payable current liabilities total current liabilities deferred income taxes longterm debt noncurrent liabilities total liabilities commitments contingencies equity bristolmyers squibb company shareholders equity preferred stock convertible series par value per share authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares billion issued capital excess par value stock accumulated comprehensive loss retained earnings less cost treasury stock million common shares million common shares total bristolmyers squibb company shareholders equity noncontrolling interest total equity total liabilities equity accompanying notes integral part consolidated financial statements bristolmyers squibb company consolidated statements cash flows dollars millions year ended december cash flows operating activities net lossearnings adjustments reconcile net lossearnings net cash provided operating activities depreciation amortization net deferred income taxes stockbased compensation impairment charges pension settlements amortization divestiture gains royalties iprd charge myokardia acquisition asset acquisition charges equity investment gainslosses contingent consideration fair value adjustments adjustments changes operating assets liabilities receivables inventories accounts payable income taxes payable net cash provided operating activities cash flows investing activities sale maturities marketable debt securities purchase marketable debt securities capital expenditures divestiture proceeds acquisition payments net cash acquired net cash used investing activities cash flows financing activities shortterm debt obligations net issuance longterm debt repayment longterm debt repurchase common stock dividends net cash used inprovided financing activities effect exchange rates cash cash equivalents restricted cash increase cash cash equivalents restricted cash cash cash equivalents restricted cash beginning year cash cash equivalents restricted cash end year accompanying notes integral part consolidated financial statements note accounting policies recently issued accounting standards basis consolidation consolidated financial statements prepared conformity us gaap including accounts bristolmyers squibb company controlled majorityowned subsidiaries certain variable interest entities intercompany balances transactions eliminated material subsequent events evaluated disclosed report issuance date refer summary abbreviated terms end terms used throughout document alliance license arrangements assessed determine whether terms provide economic control entity requiring consolidation entity entities controlled means majority voting interest referred variable interest entities consolidated bms power direct activities variable interest entity significantly impacts economic performance obligation absorb losses right receive benefits could potentially significant entity business segment information bms operates single segment engaged discovery development licensing manufacturing marketing distribution sale innovative medicines help patients prevail serious diseases global research development organization supply chain organization responsible discovery development manufacturing supply products regional commercial organizations market distribute sell products business also supported global corporate staff functions consistent bmss operational structure chief executive officer ceo chief operating decision maker manages allocates resources global corporate level managing allocating resources global corporate level enables ceo assess overall level resources available best deploy resources across functions therapeutic areas regional commercial organizations research development projects line overarching longterm corporatewide strategic goals rather product franchise basis determination single segment consistent financial information regularly reviewed ceo purposes evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods information product regional revenue see note revenue use estimates judgments preparation financial statements requires use management estimates judgments assumptions significant assumptions estimates used determining accounting acquisitions impairments goodwill intangible assets sales rebate return accruals legal contingencies income taxes actual results may differ estimates reclassifications certain reclassifications made conform prior period consolidated financial statements current period presentation cash payments resulting licensing arrangements including upfront contingent milestones previously included operating activities consolidated statements cash flows presented investing activities adjustment resulted increase net cash provided operating activities net cash used investing activities million billion deferred income previously presented separately consolidated statements cash flows presented operating assets liabilities reclassifications impact net assets net earnings cash cash equivalents restricted cash cash cash equivalents include bank deposits time deposits commercial paper money market funds cash equivalents consist highly liquid investments original maturities three months less time purchase recognized cost approximates fair value cash restricted withdrawal general use contractually legally restricted including escrow litigation settlements funds restricted annual company contributions defined contribution plan us restricted cash million million december respectively marketable debt securities marketable debt securities classified availableforsale date purchase reported fair value fair value determined based observable market quotes valuation models using assessments counterparty credit worthiness credit default risk underlying security overall capital market liquidity marketable debt securities reviewed impairment assessing decline market value investment carrying value temporary considers intent ability retain investment period time sufficient allow anticipated recovery market value duration extent market value less cost investee 's financial condition investments equity securities investments equity securities readily determinable fair values recorded fair value changes fair value recorded incomeexpense net investments equity securities without readily determinable fair values recorded cost minus impairment plus minus changes estimated fair value resulting observable price changes orderly transactions identical similar investment issuer changes estimated fair value investments equity securities without readily determinable fair values recorded incomeexpense net investments less owned companies accounted using equity method accounting ability exercise significant influence operating financial decisions investee maintained proportional share investees net income losses equity investments accounted using equity method included incomeexpense net investments equity securities without readily determinable fair values investments equity accounted using equity method assessed potential impairment quarterly basis based qualitative factors inventory valuation inventories stated lower average cost net realizable value property plant equipment depreciation expenditures additions renewals improvements capitalized cost depreciation computed straightline method based estimated useful lives related assets ranging years buildings years machinery equipment fixtures current facts circumstances periodically evaluated determine carrying value depreciable assets held used may recoverable circumstances exist estimate undiscounted future cash flows generated longlived asset appropriate grouping assets compared carrying value determine whether impairment exists lowest level identifiable cash flows asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques using unobservable fair value inputs discounted value estimated future cash flows capitalized software eligible costs obtain internal use software capitalized amortized estimated useful life software ranging three ten years acquisitions businesses acquired consolidated upon obtaining control fair value assets acquired liabilities assumed recognized date acquisition excess purchase price estimated fair values net assets acquired recognized goodwill business acquisition costs expensed incurred contingent consideration potential development regulatory approval salesbased milestones salesbased royalties included purchase price business combinations excluded asset acquisitions certain transactions accounted asset acquisitions since determined business term defined asc primarily significant processes acquired substantially relative fair value allocated single asset amounts allocated investigational compounds asset acquisitions expensed date acquisition goodwill acquired inprocess research development intangible assets fair value acquired intangible assets determined using incomebased approach referred excess earnings method utilizing level fair value inputs market participant valuations assume global view considering potential jurisdictions indications based discounted aftertax cash flow projections risk adjusted estimated probability technical regulatory success finitelived intangible assets including licenses marketed product rights iprd projects reach commercialization amortized straightline basis estimated useful life estimated useful lives determined considering period assets expected contribute future cash flows finitelived intangible assets tested impairment facts circumstances suggest carrying value asset may recoverable carrying value exceeds projected undiscounted pretax cash flows intangible asset impairment loss equal excess carrying value estimated fair value discounted aftertax cash flows recognized goodwill tested least annually impairment assessing qualitative factors determining whether likely fair value net assets carrying amounts examples qualitative factors assessed include bmss share price financial performance compared budgets longterm financial plans macroeconomic industry market conditions well substantial excess fair value carrying value net assets annual impairment test performed prior year relevant factor assessed individually aggregate iprd tested impairment annual basis frequently events occur circumstances change would indicate potential reduction fair values assets carrying value impairment charges recognized extent carrying value iprd determined exceed fair value restructuring restructuring charges recognized result actions streamline operations realize synergies acquisitions reduce number facilities estimating impact restructuring plans including future termination benefits integration expenses exit costs requires judgment actual results could vary estimates restructuring charges recognized upon meeting certain criteria including finalization committed plans reliable estimates discussions local works councils certain markets contingencies loss contingencies legal proceedings claims may occur government investigations shareholder lawsuits product environmental liability contractual claims tax matters accruals recognized probable liability incurred amount loss reasonably estimated gain contingencies including contingent proceeds related divestitures recognized realized legal fees expensed incurred revenue recognition refer note revenue detailed discussion accounting policies related revenue recognition including deferred revenue royalties refer note alliances detail regarding alliances research development research development costs expensed incurred clinical study costs accrued service periods specified contracts adjusted necessary based upon ongoing review level effort costs actually incurred research development costs presented net reimbursements alliance partners upfront contingent development milestone payments asset acquisitions investigational compounds also included research development expense alternative future uses advertising product promotion costs advertising product promotion costs expensed incurred advertising product promotion costs included marketing selling administrative expenses million million million foreign currency translation foreign subsidiary earnings translated us dollars using average exchange rates net assets foreign subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recognized comprehensive lossincome income taxes provision income taxes includes income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax basis assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made tax benefits recognized uncertain tax position likely tax position sustained examination taxing authorities based technical merits position tax benefit recognized financial statements particular tax position based largest benefit likely realized upon settlement recently adopted accounting standards financial instruments measurement credit losses june fasb issued amended guidance measurement credit losses financial instruments entities required use forwardlooking estimated loss model availableforsale debt security credit losses recognized allowances rather reduction amortized cost bms adopted amended guidance modified retrospective approach january amended guidance impact bmss results operations note revenue following table summarizes disaggregation revenue nature year ended december dollars millions net product sales alliance revenues revenues total revenues net product sales represent total revenues years ended december products sold principally wholesalers distributors specialty pharmacies lesser extent directly retailers hospitals clinics government agencies customer orders generally fulfilled within days receipt resulting minimal order backlog contractual performance obligations usually limited transfer control product customer transfer occurs either upon shipment upon receipt product considering customer obtains legal title product bms obtains right payment points customers able direct use obtain substantially remaining benefits product gross revenue three largest pharmaceutical wholesalers us percentage global gross revenues follows year ended december mckesson corporation amerisourcebergen corporation cardinal health inc wholesalers initially invoiced contractual list prices payment terms typically days based customary practices country revenue reduced wholesaler list price time recognition expected chargebacks discounts rebates sales allowances product returns referred gtn adjustments reductions attributed various commercial arrangements managed healthcare organizations government programs medicare medicaid b drug pricing program containing various pricing implications mandatory discounts pricing protection wholesaler list price discounts medicare part beneficiaries coverage gap addition nonus government programs include different pricing schemes cost caps volume discounts outcomebased pricing pricing clawbacks determined sales individual companies aggregation companies participating specific market chargebacks cash discounts reflected reduction receivables settled issuance credits customer typically within one month rebates discounts adjustments including medicaid medicare reflected liability settled cash payments customer typically within various time periods ranging months one year significant judgment required estimating gtn adjustments considering legal interpretations applicable laws regulations historical experience payer channel mix current contract prices applicable programs unbilled claims processing time lags inventory levels distribution channel following table summarizes gtn adjustments year ended december dollars millions gross product sales gtn adjustmentsa chargebacks cash discounts medicaid medicare rebates rebates returns discounts adjustments total gtn adjustments net product sales includes adjustments provisions product sales made prior periods resulting changes estimates million million million alliance revenues consist primarily amounts related collaborations outlicensing arrangements arrangements evaluated whether represent contracts within scope revenue recognition guidance entirety contain aspects within scope guidance either directly reference based upon application guidance related derecognition nonfinancial assets asc performance obligations identified separated party benefit directly rights goods services either together readily available resources rights goods services highly interdependent interrelated transaction prices arrangements may include fixed upfront amounts well variable consideration contingent development regulatory milestones salesbased milestones royalties likely amount method used estimate contingent development regulatory salesbased milestones ultimate outcomes binary nature expected value method used estimate royalties broad range potential outcomes exist except instances royalties relate license variable consideration included transaction price extent significant reversal amount cumulative revenue recognized probable occurring uncertainty associated variable consideration subsequently resolved significant judgment required estimating amount variable consideration recognize assessing factors outside bmss influence likelihood regulatory success limited availability third party information expected duration time resolution lack relevant past experience historical practice offering fee concessions large number broad range possible amounts extent arrangements include multiple performance obligations separable transaction price assigned distinct performance obligation reflective relative standalone selling price recognized point time upon transfer control three types outlicensing arrangements typically utilized arrangements bms outlicenses intellectual property another party performance obligations ii arrangements include license additional performance obligation supply product upon request third party iii collaboration arrangements include transferring license third party jointly develop commercialize product outlicensing arrangements consist single performance obligation satisfied upon execution agreement development commercialization rights transferred third party upfront fees recognized immediately included incomeexpense net although contingent development regulatory milestone amounts assessed period likelihood achievement typically constrained recognized uncertainty subsequently resolved full amount milestone included incomeexpense net salesbased milestones royalties recognized milestone achieved subsequent sales occur salesbased milestones included incomeexpense net royalties included alliance revenues certain outlicensing arrangements may also include contingent performance obligations supply commercial product third party upon request license supply obligations accounted separate performance obligations considered distinct third party benefit license either together supply resources readily available obligations separately identifiable obligations contract accordance revenue recognition guidance considering standalone selling prices situations upfront fees contingent development regulatory milestone amounts salesbased milestone royalties allocated license recognized manner described consideration supply obligation usually based upon stipulated costplus margin contractual terms represent standalone selling price supply consideration recognized point time upon transfer control product third party included alliance revenues fee allocation license supply represents amount consideration expected entitled satisfaction separate performance obligations although collaboration arrangements unique nature parties active participants operating activities exposed significant risks rewards depending commercial success activities performance obligations inherent arrangements may include transfer certain development commercialization rights ongoing development commercialization services product supply obligations except certain product supply obligations considered distinct accounted separate performance obligations similar manner discussed performance obligations considered distinct combined single performance obligation since transferred rights highly integrated interrelated obligation jointly develop commercialize product third party result upfront fees recognized ratably time throughout expected period collaboration activities included incomeexpense net license combined development commercialization obligations contingent development regulatory milestones longer constrained recognized similar manner prospective basis royalties profit sharing recognized underlying sales profits occur included alliance revenues refer note alliances information following table summarizes disaggregation revenue product region year ended december dollars millions prioritized brands revlimid eliquis opdivo orencia pomalystimnovid sprycel yervoy abraxane empliciti reblozyl inrebic onureg zeposia established brands vidaza baraclude brandsa total revenues united states europe rest world otherb total revenues includes bms celgene products b revenues include royalties alliancerelated revenues products sold bmss regional commercial organizations contract assets primarily estimated future royalties termination fees eligible licensing exclusion therefore recognized upon adoption asc asc contract assets reduced receivables increased period underlying sales occur cumulative catchup adjustments revenue affecting contract assets contract liabilities material year ended december revenue recognized performance obligations satisfied prior periods million million consisting primarily royalties outlicensing arrangements revised estimates gtn adjustments related prior period sales contract assets material december sales commissions incremental costs obtaining customer contracts expensed incurred amortization periods would less one year note alliances bms enters collaboration arrangements third parties development commercialization certain products although arrangements unique nature parties active participants operating activities collaboration exposed significant risks rewards depending commercial success activities bms may either inlicense intellectual property owned party outlicense intellectual property party arrangements also typically include research development manufacturing andor commercial activities cover single investigational compound commercial product multiple compounds andor products various life cycle stages rights obligations parties global limited geographic regions bms refer collaborations alliances partners alliance partners common activities bms alliance partners presented results operations follows bms principal end customer sale product sales included net product sales bms 's alliance partner principal end customer sale bmss contractual share thirdparty sales andor royalty income included alliance revenues sale commercial products considered part bmss ongoing major central operations refer note revenue information regarding recognition criteria amounts payable bms alliance partners principal end customer sale supply commercial products included alliance revenues sale commercial products considered part bmss ongoing major central operations profit sharing royalties salesbased fees payable bms alliance partners included cost products sold incurred cost reimbursements parties recognized incurred included cost products sold marketing selling administrative expenses research development expenses based underlying nature related activities subject reimbursement upfront contingent development regulatory approval milestones payable bms alliance partners investigational compounds commercial products deferred amortized expected period bms 's development copromotion obligation market exclusivity period periods related compounds products expected contribute future cash flows amortization presented consistent nature payment arrangement example amounts received investigational compounds presented incomeexpense net activities performed time related sale commercial products included bmss ongoing major central operations amounts received commercial products presented alliance revenue sale commercial products considered part bmss ongoing major central operations upfront contingent regulatory approval milestones payable bms alliance partners commercial products capitalized amortized shorter contractual term periods related products expected contribute future cash flows upfront contingent milestones payable bms alliance partners prior regulatory approval expensed incurred included research development expense royalties contingent consideration payable bms alliance partners related divestiture businesses included incomeexpense net earned payments bms alliance partners presented cash flows operating activities selected financial information pertaining alliances follows including net product sales bms principal thirdparty customer sale products subject alliance expenses summarized include amounts attributed activities products alliance payments alliance partners related amortization payments deferred capitalized year ended december dollars millions revenues alliances net product sales alliance revenues total revenues payments tofrom alliance partners cost products sold marketing selling administrative research development incomeexpense net selected alliance balance sheet information december dollars millions receivables alliance partners accounts payable alliance partners deferred income alliancesa includes unamortized upfront milestone payments specific information pertaining significant alliances discussed including nature purpose significant rights obligations parties specific accounting policy elections statements earnings classification amounts attributable payments parties pfizer bms pfizer jointly develop commercialize eliquis anticoagulant discovered bms pfizer funds development costs depending study profits losses shared equally global basis except certain countries pfizer commercializes eliquis pays bms sales based fee coexclusive license rights granted pfizer exchange upfront payment potential milestone payments parties assumed certain obligations actively participate joint executive committee various operating committees joint responsibilities research development distribution sales marketing activities alliance using resources infrastructures bms pfizer manufacture product alliance bms principal end customer product sales us significant countries europe well canada australia china japan south korea certain smaller countries pfizer full commercialization rights bms supplies product pfizer cost plus percentage net sales price endcustomers recorded full upon transfer control product pfizer bms allocate consideration rights transferred pfizer rights sold separately bms party could pfizer receive benefit delivered rights without fulfillment ongoing obligations bms alliance agreement global alliance treated single unit accounting upfront proceeds subsequent contingent milestone proceeds amortized expected period bmss copromotion obligation market exclusivity period bms received million nonrefundable upfront milestone licensing payments amortized included incomeexpense net eliquis commercial product commencement alliance summarized financial information related alliance follows year ended december dollars millions revenues pfizer alliance net product sales alliance revenues total revenues payments tofrom pfizer cost products sold profit sharing incomeexpense net amortization deferred income selected alliance balance sheet information december dollars millions receivables accounts payable deferred income ono bms ono jointly develop commercialize opdivo yervoy several bms investigational compounds japan south korea taiwan bms responsible supply products profits losses development costs shared equally combination therapies involving compounds parties otherwise sharing activities involving one partys compounds bms ono also jointly develop commercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulations jointly promoted parties assigned customer accounts bms responsible product supply copromotion fee paid sale made partys assigned customer ono exercised right accept nktr alliance bms upon completion phase clinical study opdivo nktr ono territory ono partially reimbursed bms development costs incurred study shares certain future development costs contingent milestone payments profits losses collaboration nektar ono granted bms exclusive license development commercialization ono onos prostaglandin e receptor antagonist rights terminated parties summarized financial information related alliance follows year ended december dollars millions revenues ono alliances net product sales alliance revenues total revenues bms principal end customer product sales exclusive right develop manufacture commercialize opdivo worldwide except japan south korea taiwan ono entitled receive royalties north america territories excluding three countries listed subject customary adjustments nektar bms nektar commenced worldwide license collaboration development commercialization bempegaldesleukin nktr nektars investigational immunostimulatory therapy designed selectively expand specific cancerfighting cells natural killer cells directly tumor micro environment january parties amended collaboration agreement opdivo nktr combination therapy currently phase iii clinical studies metastatic melanoma adjuvant melanoma muscleinvasive bladder cancer rcc joint development plan agreed parties part original agreement updated part january amendment specifies development certain indications tumor types party responsible supply product bmss share development costs associated therapies comprising bms medicine used combination nktr subject certain cost caps nektar january amendment retains cost sharing percentages original agreement parties also jointly commercialize therapies subject regulatory approval bmss share global nktr profits losses subject certain annual loss caps nektar bms paid nektar billion rights discussed million shares nektar common stock represented ownership interest bmss equity ownership subject certain lockup standstill voting provisions fiveyear period amount upfront payment allocated equity investment million considering nektars stock price date closing current limitations trading securities remaining billion upfront payment allocated rights discussed included research development expense bms also pay billion upon achievement contingent development regulatory salesbased milestones life alliance period research development expense payable agreement nektar million million million bluebird bms bluebird jointly develop commercialize novel diseasealtering gene therapy product candidates targeting bcma collaboration arrangement began included right bms license antibcma products resulting collaboration ii right bluebird participate development commercialization licensed products resulting collaboration codevelopment profit share us exchange reduction milestone payments iii salesbased milestones royalties payable bluebird upon commercialization licensed products resulting collaboration bluebird declined exercise codevelopment profit sharing rights options license idecabtagene vicleucel idecel bb bb exercised respectively bms bluebird share equally profits losses relating developing commercializing manufacturing idecel within us bms exclusively responsible development commercialization idecel outside us bms responsible worldwide development including related funding substantial completion bluebird ongoing phase clinical trial commercialization bb bluebird option codevelop copromote share equally profits losses us bms bluebird amended collaboration arrangement among items bms assuming contract manufacturing agreements relating idecel adherent lentiviral vector time bms assuming responsibility manufacturing idecel suspension lentiviral vector outside us bluebird responsible manufacturing idecel suspension lentiviral vector us parties also released future exclusivity related bcmadirected cell therapies addition bms agreed buy obligation pay bluebird future exus milestones royalties idecel bb payment million included research development expense cost sharing payments parties material otsuka bms otsuka copromoted sprycel us eu bms responsible development manufacture product also principal end customer product sales fee paid otsuka based net sales levels oncology territory us japan eu equated million first billion annual net sales plus net sales excess billion revenues earned otsuka alliance billion billion payments otsuka million million recorded cost product sold effective january otsuka longer copromoting sprycel us result arrangement longer considered collaboration asc revenues earned fees paid otsuka oncology territory included select financial information table note acquisitions divestitures licensing arrangements acquisitions business combination celgene november bms completed celgene acquisition acquisition expected position bms leading biopharmaceutical company sustained innovation longterm growth address needs patients cancer inflammatory immunologic cardiovascular diseases high value innovative medicines leading scientific capabilities share celgene common stock converted right receive one share bms common stock cash celgene shareholders also received one tradeable contingent value right cvr share celgene common stock representing right receive cash subject achievement future regulatory milestones aggregate cash paid connection celgene acquisition billion billion net cash acquired bms funded acquisition cash onhand debt proceeds described note financial instruments fair value measurements transaction accounted business combination requires assets acquired liabilities assumed recognized fair value acquisition date assessment fair value assets acquired liabilities assumed finalized measurement period adjustments reflected primarily resulted completing valuations real estate personal property revised future cash flow estimates certain intangible assets changes estimated tax basis certain intangible assets based upon tax ruling reduced deferred income tax liabilities changes certain equity investments legal contingency income tax liabilities related impact net earnings would recognized previous periods adjustments recognized acquisition date material consolidated financial statements total consideration acquisition consisted following amounts millions except per share data total consideration celgene shares outstanding november cash per share cash consideration outstanding shares celgene shares outstanding november closing price bms common stock november estimated fair value share consideration celgene shares outstanding november closing price cvra fair value cvrs fair value replacement options fair value replacement restricted share awards fair value cvrs issued option share award holders fair value sharebased compensation awards attributable precombination serviceb total consideration transferred closing price cvr based first trade november b fair value awards attributed postcombination services billion included compensation costs refer note employee stock benefit plans information purchase price allocation resulted following amounts allocated assets acquired liabilities assumed acquisition date based upon respective fair values summarized amounts recognized acquisition date previously measurement period purchase price dollars millions reported adjustments allocation cash cash equivalents receivables inventories property plant equipment intangible assetsa otezla assets heldforsaleb assets accounts payable income taxes payable deferred income tax liabilities debt liabilities identifiable net assets acquired goodwillc total consideration transferred intangible assets consists currently marketed product rights approximately billion amortized years calculated using weightedaverage useful life assets iprd approximately billion amortized valued using multiperiod excess earnings method method starts forecast expected future net cash flows associated asset involves adjusting forecast present value applying appropriate discount rate reflects risk factors associated cash flow streams b amount includes million inventory billion developed product rights million accrued liabilities million noncurrent liabilities refer divestitures information c goodwill represents goingconcern value associated future product discovery beyond existing pipeline expected value synergies resulting cost savings avoidance attributed identifiable assets goodwill deductible tax purposes bmss consolidated statement earnings year ended december include billion revenues billion net loss associated result operations celgene acquisition date december acquisition expenses million year ended december including financial advisory legal proxy filing regulatory financing fees hedge costs following unaudited pro forma information prepared celgene acquisition otezla divestiture occurred january unaudited supplemental pro forma consolidated results purport reflect combined companys results operations would project future results operations combined company unaudited supplemental pro forma consolidated results reflect historical financial information bms celgene adjusted give effect celgene acquisition otezla divestitures occurred january primarily following adjustments amortization expenses primarily related fair value adjustments celgenes intangible assets inventories debt nonrecurring acquisitionrelated costs directly attributable celgene acquisition tax expense directly attributable otezla divestiture interest expense including amortization deferred financing fees attributable celgene acquisition financing elimination historical revenue expenses related otezla refer divestitures adjustments adjusted applicable tax impact using estimated weightedaverage statutory tax rate applied applicable pro forma adjustments year ended december amounts million total revenues net earningsloss asset acquisitions myokardia november bms acquired myokardia clinicalstage biopharmaceutical company pioneering precision medicine approach discover develop commercialize targeted therapies treatment serious cardiovascular diseases bms subsidiary completed tender offer acquire issued outstanding shares myokardias common stock accepted shares validly tendered withdrawn expiration time tender offer per share billion including cash settlements equity stock awards acquisition provides bms rights myokardias lead asset mavacamten potential firstinclass cardiovascular medicine treatment obstructive hypertrophic cardiomyopathy completed phase iii development anticipated nda submission first quarter bms funded transaction combination cash hand operations net proceeds received connection senior unsecured notes offering consideration transferred allocated based relative fair value gross assets acquired transaction accounted asset acquisition since mavacamten represented substantially fair value gross assets acquired excluding cash deferred income taxes result billion iprd charge recognized fourth quarter following summarizes total consideration transferred allocation consideration transferred assets acquired liabilities assumed amounts million amounts cash consideration outstanding shares cash consideration stock awards consideration paid less charge unvested stock awardsa transaction costs consideration allocated intangible assetsb cash cash equivalents deferred income taxes assets liabilities total assets acquired net represents accelerated vesting myokardia stock awards included marketing selling administrative expense million research development expense million december b includes iprd billion billion related mavacamten licenses million forbius bms acquired outstanding shares forbius privately held clinicalstage protein engineering company designs develops biotherapeutics treatment cancer fibrotic diseases acquisition provides bms full rights forbiuss tgfbeta program including programs lead investigational asset avid phase development bms accounted transaction asset acquisition since avid represented substantially fair value gross assets acquired transaction price included upfront payment million contingent development regulatory salesbased milestone payments million upfront payment included research development expense except million allocated deferred tax assets research development expense also includes million million resulting occurrence certain development events attributed cormorant asset acquisition completed divestitures following table summarizes financial impact divestitures including royalties included incomeexpense net revenue pretax earnings related divestitures material periods presented excluding divestiture gains losses proceedsa divestiture gains royalty income dollars millions diabetes business erbitux business manufacturing operations plavix avaproavalide otezla upsa business mature brands total includes royalties received subsequent related sale asset business diabetes business february bms astrazeneca terminated diabetes business alliance agreements bms sold astrazeneca substantially diabetes business comprising alliance consideration transaction included tiered royalty payments ranging based net sales royalties million million million september bms transferred percentage future royalty rights amylin net product sales us cppib transferred rights represent approximately potential future royalties bms entitled exchange transfer bms received additional tieredbased royalty amylin net product sales us cppib including million paid million million november bms transferred percentage future royalty rights portion onglyza farxiga net product sales royalty pharma transferred rights represent approximately potential future royalties bms entitled products exchange transfer bms received additional tieredbased royalty onglyza farxiga net product sales royalty pharma including million million paid million erbitux business bms commercialization agreement lilly lillys subsidiary imclone codevelopment promotion erbitux us canada japan bms principal end customer product sales north america paid lilly distribution fee erbitux net sales north america plus share certain royalties paid lilly october bms transferred rights erbitux north america lilly exchange tiered salesbased royalties september including million bms transferred cocommercialization rights japan merck kgaa exchange salesbased royalties result adoption asc estimated future royalties resulting transfer rights merck kgaa recorded cumulative effect adjustment retained earnings million change estimated future royalties included manufacturing operations bms sold manufacturing packaging facility anagni italy catalent inc transaction accounted sale business divestiture included transfer facility majority employees site inventories certain thirdparty contract manufacturing obligations assets reduced relative fair value considering purchase price resulting impairment charge million included cost products sold catalent inc provide certain manufacturing packaging services bms period time bms sold small molecule active pharmaceutical ingredient manufacturing operations swords ireland sk biotek co ltd proceeds million received transaction accounted sale business divestiture included transfer facility majority employees site inventories certain thirdparty contract manufacturing obligations plavix avaproavalide sanofi reacquired bms 's codevelopment cocommercialization agreements plavix avaproavalide consideration transfer rights included quarterly royalties december million terminal payment received million allocated optout markets million allocated bms 's interest europe asia territory partnership royalties expected received portion terminal payment allocated optout markets reflected contract asset cumulative effect adjustment upon adoption asc bms fulfilled performance obligation million allocated bms 's partnership interest deferred december recognized equity investment gain transferred sanofi royalties earned sanofi territory covering americas australia optout markets presented alliance revenues aggregated million royalties attributed territory covering europe asia earned territory partnership paid bms included equity net lossincome affiliates amounted million otezla order complete celgene acquisition bms required ftc divest certain products november bms completed divestiture otezla apremilast amgen billion cash transaction accounted asset divestiture otezla acquired part celgene acquisition classified heldforsale time acquisition fair value otezla net assets consisted billion developed product rights million inventory upsa business bms sold upsa consumer health business including shares upsa sas bmss assets liabilities relating upsa product portfolio transaction accounted sale business mature brands mature brand sold resulting proceeds million divestiture gains million several mature brands sold cheplapharm resulting proceeds million divestiture gains million licensing arrangements following table summarizes financial impact keytruda royalties tecentriq royalties upfront milestone licensing fees products obtained commercial approval included incomeexpense net year ended december dollars millions keytruda royalties tecentriq royalties upfront licensing fees contingent milestone income amortization deferred income royalties total tecentriq patent license bms ono entered global patent license agreement roche group related tecentriq atezolizumab roches antipdl antibody agreement roche paid million included royalties nine months ended september pay singledigit royalties worldwide net sales tecentriq december upfront payment royalties shared bms ono consistent existing agreements bms recorded million incomeexpense net settlement million royalties fourth quarter dragonfly bms obtained global exclusive license dragonflys interleukin il investigational immunotherapy program including extended halflife cytokine df bms responsible development subsequent commercialization df related products worldwide including strategic decisions regulatory responsibilities funding manufacturing dragonfly continue involved development df current certain future phase iii clinical trials bms paid million dragonfly rights including million following commencement phase combination clinical study included research development expense dragonfly eligible receive additional contingent consideration comprised development regulatory salesbased milestone payments billion royalties global net sales note incomeexpense net year ended december dollars millions interest expense contingent consideration royalties licensing income equity investment gainslosses integration expenses provision restructuring litigation settlements transition service fees investment income reversion excise tax divestiture gains intangible asset impairment pension postretirement acquisition expenses incomeexpense net note restructuring celgene acquisition plan restructuring integration plan implemented initiative realize sustainable run rate synergies resulting cost savings avoidance celgene acquisition currently expected approximately billion synergies expected realized cost products sold marketing selling administrative expenses research development expenses charges approximately billion expected incurred cumulative charges approximately billion recognized including integration planning execution expenses employee termination benefit costs accelerated stockbased compensation contract termination costs shutdown costs associated site exits cash outlays connection actions expected approximately billion employee workforce reductions approximately myokardia acquisition plan restructuring integration plan initiated realize expected cost synergies resulting cost savings avoidance myokardia acquisition charges approximately million expected incurred consist integration planning execution expenses employee termination benefit costs costs company transformation restructuring plan announced evolve streamline bmss operating model cumulative charges approximately billion recognized actions since announcement actions plan completed december following provides charges related restructuring initiatives type cost year ended december dollars millions celgene acquisition plan myokardia acquisition plan company transformation total charges employee termination costs termination costs provision restructuring integration expenses accelerated depreciation asset impairments shutdown costs total charges cost products sold marketing selling administrative research development incomeexpense net total charges following summarizes charges spending related restructuring plan activities year ended december dollars millions liability december ceaseuse liability reclassification liability january provision restructuringa foreign currency translation payments liability december includes reductions liability resulting changes estimates million million million respectively excludes million million accelerated stockbased compensation relating celgene acquisition plan note income taxes provisionbenefit income taxes consisted year ended december dollars millions current us nonus total current deferred us nonus total deferred total provision effective tax rate reconciliation effective tax rate us statutory federal income tax rate follows earnings income taxes dollars millions lossearnings income taxes us nonus total us statutory rate deemed repatriation transition tax global intangible low taxed income gilti foreign tax effect certain operations ireland puerto rico switzerland internal transfer intangible assets us federal valuation allowance us federal state foreign contingent tax matters us federal research based credits contingent value rights nondeductible rd charges puerto rico excise tax state local taxes net valuation allowance foreign total tax charge deemed repatriation transition tax complete december included favorable measurement period adjustments provisional amounts recorded associated act gilti tax associated otezla divestiture million million bms longer indefinitely reinvested respect undistributed earnings foreign subsidiaries provided deferred tax liability foreign state income withholding tax would apply bms remains indefinitely reinvested respect financial statement basis excess tax basis foreign subsidiaries determination deferred tax liability respect basis difference practicable bms operates favorable tax grant puerto rico scheduled expire prior internal transfer certain intangible assets us acquired celgene transaction resulted tax charge establish deferred tax liability based fair value assets us federal valuation allowance established result nektar equity investment fair value losses would considered limited capital loss us federal state foreign contingent tax matters includes million tax benefit million tax benefit respect lapse statutes fair value adjustments contingent value rights taxable tax deductible nondeductible rd charges primarily resulted billion myokardia iprd charge puerto rico imposes excise tax gross company purchase price goods sold bmss manufacturer puerto rico excise tax recognized cost products sold intraentity sale occurs us income tax purposes excise tax deductible results foreign tax credits generally recognized bmss provision income taxes excise tax incurred deferred taxes valuation allowance components current noncurrent deferred income tax assetsliabilities follows december dollars millions deferred tax assets foreign net operating loss carryforwards state net operating loss credit carryforwards us federal net operating loss credit carryforwards milestone payments license fees foreign deferred tax assets sharebased compensation total deferred tax assets valuation allowance deferred tax assets net valuation allowance deferred tax liabilities acquired intangible assets goodwill total deferred tax liabilities deferred tax liabilities net recognized deferred income taxes assets noncurrent deferred income taxes liabilities noncurrent total us federal net operating loss carryforwards billion december carryforwards acquired result certain acquisitions subject limitations section internal revenue code net operating loss carryforwards expire varying amounts beginning foreign state net operating loss carryforwards expire varying amounts beginning certain amounts unlimited lives december valuation allowance billion exists following items billion primarily foreign net operating loss tax credit carryforwards million state deferred tax assets including net operating loss tax credit carryforwards million us federal deferred tax assets including equity fair value adjustments us federal net operating loss carryforwards changes valuation allowance follows year ended december dollars millions balance beginning year provision utilization foreign currency translation acquisitions non us rate change balance end year income tax payments billion billion million respectively business conducted various countries throughout world subject tax numerous jurisdictions significant number tax returns filed subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported requiring several years resolve liabilities established possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credit deductibility certain expenses deemed repatriation transition tax liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known effect changes estimates related contingent tax liabilities included effective tax rate reconciliation reconciliation beginning ending amount gross unrecognized tax benefits follows excluding interest penalties year ended december dollars millions balance beginning year gross additions tax positions related current year gross additions tax positions related prior years gross additions tax positions assumed acquisitions gross reductions tax positions related prior years settlements reductions tax positions related lapse statute cumulative translation adjustment balance end year additional information regarding unrecognized tax benefits follows year ended december dollars millions unrecognized tax benefits recognized would impact effective tax rate accrued interest accrued penalties accrued interest penalties payable unrecognized tax benefits included either current noncurrent income taxes payable interest penalties related unrecognized tax benefits included income tax expense bms currently examination number tax authorities proposed considering proposing material adjustments tax positions issues transfer pricing certain tax credits deductibility certain expenses bms received several notices proposed adjustments irs related transfer pricing tax positions tax years reasonably possible new issues raised tax authorities may require adjustments amount unrecognized tax benefits however estimate adjustments reasonably made time also reasonably possible total amount unrecognized tax benefits december could decrease range approximately million million next twelve months result settlement certain tax audits events expected change unrecognized tax benefits may result payment additional taxes adjustment certain deferred taxes andor recognition tax benefits following summary major tax jurisdictions tax authorities may assert additional taxes based upon tax years currently audit subsequent years likely audited us canada france germany italy japan switzerland uk note lossearnings per share year ended december amounts millions except per share data net lossearnings attributable bms used basic diluted eps calculation weightedaverage common shares outstanding basic incremental shares attributable sharebased compensation plans weightedaverage common shares outstanding diluted lossearnings per common share basic diluted total number potential shares common stock excluded diluted eps computation antidilutive impact million material note financial instruments fair value measurements financial instruments include cash cash equivalents marketable securities accounts receivable payable debt instruments derivatives changes exchange rates interest rates create exposure market risk certain derivative financial instruments used available costeffective basis hedge underlying economic exposure instruments qualify cash flow net investment fair value hedges upon meeting certain criteria including effectiveness offsetting hedged exposures changes fair value derivatives qualify hedge accounting recognized earnings occur derivative financial instruments used trading purposes financial instruments subject counterparty credit risk considered part overall fair value measurement counterparty credit risk monitored ongoing basis mitigated limiting amounts outstanding individual counterparty utilizing conventional derivative financial instruments entering agreements counterparties meet high credit quality standards consolidated financial statements would materially impacted counterparty failed perform according terms agreement collateral required party whether derivatives asset liability position terms agreements fair value measurements fair value financial instruments classified one following categories level inputs utilize unadjusted quoted prices active markets accessible measurement date identical assets liabilities fair value hierarchy provides highest priority level inputs level inputs utilize observable prices similar instruments quoted prices identical similar instruments nonactive markets additionally certain corporate debt securities utilize thirdparty matrix pricing model using significant inputs corroborated market data substantially full term assets equity fixed income funds primarily invested publicly traded securities valued respective nav underlying investments level derivative instruments valued using libor yield curves less credit valuation adjustments observable forward foreign exchange rates reporting date valuations derivative contracts may fluctuate considerably volatility underlying foreign currencies underlying interest rates driven market conditions duration contract level unobservable inputs used little market data available level financial liabilities consist acquisition related contingent consideration success payments related undeveloped product rights resulting celgene acquisition financial assets liabilities measured fair value recurring basis summarized december december dollars millions level level level level level level cash cash equivalents money market securities marketable debt securities certificates deposit commercial paper corporate debt securities derivative assets equity investments derivative liabilities contingent consideration liability contingent value rights acquisition related contingent consideration contingent consideration obligations recorded estimated fair values bms revalues obligations reporting period related contingencies resolved contingent value rights adjusted fair value using traded price securities end reporting period fair value measurements contingent consideration liabilities estimated using probabilityweighted discounted cash flow approaches based significant unobservable inputs related product candidates acquired business combinations reviewed quarterly inputs include applicable estimated probabilities timing achieving specified development regulatory milestones estimated annual sales discount rate used calculate present value estimated future payments significant changes increase decrease probabilities achieving related development regulatory events shorten lengthen time required achieve events increase decrease estimated annual sales would result corresponding increases decreases fair values obligations fair value acquisition related contingent consideration december calculated using following significant unobservable inputs ranges weighted average utilized inputs december december discount rate probability payment projected year payment development regulatory milestones transfers levels year ended december following table represents rollforward fair value level instruments year ended december year ended december dollars millions asset liability asset liability fair value january changes estimated fair value acquisitions foreign exchange fair value december availableforsale debt securities equity investments following table summarizes availableforsale debt securities december december gross unrealized gross unrealized amortized amortized dollars millions cost gains losses fair value cost gains losses fair value certificates deposit commercial paper corporate debt securities total availableforsale debt securitiesa marketable debt securities mature within five years december following summarizes carrying amount equity investments december dollars millions equity investments readily determinable fair values equity investments without readily determinable fair values equity method investment total equity investments following summarizes activity related equity investments changes fair value equity investments included incomeexpense net dollars millions net gainloss recognized equity investments readily determinable fair valuesa realized lossgain recognized equity investments readily determinable fair value sold upward adjustments equity investments without readily determinable fair value impairments downward adjustments equity investments without readily determinable fair value cumulative upward adjustments equity investments without readily determinable fair value cumulative impairments downward adjustments equity investments without readily determinable fair value net unrealized net gains equity investments still held billion million unrealized net losses equity investments still held million qualifying hedges nonqualifying derivatives cash flow hedges foreign currency forward contracts used hedge certain forecasted intercompany inventory purchases sales transactions certain foreign currency transactions fair value contracts designated cash flow hedges temporarily reported accumulated comprehensive loss included earnings hedged item affects earnings net gain loss foreign currency forward contracts expected reclassified net earnings primarily included cost products sold incomeexpense net within next months notional amount outstanding foreign currency forward contracts primarily attributed euro billion japanese yen billion december earnings impact related discontinued cash flow hedges hedge ineffectiveness significant periods presented cash flow hedge accounting discontinued forecasted transaction longer probable occurring within days originally forecasted date hedge longer effective assessments determine whether derivatives designated qualifying hedges highly effective offsetting changes cash flows hedged items performed inception quarterly basis foreign currency forward contracts designated hedging instruments used offset exposures certain foreign currency denominated assets liabilities earnings changes fair value derivatives recognized earnings occur bms may hedge portion future foreign currency exposure utilizing strategy involves purchased local currency put option written local currency call option accounted hedges future sales denominated local currency specifically bms sells writes local currency call option purchases local currency put option expiration dates local currency notional amounts different strike prices premium collected sale call option equal premium paid purchased put option resulting net premium paid combination transactions generally referred zerocost collar expiration dates notional amounts correspond amount timing forecasted foreign currency sales us dollar weakens relative currency hedged anticipated sales purchased put option value reduces zero benefit increase us dollar equivalent value anticipated foreign currency cash flows however benefit would capped strike level written call forms upper end collar treasury lock hedge contracts entered total notional value billion hedge future interest rate risk associated anticipated issuance longterm debt fund myokardia acquisition treasury lock contracts terminated upon issuance unsecured senior notes million proceeds included comprehensive lossincome net investment hedges nonus dollar borrowings million billion december designated net investment hedges hedge euro currency exposures net investment certain foreign affiliates recognized longterm debt effective portion foreign exchange gain remeasurement euro debt included foreign currency translation component accumulated comprehensive loss related offset long term debt crosscurrency interest rate swap contracts million december designated hedge japanese yen currency exposure bmss net investment japan subsidiaries contract fair value changes recorded foreign currency translation component comprehensive lossincome related offset noncurrent assets noncurrent liabilities fair value hedges fixed floating interest rate swap contracts designated fair value hedges used interest rate risk management strategy create appropriate balance fixed floating rate debt contracts underlying debt hedged benchmark risk recorded fair value effective interest rate contracts onemonth libor december plus interest rate spread gains losses resulting changes fair value underlying debt attributable hedged benchmark interest rate risk recorded interest expense associated offset carrying value debt since specific terms notional amount swap intended align debt hedged changes fair value swap recorded interest expense associated offset derivative asset liability consolidated balance sheet result net impact earnings underlying swap terminated prior maturity fair value adjustment underlying debt amortized reduction interest expense remaining term debt forward starting interest rate swap option contracts entered total notional value billion hedge future interest rate risk associated anticipated issuance longterm debt fund celgene acquisition additionally deal contingent forward starting interest rate swap contracts entered aggregate notional principal amount billion hedge interest rate risk associated issuance longterm debt fund acquisition forward starting interest rate swap option contracts terminated deal contingent forward starting interest rate swap contracts terminated upon completion celgene acquisition following summarizes fair value outstanding derivatives december december asseta liabilityb asseta liabilityb dollars millions notional fair value notional fair value notional fair value notional fair value derivatives designated hedging instruments interest rate swap contracts crosscurrency interest rate swap contracts foreign currency forward contracts derivatives designated hedging instruments foreign currency forward contracts foreign currency zerocost collar contracts included current assets noncurrent assets b included current liabilities noncurrent liabilities following table summarizes financial statement classification amount gainloss recognized hedging instruments year ended december cost incomeexpense cost incomeexpense cost incomeexpense dollars millions products sold net products sold net products sold net interest rate swap contracts crosscurrency interest rate swap contracts foreign currency forward contracts forward starting interest rate swap option contracts deal contingent forward starting interest rate swap contracts foreign currency zerocost collar contracts following table summarizes effect derivative nonderivative instruments designated hedging instruments comprehensive lossincome year ended december dollars millions derivatives qualifying cash flow hedges foreign currency forward contracts gainloss recognized comprehensive lossincomea reclassified cost products sold treasury lock hedge contracts gain recognized comprehensive lossincome derivatives qualifying net investment hedges crosscurrency interest rate swap contracts gainloss recognized comprehensive lossincome nonderivatives qualifying net investment hedges non us dollar borrowings gainloss recognized comprehensive lossincome majority expected reclassified earnings next months debt obligations bms issued aggregate principal amount billion fixed rate unsecured senior notes proceeds net discount deferred loan issuance costs billion notes rank equally right payment bmss existing future senior unsecured indebtedness redeemable time whole part varying specified redemption prices plus accrued unpaid interest bms issued aggregate principal amount approximately billion floating rate fixed rate unsecured senior notes proceeds net discount deferred loan issuance costs billion notes rank equally right payment bmss existing future senior unsecured indebtedness fixed rate notes redeemable time whole part varying specified redemption prices plus accrued unpaid interest connection celgene acquisition bms commenced offers exchange outstanding notes issued celgene approximately billion likeamount new notes issued bms exchange offers exchange transaction accounted modification assumed debt instruments following settlement exchange offers bms issued approximately billion new notes exchange celgene notes tendered exchange offers aggregate principal amount celgene notes remained outstanding following settlement exchange offers approximately billion bms entered billion term loan credit agreement consisting billion day tranche billion threeyear tranche billion five year tranche connection celgene acquisition term loan subject customary terms conditions financial covenants proceeds term loan used fund portion cash paid celgene acquisition payment related fees expenses subsequent completion acquisition bms repaid term loan entirety using cash proceeds generated otezla divestiture refer note acquisitions divestitures licensing arrangements information fair value longterm debt billion billion december respectively valued using level inputs based upon quoted market prices similar debt instruments fair value shortterm borrowings approximates carrying value due short maturities debt instruments repayment notes maturity aggregated billion billion interest payments billion million million december bms four separate revolving credit facilities totaling billion consisted day billion facility expired january threeyear billion facility expiring january two fiveyear billion facilities extended january september july respectively facilities provide customary terms conditions financial covenants may used provide backup liquidity bmss commercial paper borrowings bmss billion facility two billion revolving facilities extendable annually one year anniversary date consent lenders borrowings outstanding revolving credit facility december january bms entered day billion facility expiring january extendable annually one year anniversary date consent lenders available financial guarantees provided form bank overdraft facilities standby letters credit performance bonds approximately billion december standby letters credit guarantees issued financial institutions support various obligations including sale products hospitals foreign ministries health bonds customs duties value added tax shortterm debt obligations include december dollars millions nonus shortterm borrowings current portion longterm debt total longterm debt current portion longterm debt includes december dollars millions principal value floating rate notes due notes due notes due notes due notes due notes due floating rate notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due euro notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due euro notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due maturing total december dollars millions principal value adjustments principal value fair value interest rate swap contracts unamortized basis adjustment swap terminations unamortized bond discounts issuance costs unamortized purchase price adjustments celgene debt total current portion longterm debt longterm debt total note receivables december dollars millions trade receivables less chargebacks cash discounts less allowance expected credit loss net trade receivables alliance royalties vat receivables nonus receivables sold nonrecourse basis billion million million aggregate receivables three pharmaceutical wholesalers us represented approximately total trade receivables december respectively changes allowances expected credit loss chargebacks cash discounts follows year ended december dollars millions balance beginning year celgene acquisition provisiona utilization balance end year includes provision expected credit loss million million million certain prior year amounts previously included provision presented utilization note inventories december dollars millions finished goods work process raw packaging materials total inventories inventories noncurrent assets total inventories include fair value adjustments resulting celgene acquisition approximately million billion december respectively recognized future periods noncurrent assets include inventory expected remain hand beyond one year periods note property plant equipment december dollars millions land buildings machinery equipment fixtures construction progress gross property plant equipment less accumulated depreciation property plant equipmenta united states europe rest world total includes measurement period adjustments refer note acquisitions divestitures licensing arrangements information depreciation expense million million million note leases leased facilities office research development storage distribution purposes comprise approximately total lease obligation lease terms vary based nature operations market dynamics country however leased facilities classified operating leases remaining lease terms one year years leases contain specific renewal options periods ranging one year years notice renew must provided advance lease expiration automatic renewals advance notice required periods covered option extend lease included noncancellable lease term exercise option determined reasonably certain certain leases also contain termination options provide flexibility terminate lease ahead expiration sufficient advance notice periods covered option terminate lease included non cancellable lease term exercise option determined reasonably certain judgment required assessing whether renewal termination options reasonably certain exercised factors considered contractual terms compared current market rates leasehold improvements expected significant value costs terminate lease importance facility operations costs determined variable based index rate included measurement real estate lease liabilities variable costs include real estate taxes insurance utilities common area maintenance operating costs implicit rate leases readily determinable incremental borrowing rate applied portfolio approach discount real estate lease liabilities remaining lease obligations comprised vehicles used primarily salesforce rd facility operated third party managements direction vehicle lease terms vary country terms generally one year four years following table summarizes components lease expense year ended december dollars millions operating lease cost variable lease cost shortterm lease cost sublease income total operating lease expense operating lease rightofuse assets liabilities follows december dollars millions noncurrent assets current liabilities noncurrent liabilities total liabilities future lease payments noncancellable operating leases december follows dollars millions thereafter total future lease payments less imputed interest total lease liability rightofuse assets obtained exchange new operating lease obligations million includes million rightofuse assets acquired myokardia acquisition cash paid amounts included measurement operating lease liabilities million million cash paid net million lease incentive received undiscounted lease obligations operating leases yet commenced approximately million december obligation primarily relates research development facility constructed lessor expected ready use rightofuse asset impairment charge million incurred due site vacancy partial sublease fair value rightofuse asset determined using income approach incorporating potential future cash flows associated sublease building supplemental balance sheet information related leases follows december weighted average remaining lease term years years weighted average discount rate note goodwill intangible assets december estimated dollars millions useful lives goodwilla intangible assets licenses years acquired marketed product rightsa years capitalized software years iprd gross intangible assets less accumulated amortization intangible assets includes measurement period adjustments refer note acquisitions divestitures licensing arrangements information billion iprd reclassified acquired marketed product rights upon approval us reblozyl treatment anemia adults lowerrisk mds zeposia onureg amortization expense intangible assets billion billion million future annual amortization expense intangible assets expected approximately billion billion billion billion billion intangible asset impairment charges billion million million respectively million impairment charge recorded cost products sold resulting lower cash flow projections reflecting revised commercial forecasts inrebic resulting full impairment asset additionally million impairment charge recorded research development expense following decision discontinue orvacel program development inrebic orvacel obtained connection acquisition celgene million iprd impairment charge recorded research development expense following decision discontinue development investigational compound obtained acquisition medarex million impairment charge recorded incomeexpense net outlicensed asset obtained acquisition zymogenetics inc meet primary endpoint phase ii clinical study note supplemental financial information december dollars millions prepaid refundable income taxes research development equity investments othera current assets includes restricted cash million million december respectively december dollars millions equity investments inventories operating leases pension postretirement restricted cash noncurrent assets december dollars millions rebates returns income taxes payable employee compensation benefits research development dividends interest royalties operating leases contingent value rights current liabilities december dollars millions income taxes payable contingent value rights pension postretirement operating leases deferred income deferred compensation noncurrent liabilities note equity accumulated capital excess common stock treasury stock par value comprehensive retained noncontrolling dollars shares millions shares par value stock loss earnings shares cost interest balance january accounting change cumulative effecta adjusted balance january net earnings comprehensive lossincome cash dividends declaredb share repurchase program stock compensation adoption asu distributions balance december accounting change cumulative effecta adjusted balance january net earnings comprehensive lossincome celgene acquisition cash dividends declaredb share repurchase program stock compensation distributions balance december net loss comprehensive lossincome cash dividends declaredb share repurchase program stock compensation distributions balance december cumulative effect resulting adoption asu asu b cash dividends declared per common share bms share repurchase program authorized board directors allowing repurchases shares effected open market privately negotiated transactions compliance rule b exchange act including rule b trading plans share repurchase program expiration date may suspended discontinued time treasury stock recognized cost reacquire shares shares issued treasury recognized utilizing firstin firstout method bms repurchased approximately million shares common stock billion year ended december remaining share repurchase capacity share repurchase program approximately billion december bms executed accelerated share repurchase agreements asr repurchase aggregate billion common stock asr funded cash hand approximately million shares common stock billion aggregate repurchase price received bms included treasury stock agreement settled approximately million shares common stock received bms transferred treasury stock components comprehensive lossincome follows year ended december dollars millions pretax tax tax pretax tax tax pretax tax tax derivatives qualifying cash flow hedges unrealized lossesgains reclassified net earningsa derivatives qualifying cash flow hedges pension postretirement benefits actuarial lossesgains amortizationb settlementsb pension postretirement benefits availableforsale securities unrealized gainslosses realized gainslossesb availableforsale securities foreign currency translation comprehensive lossincome included cost products sold b included incomeexpense net accumulated balances related component comprehensive lossincome net taxes follows december dollars millions derivatives qualifying cash flow hedges pension postretirement benefits availableforsale securities foreign currency translation accumulated comprehensive loss note retirement benefits bms sponsors defined benefit pension plans defined contribution plans termination indemnity plans regular fulltime employees principal defined benefit pension plan bristolmyers squibb retirement income plan plan covered us employees future benefits related service plan eliminated bms contributed least minimum amount required erisa plan benefits based primarily participants years credited service final average compensation bms announced plans fully terminate plan pension obligations related plan distributed combination lump sum payments eligible plan participants elected payments purchase group annuity contracts wholly owned insurance subsidiaries athene holding ltd athene billion distributed plan participants elected lump sum payments election window group annuity contracts purchased athene billion remaining plan participants athene irrevocably assumed pension obligations transactions fully terminated plan resulted billion noncash pretax pension settlement charge principal us defined benefit pension plan overfunded termination result excess plan assets million reflected bms assets december assets primarily reported long term restricted cash due election contribute assets bristolmyers squibb savings investment program qualified replacement plan election requires assets used fund future annual company contribution bristol myers squibb savings investment program bms acquired celgene november certain celgenes international subsidiaries funded unfunded defined benefit pension plans recorded fair value celgene plans using assumptions accounting policies consistent disclosed bms upon acquisition excess projected benefit obligation plan assets recognized liability previously existing deferred actuarial gains losses unrecognized service costs benefits eliminated net periodic benefit costcredit defined benefit pension plans includes year ended december dollars millions service cost benefits earned year interest cost projected benefit obligation expected return plan assets amortization prior service credits amortization net actuarial loss settlements curtailments net periodic pension benefit costcredit pension settlement charges recognized determining annual lump sum payments exceed annual interest service costs certain pension plans including primary us pension plan changes defined benefit pension plan obligations assets funded status amounts recognized consolidated balance sheets follows year ended december dollars millions benefit obligations beginning year service costbenefits earned year interest cost settlements curtailments actuarial losses benefits paid acquisitiondivestiture foreign currency benefit obligations end year fair value plan assets beginning year actual return plan assets employer contributions settlements benefits paid asset transfer acquisitiondivestiture foreign currency fair value plan assets end year unfunded status assetsliabilities recognized noncurrent assets current liabilities noncurrent liabilities funded status recognized accumulated comprehensive loss net actuarial losses prior service credit total accumulated benefit obligation defined benefit pension plans billion billion december respectively additional information related pension plans follows december dollars millions pension plans projected benefit obligations excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligations excess plan assets accumulated benefit obligation fair value plan assets actuarial assumptions weightedaverage assumptions used determine defined benefit pension plan obligations follows december discount rate rate compensation increase interest crediting rate weightedaverage actuarial assumptions used determine defined benefit pension plan net periodic benefit costcredit follows year ended december discount rate expected longterm return plan assets rate compensation increase interest crediting rate yield high quality corporate bonds matching duration benefit obligations used determining discount rate citi pension discount curve used developing discount rate us plans expected return plan assets assumption plan based managements expectations longterm average rates return achieved underlying investment portfolio several factors considered developing expected return plan assets including longterm historical returns input external advisors individual asset class return forecasts developed based upon market conditions example priceearnings levels yields longterm growth expectations expected longterm rate return weightedaverage target asset allocation individual asset class actuarial gains losses resulted changes actuarial assumptions changes discount rate revised mortality rates differences assumed actual experience differences actual expected return plan assets actuarial losses related plan benefit obligations primarily result decreases discount rates actuarial gains related plan benefit obligations primarily result increases discount rates gains losses amortized life expectancy plan participants us plans years expected remaining service periods plans extent exceed higher marketrelated value projected benefit obligation respective plan postretirement benefit plans comprehensive medical group life benefits provided substantially legacy bms us retirees electing participate comprehensive medical group life plans lesser extent certain benefits nonus employees medical plan contributory contributions adjusted periodically vary date retirement life insurance plan noncontributory postretirement benefit plan assets consist principally fixedincome securities postretirement benefit plan obligations million million december respectively fair value plan assets million december weightedaverage discount rate used determine benefit obligations december respectively net periodic benefit credits material result bristolmyers squibb retirement income plan 's termination million assets held separate account within pension trust used fund retiree medical plan payments reverted back company resulting excise tax million plan assets fair value pension postretirement plan assets asset category december follows december december dollars millions level level level total level level level total plan assets equity securities equity funds fixed income funds corporate debt securities us treasury agency securities insurance contracts cash cash equivalents plan assets subject leveling plan assets measured nav practical expedient net plan assets investment valuation policies per investment class follows level inputs utilize unadjusted quoted prices active markets accessible measurement date identical assets liabilities fair value hierarchy provides highest priority level inputs instruments include equity securities equity funds fixed income funds publicly traded national securities exchange cash cash equivalents cash cash equivalents highly liquid investments original maturities three months less time purchase recognized cost approximates fair value pending trade sales purchases included cash cash equivalents final settlement level inputs utilize observable prices similar instruments quoted prices identical similar instruments nonactive markets observable inputs corroborated market data substantially full term assets liabilities equity funds fixed income funds classified level within fair value hierarchy valued nav shares held year end represents fair value corporate debt securities us treasury agency securities classified level within fair value hierarchy valued utilizing observable prices similar instruments quoted prices identical similar instruments markets active level unobservable inputs used little market data available insurance contracts held certain foreign pension plans carried contract value approximates estimated fair value based fair value underlying investment insurance company investments using practical expedient consist primarily multiasset funds redeemable either daily weekly monthly basis investment strategy maximize return maintaining appropriate level risk provide sufficient liquidity benefit obligations plan expenses individual plan investment allocations determined local fiduciary committees composition total assets pension plans december broadly characterized allocation equity securities debt securities investments contributions estimated future benefit payments contributions pension plans million million million expected material estimated annual future benefit payments nonterminating plans including lump sum payments approximately million approximately million next four years subsequent five year period savings plans principal defined contribution plan bristolmyers squibb savings investment program contributions based employee contributions level company match expense attributed defined contribution plans us approximately million million respectively note employee stock benefit plans may shareholders approved plan replaced stock incentive plan plan provides million shares authorized grants plus shares outstanding awards plan february expire forfeited canceled withheld satisfy tax withholding obligations december million shares available award shares issued treasury stock satisfy bmss obligations plan part celgene acquisition bms assumed stock incentive plan equity incentive plan referred together bms plans plans plans provided granting options restricted stock units rsus performance share units psus sharebased performancebased awards former celgene employees officers nonemployee directors additionally terms plans provided accelerated vesting awards upon change control followed involuntary termination without cause december million shares available award celgene plans outstanding celgene equity awards assumed bms converted bms equity awards acquisition replacement bms awards generally terms conditions including vesting former celgene awards exchanged shares issued treasury stock satisfy bmss obligations plans cvrs also issued holders vested unexercised money options outstanding acquisition date celgene rsu holders unvested money options outstanding acquisition date awards vesting prior march also eligible receive cvrs celgene rsu holders unvested money options outstanding acquisition date awards vesting march eligible receive cash value per preconverted celgene rsu money options cvr milestones achieved contractual obligation pay contingent value rights terminated january fda approve lisocel jcar december executive officers key employees may granted options purchase common stock less market price date option granted options generally become exercisable ratably four years maximum term years plans provide granting stock appreciation rights whereby grantee may surrender exercisable rights receive common stock andor cash measured excess market price common stock option exercise price primarily utilize treasury shares satisfy exercise stock options rsus may granted key employees subject restrictions continuous employment generally vesting occurs ratably three four year period grant date stock unit right receive stock end specified vesting period voting rights market share units msus granted executives vesting conditioned upon continuous employment vesting date payout factor least share price award date payout factor share price vesting date divided share price award date maximum share price used payout factor calculated using average closing prices grant vest date nine trading days immediately preceding grant vest date vesting occurs ratably four years psus granted executives three year cycle granted target number units subject adjustment number shares issued psus vest determined based achievement performance goals based bmss threeyear total shareholder return relative peer group companies vesting conditioned upon continuous employment occurs third anniversary grant date stockbased compensation expense awards ultimately expected vest recognized vesting period forfeitures estimated based historical experience time grant revised subsequent periods actual forfeitures differ estimates stockbased compensation expense follows year ended december dollars millions cost products sold marketing selling administrative research development incomeexpense net total stockbased compensation expense income tax benefita income tax benefit excludes excess tax benefits sharebased compensation awards vested exercised million million million total stockbased compensation expense years ended december includes million million respectively related celgene postcombination service period million million respectively accelerated vesting awards related celgene acquisition also includes million million related cvr obligation unvested stock awards post combination service period refer note acquisitions divestitures licensing arrangements information related celgene acquisition replacement stock options granted celgene option holders acquisition issued consistent vesting conditions replaced award replacement stock options contractual terms years initial grant date majority stock options outstanding vest onefourth increments four year period although certain awards cliff vest longer shorter service periods celgene option holders may elect exercise options time option term however shares purchased vested date exercise shall subject forfeiture lapse accordance established vesting time period fair value acquisition date attributable postcombination service adjusted estimated forfeitures recognized expense straightline basis remaining vesting period bms estimated fair value replacement options using black scholes option pricing model following assumptions year ended december weighted average riskfree interest rate expected volatility weighted average expected term years expected dividend yield riskfree interest rate based rates available us federal reserve treasury constant maturities remaining term equal options ' expected life time replacement award expected volatility replacement stock option awards estimated based blend implied volatility five year historical volatility bms publicly traded stocks expected term employee share option period time option expected outstanding based historical forecasted exercise behavior dividend yield estimated based bms annual dividend rate time award replacement following table summarizes stock compensation activity year ended december stock optionsa restricted stock units market share units performance share units weighted weighted weighted weighted average number average number average number average number exercise price nonvested grantdate nonvested grantdate nonvested grantdate shares millions options shares awards fair value awards fair value awards fair value balance january granted releasedexercised adjustments actual payout forfeitedcanceled balance december expected vest december substantially million unvested stock options weightedaverage exercise price expected vest restricted performance share dollars millions stock options stock units market share units units unrecognized compensation cost expected weightedaverage period years compensation cost recognized amounts millions except per share data weightedaverage grant date fair value per share stock options replacement awards restricted stock units replacement awards restricted stock units market share units performance share units fair value awards vested restricted stock units replacement awards restricted stock units market share units performance share units total intrinsic value stock options exercised fair value rsus msus psus approximates closing trading price bmss common stock grant date adjusting units eligible accrued dividends addition fair value msus psus considers probability satisfying payout factor total shareholder return respectively fair value replacement rsus approximates closing trading price bms common stock date acquisition adjusting units eligible accrued dividends fair value acquisition date attributable postcombination service adjusted estimated forfeitures recognized expense straightline basis remaining vesting period following table summarizes significant outstanding exercisable options december number options weightedaverage remaining weightedaverage aggregate intrinsic value range exercise prices millions contractual life years exercise price per share millions outstanding exercisable aggregate intrinsic value preceding table represents total pretax intrinsic value based closing stock price december note legal proceedings contingencies bms certain subsidiaries involved various lawsuits claims government investigations legal proceedings arise ordinary course business claims proceedings involve various types parties including governments competitors customers suppliers service providers licensees employees shareholders among others matters may involve patent infringement antitrust securities pricing sales marketing practices environmental commercial contractual rights licensing obligations health safety matters consumer fraud employment matters product liability insurance coverage among others resolution matters often develops long period time expectations change result new findings rulings appeals settlement arrangements legal proceedings significant bms believes could become significant material described bms believe matters except otherwise specifically noted material adverse effect financial position liquidity bms believes substantial defenses matters outcomes bmss legal proceedings contingencies inherently unpredictable subject significant uncertainties assurance increase scope one pending matters future lawsuits claims government investigations legal proceedings material bmss financial position results operations cash flows particular period furthermore failure enforce bmss patent rights would likely result substantial decreases respective product revenues generic competition unless otherwise noted bms unable assess outcome respective matters able estimate possible loss range losses could potentially result matters contingency accruals recognized probable liability incurred amount related loss reasonably estimated developments legal proceedings matters could cause changes amounts previously accrued evaluated reporting period discussion bmss tax contingencies see note income taxes intellectual property antipd antibody litigation september danafarber cancer institute danafarber filed complaint us district court district massachusetts seeking correct inventorship six related us patents directed methods treating cancer using pd pdl antibodies specifically danafarber seeking add two scientists inventors patents october pfizer allowed intervene case alleging one scientists identified danafarber employed company eventually acquired pfizer relevant period february bms settled lawsuit pfizer bench trial lawsuit danafarber took place february may court issued opinion ruling two scientists added inventors patents decision appealed us court appeals federal circuit federal circuit affirmed district court opinion bms filed petition reconsider decision federal circuit en banc denied october june danafarber filed new lawsuit district massachusetts bms seeking damages result courts decision adding scientists inventors car october day fda approved kite pharma incs kite yescarta product juno along sloan kettering institute cancer research ski filed complaint kite us district court central district california complaint alleged yescarta infringes certain claims us patent patent concerning car cell technologies kite filed answer counterclaims asserting noninfringement invalidity patent december following eightday trial jury rejected kites defenses finding kite willfully infringed patent awarding juno ski reasonable royalty consisting million upfront payment running royalty kites sales yescarta expiration patent august january kite renewed previous motion judgment matter law also moved new trial juno filed motion seeking enhanced damages supplemental damages ongoing royalties prejudgment interest march court denied kites motions entirety april court granted part junos motion entered final judgment awarding juno ski approximately billion royalties interest enhanced damages running royalty kites sales yescarta december expiration patent august april kite appealed final judgment us court appeals federal circuit date scheduled oral hearing appeal eliquis us bms received notice letters twentyfive generic companies notifying bms filed andas containing paragraph iv certifications seeking approval generic versions eliquis result two eliquis patents listed fda orange book challenged composition matter patent claiming apixaban specifically formulation patent response bms along partner pfizer initiated patent infringement actions hatchwaxman act generic filers us district court district delaware april august us patent trademark office granted patent term restoration composition matter patent november thereby restoring term eliquis composition matter patent bmss basis projected loe bms settled number anda filers settlements affect bmss projected loe eliquis trial remaining anda filers took place late august us district court issued decision finding remaining anda filers products infringed eliquis composition matter formulation patents eliquis patents invalid remaining anda filers appealed court appeals federal circuit plavix australia sanofi notified august genrx proprietary limited genrx obtained regulatory approval application clopidogrel bisulfate mg tablets australia genrx formerly subsidiary apotex inc subsequently changed name apotex genrxapotex august genrxapotex filed application federal court australia seeking revocation sanofis australian patent case nsd sanofi filed counterclaims infringement sought injunction september federal court australia granted sanofis injunction subsidiary bms subsequently added party proceedings february second company spirit pharmaceuticals pty ltd also filed revocation suit patent case consolidated genrxapotex case august federal court australia held claims patent covering clopidogrel bisulfate hydrochloride hydrobromide taurocholate salts valid federal court also held process claims pharmaceutical composition claims claim directed clopidogrel pharmaceutically acceptable salts invalid bms sanofi filed notices appeal full court federal court australia full court appealing holding invalidity claim covering clopidogrel pharmaceutically acceptable salts process claims pharmaceutical composition claims genrxapotex appealed holding validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claims september full court held claims patent invalid march high court australia denied request bms sanofi hear appeal full court decision case remanded federal court proceedings related damages sought genrx apotex bms genrxapotex settled genrxapotex case dismissed australian government intervened matter seeking maximum damages million aud million plus interest would split bms sanofi alleged losses experienced paying higher price branded plavix period injunction place bms sanofi dispute australian government entitled damages trial concluded september april federal court issued decision dismissing australian governments claim damages may australian government appealed federal court 's decision appeal hearing scheduled february pomalyst canada celgene received notice allegation january natco pharma canada inc natco canada notifying celgene filed abbreviated new drug submission ands canadas minister health respect certain celgenes canadian patents natco canada seeking market generic version pomalyst canada response celgene initiated patent infringement action federal court canada natco canada alleges asserted patents invalid andor infringed trial scheduled begin november celgene received second notice allegation november natco canada notifying celgene filed second ands canadas minister health respect certain celgenes canadian patents natco canada seeking market generic version pomalyst canada response celgene initiated patent infringement action federal court canada natco canada alleges asserted patents invalid andor infringed trial date scheduled matter celgene received two notices allegation march dr reddys laboratories ltd drl canada notifying celgene filed ands canadas minister health respect certain celgenes canadian patents drl canada seeking market generic version pomalyst canada response celgene initiated two patent infringement actions federal court canada drl canada alleges asserted patents invalid andor infringed trial scheduled begin january pomalyst us beginning celgene received notice letters behalf teva pharmaceuticals usa inc teva apotex inc apotex apotex corp hetero labs limited hetero labs limited unitv hetero drugs limited hetero usa inc collectively hetero eugia pharma specialities limited aurobindo pharma ltd collectively aurobindo mylan pharmaceuticals inc breckenridge pharmaceutical inc breckenridge notifying celgene filed andas containing paragraph iv certifications seeking approval market generic versions pomalyst us response celgene filed patent infringement actions companies us district court district new jersey asserting certain fda orange booklisted patents companies filed answers counterclaims declaratory judgment actions alleging asserted patents invalid unenforceable infringed litigations subsequently consolidated march celgene subsequently filed additional patent infringement actions us district court district new jersey companies asserting newlyissued patent listed fda orange book covers formulations comprising pomalidomide companies filed responsive pleadings april june alleging patent invalid infringed court consolidated additional litigations previouslyconsolidated litigations september court granted mylan pharmaceuticals incs motion dismiss decision celgene appealed october breckenridge aurobindo received final approval fda respective andas november celgene breckenridge entered confidential settlement agreement pursuant terms confidential settlement agreement january court enjoined breckenridge infringing asserted patents unless extent otherwise specifically authorized celgene dismissed breckenridge proceedings final pretrial conference concerning consolidated litigations scheduled february expected delayed february march celgene filed additional patent infringement actions us district court district new jersey companies asserting certain patents listed fda orange book cover polymorphic forms pomalidomide companies filed answers andor counterclaims alleging patents invalid andor infringed actions consolidated earlierfiled actions companies trial date set matter june celgene received notice letter dr reddys laboratories ltd dr reddys laboratories inc together drl notifying celgene filed anda containing paragraph iv certifications seeking approval market generic version pomalyst us response celgene initiated patent infringement action drl us district court district new jersey asserting certain fda orange booklisted patents drl filed answer counterclaims alleging patents invalid andor infringed march celgene filed additional patent infringement action us district court district new jersey drl asserting newlyissued patent listed fda orange book covers formulations comprising pomalidomide consolidated drl case court set trial date consolidated action february celgene filed additional patent infringement action us district court district new jersey drl asserting certain patents listed fda orange book cover polymorphic forms pomalidomide drl responded complaint trial date set matter revlimid us celgene received notice letters behalf zydus pharmaceuticals usa inc cipla ltd cipla apotex sun pharma global fze sun pharma global inc sun pharmaceutical industries inc sun pharmaceutical industries limited hetero mylan pharmaceuticals inc mylan inc mylan nv collectively mylan aurobindo pharma limited eugia pharma specialities limited aurobindo pharma usa inc aurolife pharma llc lupin limited notifying celgene filed andas containing paragraph iv certifications seeking approval market generic versions revlimid us response celgene filed patent infringement actions companies us district court district new jersey asserting certain fda orange booklisted patents well litigations asserting nonfda orange booklisted patents certain defendants filed answers andor counterclaims alleging asserted patents invalid andor infringed trial date scheduled new jersey actions celgene also filed patent infringement action mylan us district court northern district west virginia west virginia action asserting certain fda orange booklisted patents mylan filed answer counterclaims alleging patents invalid andor infringed trial scheduled begin west virginia action october december celgene settled outstanding claims litigation cipla pursuant settlement celgene agreed provide cipla license celgenes patents required manufacture sell certain volumelimited amounts generic lenalidomide united states beginning certain date march volumelimited license date previously provided natco addition celgene agreed provide cipla license celgenes patents required manufacture sell unlimited quantity generic lenalidomide united states beginning january sprycel us august bms received notice letter dr reddys laboratories inc notifying bms filed anda containing paragraph iv certifications seeking approval generic version sprycel us challenging two fda orange booklisted monohydrate form patents expiring response bms filed patent infringement action us district court district new jersey trial date scheduled bms received notice letter lupin notifying bms filed anda containing paragraph iv certifications seeking approval generic version sprycel us challenging two fda orange booklisted monohydrate form patents expiring response bms filed patent infringement actions us district courts district new jersey delaware trial date scheduled pricing sales promotional practices litigation plavix state attorneys general lawsuits bms certain sanofi entities defendants consumer protection actions brought attorneys general hawaii new mexico relating labeling sales andor promotion plavix trial hawaii matter concluded november decision expected first quarter product liability litigation bms party various product liability lawsuits plaintiffs cases seek damages relief various grounds alleged personal injury economic loss previously disclosed addition lawsuits bms also faces unfiled claims involving products abilify bms otsuka codefendants product liability litigation related abilify plaintiffs allege abilify caused engage compulsive gambling impulse control disorders cases filed state federal courts additional cases pending canada judicial panel multidistrict litigation consolidated federal court cases pretrial purposes us district court northern district florida february bms otsuka entered master settlement agreement establishing proposed settlement program resolve abilify compulsivity claims filed january mdl well various state courts including california new jersey date approximately cases comprising approximately plaintiffs dismissed based participation settlement program failure comply settlement related court orders us less cases remain pending behalf plaintiffs either chose participate settlement program filed claims settlement cutoff date ten cases pending canada four class actions six individual injury claims ten cases three active class actions quebec ontario one individual injury claim class actions certified proceed separately subject pending appeal ontario class certification decision byetta amylin former subsidiary bms lilly codefendants product liability litigation related byetta december approximately separate lawsuits pending behalf approximately active plaintiffs including pending settlements include injury plaintiffs well claims spouses andor beneficiaries various courts us majority cases brought individuals allege personal injury sustained using byetta primarily pancreatic cancer cases claiming alleged wrongful death majority cases pending federal court san diego mdl coordinated proceeding california superior court los angeles jccp november defendants motion summary judgment based federal preemption granted mdl jccp november ninth circuit reversed mdl summary judgment order remanded case mdl november california court appeal reversed state court summary judgment order remanded cases jccp proceedings amylin filed motion summary judgment based federal preemption motion summary judgment based absence general causation evidence heard amylin product liability insurance covering substantial number claims involving byetta exhausted part bmss global diabetes business divestiture bms sold byetta astrazeneca february additional liability amylin respect byetta expected shared astrazeneca onglyza bms astrazeneca codefendants product liability litigation related onglyza plaintiffs assert claims including claims wrongful death result heart failure cardiovascular injuries allege caused use onglyza december claims pending state federal court behalf approximately individuals allege ingested product suffered injury february judicial panel multidistrict litigation ordered federal cases transferred mdl us district court eastern district kentucky significant majority claims pending mdl part bmss global diabetes business divestiture bms sold onglyza astrazeneca february potential liability respect onglyza expected shared astrazeneca securities litigation bms securities class action since february two separate putative class action complaints filed us district northern district california us district court southern district new york bms bmss chief executive officer giovanni caforio bmss chief financial officer time charles bancroft certain former current executives bms case california voluntarily dismissed remaining complaint alleges violations securities laws bmss disclosures related checkmate clinical trial lung cancer september court granted bmss motion dismiss allowed plaintiffs leave file amended complaint october plaintiffs filed amended complaint bms moved dismiss amended complaint september court granted bmss motion dismiss prejudice plaintiffs appealed court 's decision october celgene securities class action beginning march two putative class actions filed celgene certain officers us district court district new jersey celgene securities class action complaints allege defendants violated federal securities laws making misstatements andor omissions concerning trials ged celgenes outlook projected sales otezla new drug application zeposia court consolidated two actions appointed lead plaintiff lead counsel coliaison counsel putative class february defendants filed motion dismiss plaintiffs amended complaint full december court denied motion dismiss part granted motion dismiss part including claims arising alleged misstatements regarding ged although court gave plaintiff leave replead dismissed claims elected dismissed claims dismissed prejudice november court granted class certification respect remaining claims december defendants sought leave appeal courts class certification decision trial date scheduled april certain schwab management investment companies behalf certain schwab funds filed individual action us district court district new jersey asserting largely allegations celgene securities class action remaining defendants action july defendants filed motion dismiss plaintiffs ' complaint full litigation average manufacturer price litigation bms defendant qui tam whistleblower lawsuit us district court eastern district pennsylvania us government declined intervene complaint alleges bms inaccurately reported average manufacturer prices centers medicare medicaid services lower owed similar claims filed companies january bms reached agreement principle resolve matter subject negotiation definitive settlement agreement contingencies bms provide assurances efforts reach final settlement successful hiv medication antitrust lawsuits bms two manufacturers hiv medications defendants related lawsuits pending northern district california lawsuits allege defendants agreements develop sell fixeddose combination products treatment hiv including atripla evotaz violate antitrust laws currently pending actions asserted behalf indirect purchasers initiated northern district california southern district florida florida matter transferred northern district california july court granted part defendants motion dismiss including dismissing prejudice plaintiffs claims overarching conspiracy plaintiffs theories based alleged payment royalties patent expiration claims however remain trial indirect purchasers claims scheduled august september october two purported class actions also filed asserting similar claims behalf direct purchasers defendants motions dismiss compel arbitration matters scheduled heard february trial direct purchasers claims scheduled humana litigations may humana inc humana filed lawsuit celgene pike county circuit court commonwealth kentucky humanas complaint alleges celgene engaged unlawful offlabel marketing connection sales thalomid revlimid asserts claims celgene fraud breach contract negligent misrepresentation unjust enrichment violations new jerseys racketeer influenced corrupt organizations act complaint seeks among things treble punitive damages injunctive relief attorneys fees costs april celgene filed motion dismiss humanas complaint court denied january trial date scheduled may celgene filed suit humana pharmacy inc hpi humana subsidiary delaware superior court celgenes complaint alleges hpi breached contractual obligations celgene assigning claims humana humana asserting complaint seeks damages hpis breach well declaratory judgment september hpi filed motion dismiss celgenes complaint march humana filed separate lawsuit celgene us district court district new jersey humanas complaint alleges celgene violated various antitrust consumer protection unfair competition laws delay prevent generic competition thalomid revlimid brand drugs including allegedly refusing sell samples products generic manufacturers purposes bioequivalence testing intended included andas approval market generic versions products b allegedly bringing unjustified patent infringement lawsuits procuring invalid patents andor entering anticompetitive patent settlements c allegedly securing exclusive supply contract supply thalidomide active pharmaceutical ingredient complaint purports assert claims behalf humana subsidiaries several capacities including direct purchaser indirect purchaser seeks among things treble punitive damages injunctive relief attorneys fees costs celgene filed motion dismiss humanas complaint court stayed discovery pending adjudication motion trial date scheduled thalomid revlimid antitrust class action litigation related proceedings beginning november certain putative class action lawsuits filed celgene us district court district new jersey alleging celgene violated various antitrust consumer protection unfair competition laws allegedly securing exclusive supply contract alleged purpose preventing generic manufacturer securing supply thalidomide active pharmaceutical ingredient b allegedly refusing sell samples thalomid revlimid brand drugs various generic manufacturers alleged purpose bioequivalence testing necessary andas submitted fda approval market generic versions products c allegedly bringing unjustified patent infringement lawsuits order allegedly delay approval proposed generic versions thalomid revlimid andor allegedly entering settlements patent infringement lawsuits certain generic manufacturers allegedly anticompetitive effects plaintiffs behalf putative classes thirdparty payers seeking injunctive relief damages various lawsuits consolidated master action purposes october plaintiffs filed motion certification two damages classes laws thirteen states district columbia nationwide injunction class celgene filed opposition plaintiffs motion motion judgment pleadings dismissing state law claims plaintiffs longer seek represent class october court denied plaintiffs motion class certification celgenes motion judgment pleadings december plaintiffs filed new motion class certification celgene opposed july parties reached settlement putative class plaintiff claims would dismissed prejudice december certain thirdparty payors members settlement class refused release potential claims participate settlement celgene exercised right terminate settlement agreement march celgene reached revised settlement class plaintiffs may court preliminarily approved settlement october court entered final order approving settlement dismissed matter settlement resolve claims certain entities opted first settlement march united healthcare services inc uhs affiliates opted first settlement thalomid revlimid antitrust class action litigation filed lawsuit celgene us district court district minnesota uhss complaint makes largely claims allegations class action litigation addition certain claims regarding donations directed copay assistance complaint purports assert claims behalf uhs subsidiaries several capacities including direct purchaser indirect purchaser seeks among things treble punitive damages injunctive relief attorneys fees costs december celgenes motion transfer action district new jersey granted case pending court july blue cross blue shield association bcbsa sued celgene bms behalf federal employee program us district court district columbia bcbsas complaint makes largely claims allegations class action litigation motion transfer matter district new jersey pending august health care service corporation hcsc bcbsm inc dba blue cross blue shield minnesota blue cross blue shield florida inc dba florida blue sued celgene bms state courts minnesota complaint makes largely claims allegations class action litigation adds allegations behalf hcsc alleged offlabel marketing thalomid revlimid september celgene bms removed action us district court district minnesota motions remand dismiss action transfer venue district new jersey pending january cigna corporation cigna sued celgene bms us district court eastern district pennsylvania cignas complaint makes largely claims allegations class action litigation cignas complaint purports assert claims behalf cigna subsidiaries several capacities including direct purchaser indirect purchaser celgenes bmss response complaint due march government investigations like pharmaceutical companies bms certain subsidiaries subject extensive regulation national state local authorities us countries bms operates result bms time time subject various governmental regulatory inquiries investigations well threatened legal actions proceedings possible criminal charges substantial fines andor civil penalties could result government regulatory investigations environmental proceedings previously reported bms party several environmental proceedings matters responsible various state federal foreign laws including cercla certain costs investigating andor remediating contamination resulting past industrial activity bmss current former sites waste disposal reprocessing facilities operated third parties cercla matters respect cercla matters bms responsible various state federal foreign laws bms typically estimates potential costs based information obtained us environmental protection agency counterpart state foreign agency andor studies prepared independent consultants including total estimated costs site expected costsharing potentially responsible parties bms accrues liabilities probable reasonably estimable bms estimated share future costs sites million december represents sum best estimates best estimate reasonably made estimates minimal probable amount among range costs without taking account potential recoveries parties amount includes estimated costs additional probable loss associated previously disclosed north brunswick township high school remediation site note selected quarterly financial data unaudited year ended december dollars millions except per share data first quarter second quarter third quarter fourth quarter year total revenues gross margin net lossearnings net lossearnings attributable noncontrolling interest bms lossearnings per common share basica lossearnings per common share diluteda cash dividends declared per common share cash cash equivalents marketable debt securitiesb total assets longterm debtc equity year ended december dollars millions except per share data first quarter second quarter third quarter fourth quarterd yeard total revenues gross margin net earningsloss net earningsloss attributable noncontrolling interest bms earningsloss per common share basica earningsloss per common share diluteda cash dividends declared per common share cash cash equivalents marketable debt securitiesb total assets longterm debtc equity earnings per share quarters may add amounts year period computed discrete basis b marketable debt securities includes current noncurrent assets c longterm debt includes current portion commencing november celgenes operations included consolidated financial statements refer note acquisitions divestitures licensing arrangements additional information following specified items affected comparability results year ended december dollars millions first quarter second quarter third quarter fourth quarter year inventory purchase price accounting adjustments intangible asset impairment employee compensation charges site exit costs cost products sold employee compensation charges site exit costs marketing selling administrative license asset acquisition charges iprd impairments inventory purchase price accounting adjustments employee compensation charges site exit costs research development iprd charge myokardia acquisition amortization acquired intangible assets interest expensea contingent consideration royalties licensing income equity investment lossesgains integration expenses provision restructuring litigation settlements reversion excise tax divestiture gainslosses incomeexpense net increase pretax income income taxes items income taxes attributed otezla divestiture income taxes attributed internal transfer intangible assets income taxes increase net earnings year ended december dollars millions first quarter second quarter third quarter fourth quarter year inventory purchase price accounting adjustments employee compensation charges site exit costs cost products sold employee compensation charges site exit costs marketing selling administrative license asset acquisition charges iprd impairments employee compensation charges site exit costs research development amortization acquired intangible assets interest expensea contingent consideration royalties licensing income equity investment gainslosses integration expenses provision restructuring litigation settlements investment income divestiture lossesgains pension postretirement acquisition expenses incomeexpense net increase pretax income income taxes items income taxes attributed otezla divestiture income taxes increase net earnings includes amortization purchase price adjustments celgene debt report independent registered public accounting firm shareholders board directors bristolmyers squibb company opinion financial statements audited accompanying consolidated balance sheets bristolmyers squibb company subsidiaries company december related consolidated statements earnings comprehensive lossincome cash flows three years period ended december related notes collectively referred financial statements opinion financial statements present fairly material respects financial position company december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also audited accordance standards public company accounting oversight board united states pcaob company 's internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion company 's internal control financial reporting basis opinion financial statements responsibility company 's management responsibility express opinion company 's financial statements based audits public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement whether due error fraud audits included performing procedures assess risks material misstatement financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation financial statements believe audits provide reasonable basis opinion critical audit matters critical audit matters communicated matters arising currentperiod audit financial statements communicated required communicated audit committee relate accounts disclosures material financial statements involved especially challenging subjective complex judgments communication critical audit matters alter way opinion financial statements taken whole communicating critical audit matters providing separate opinions critical audit matters accounts disclosures relate grosstonet us rebate accruals us medicaid medicare part managed healthcare refer note revenue financial statements critical audit matter description fully disclosed note financial statements company reduces gross product sales list price time revenue recognized expected chargebacks discounts rebates sales allowances product returns referred grosstonet gtn adjustments reductions attributed various commercial arrangements managed healthcare organizations government programs mandate various reductions list price chargebacks cash discounts reflected reduction receivables settled issuance credits customer rebates discounts adjustments reflected liability settled cash payments certain gtn liabilities related us medicaid medicare part managed healthcare organizations rebate programs gtn us rebate accruals involve use significant assumptions judgments calculation significant assumptions judgments include consideration legal interpretations applicable laws regulations historical claims experience payer channel mix current contract prices unbilled claims claims submission time lags inventory levels distribution channel given complexity involved determining significant assumptions used calculating gtn us rebate accruals auditing estimates involved especially subjective judgment critical audit matter addressed audit audit procedures related gtn us rebate accruals included following among others evaluated appropriateness consistency companys methods assumptions used calculate gtn us rebate accruals tested effectiveness internal controls review companys estimation model including underlying assumptions key inputs companys process calculate gtn us rebate accruals tested mathematical accuracy gtn us rebate accruals tested significant assumptions key inputs used calculate gtn us rebate accruals evaluated companys ability estimate gtn us rebate accruals accurately comparing actual amounts incurred gtn us rebate accruals historical estimates tested overall reasonableness gtn us rebate accruals recorded period end developing expectation comparison actual recorded balances involved audit professionals industry quantitative analytics experience assist us performing auditing procedures taxes unrecognized tax benefit liabilities us transfer pricing refer note income taxes financial statements critical audit matter description fully disclosed note financial statements company recognizes certain income tax benefits associated transactions us operating companies related foreign affiliates income tax benefits estimated based transfer pricing agreements thirdparty transfer pricing studies companys judgment whether morelikelythannot benefits realized tax benefits may ultimately realized company determined judgment accrued unrecognized tax benefit liabilities amounts recognized unrecognized tax benefit liabilities related us transfer pricing may significantly affected subsequent periods due various factors changes tax law identification additional relevant facts change companys judgment regarding measurement tax benefits upon ultimate settlement taxing authorities given complexity associated assumptions used calculate unrecognized tax benefit liabilities related us transfer pricing coupled significant judgments made company determination auditing estimates involved especially subjective judgment critical audit matter addressed audit audit procedures related unrecognized tax benefit liabilities related us transfer pricing included following among others evaluated appropriateness consistency companys methods assumptions used identification recognition measurement disclosure unrecognized tax benefit liabilities tested effectiveness internal controls review underlying assumptions key inputs companys process calculate unrecognized tax benefit liabilities obtained understanding companys related party transactions transfer pricing policies tested mathematical accuracy unrecognized tax benefit liabilities tested completeness unrecognized tax benefit liabilities tested reasonableness underlying tax positions amounts accrued selection unrecognized tax benefit liabilities reviewing companys evaluation relevant facts tax law associated tax position testing significant assumptions inputs used calculate unrecognized tax benefit liabilities reference third party data information produced entity understanding transfer pricing principles tax laws inquires management evaluated whether company appropriately considered new information could significantly change recognition measurement disclosure unrecognized tax benefit liabilities involved income tax specialists audit professionals industry experience assist us performing auditing procedures deloitte touche llp parsippany new jersey february served companys auditor since item changes disagreements accountants accounting financial disclosure none item controls procedures evaluation disclosure controls procedures december management carried evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure controls procedures defined exchange act rules ae de end period covered based evaluation management concluded december disclosure controls procedures effective managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting defined exchange act rule af supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance united states generally accepted accounting principles due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp independent registered public accounting firm audited companys financial statements included report form k issued report effectiveness companys internal control financial reporting december included herein changes internal control financial reporting changes companys internal control financial reporting quarter ended december materially affected reasonably likely materially affect companys internal control financial reporting item b information none report independent registered public accounting firm shareholders board directors bristolmyers squibb company opinion internal control financial reporting audited internal control financial reporting bristolmyers squibb company subsidiaries company december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued coso also audited accordance standards public company accounting oversight board united states pcaob consolidated financial statements year ended december company report dated february expressed unqualified opinion consolidated financial statements basis opinion companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying management 's report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audit accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp parsippany new jersey february part iii item directors executive officers registrant reference made proxy statement respect directors incorporated herein reference made part hereof response information required item b information required item respect executive officers included part ia reliance general instruction g instruction item b regulation sk incorporated herein reference made part hereof response information required item item executive compensation reference made proxy statement respect executive compensation incorporated herein reference made part hereof response information required item item security ownership certain beneficial owners management related stockholder matters reference made proxy statement respect security ownership certain beneficial owners management incorporated herein reference made part hereof response information required item item certain relationships related transactions reference made proxy statement respect certain relationships related transactions incorporated herein reference made part hereof response information required item item auditor fees reference made proxy statement respect auditor fees incorporated herein reference made part hereof response information required item part iv item